Metabonomic and epidemiological analyses of maternal parameters and exposures during pregnancy and their influence on fetal growth amongst the INMA birth cohort by Maitre, Léa
  
 
Metabonomic and epidemiological analyses of 
maternal parameters and exposures during 
pregnancy and their influence on fetal growth 
amongst the INMA birth cohort 
 
Thesis submitted by 
Léa Maitre 
For the degree of Doctor of Philosophy of Imperial College London 
 
Supervisors: Dr. Mireille Toledano & Dr. Muireann Coen  
Department of Epidemiology and Biostatistics 
School of Public Health 
& 
Section of Computational Systems Medicine 
Department of Surgery and Cancer 
Faculty of Medicine 
Imperial College London 
2015  
E r r o r !  R e f e r e n c e  s o u r c e  n o t  f o u n d . E r r o r !  
R e f e r e n c e  s o u r c e  n o t  f o u n d . | 2 
Declaration of Originality 
I certify that this thesis and the research to which it refers are the product of my own 
work, and that any ideas, contributions or quotations from the work of other people, 
published or otherwise, are fully acknowledged in accordance with the standard 
referencing practices of the discipline. In the scope of this thesis, I selected the 
pregnant woman urine samples that will be analysed and aliquoted the urine 
samples from the Sabadell subcohort in the CREAL laboratories in Barcelona, Spain 
and shipped them to London. I prepared the buffer and samples for NMR analysis in 
the laboratories at Imperial College London, set up the NMR experiments and 
carried on the NMR analysis of all the urine samples presented in this thesis. I also 
conducted all the statistical analyses and data processing in Matlab and R. I 
conducted the metabolite identification of steroid hormone by products in the NMR 
spectra by setting up 2D NMR experiments on 600MHz and 800MHz spectrometers 
and preparing the samples for fractionation analysis. Dr Matthew Lewis set up the 
HPLC instrument for the sample fractionation and I took care of the evaporation and 
resolubilization of the samples and the NMR analysis on the 800MHz NMR 
spectrometer. I also assisted in the LC-MS/MS analysis and interpretation of the 
purified urine samples with the help of Dr Mathew Lewis. Finally I conducted the 
final interpretation of the LC-MS/MS fragment patterns with the help of database, 
standard references and literature. The trichloroacetic acid analysis in the urine was 
performed in the Health and Safety laboratories by Dr Kates Jones and her team 
after I aliquoted and shipped to the samples to Buxton. I performed the specific 
gravity measurements in the laboratories in Buxton for correction of dilution factors 
in the urine. 
Copyright declaration 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. 
Researchers are free to copy, distribute or transmit the thesis on the condition that 
they attribute it, that they do not use it for commercial purposes and that they do not 
alter, transform or build upon it. For any reuse or redistribution, researchers must 
make clear to others the licence terms of this work 
  
E r r o r !  R e f e r e n c e  s o u r c e  n o t  f o u n d . E r r o r !  
R e f e r e n c e  s o u r c e  n o t  f o u n d . | 3 
Abstract 
Fetal growth aberrations, including fetal growth restriction (FGR) and macrosomia, 
convey the highest risk of perinatal mortality and morbidity, as well as increasing the 
chance of developing chronic disease in later life. Using Metabolic 
profiling/metabolomics approaches in maternal urine samples collected in a 
prospective mother-child cohort can provide information on the early-life exposome 
and can be linked to child health outcomes as well as potentially identify new 
biomarkers of exposure. The aims of this PhD were to characterise intra and inter-
individual variations in maternal urine profiles during pregnancy, predict fetal growth 
outcomes and identify environmental sources of metabolic variations. 
We applied an exploratory metabolic profiling approach using 1H nuclear magnetic 
resonance (NMR) spectroscopy to maternal urine samples at the first (n=806) and 
third trimesters of gestation (n=886), collected as part of the Infancia y Medio 
Ambiente (INMA)–Environment and Childhood Study, a large prospective mother-
child population-based cohort study cohorts based in eight Spanish cities. An 
exploratory metabolomics approach was applied using 1H nuclear magnetic 
resonance (NMR) spectroscopy for profiling and LC-MS/MS for metabolite 
identification. Metabolites were used to predict longitudinal measures of fetal growth 
in terms of body weight and head size (estimated at 12th, 20th and 34th gestational 
weeks and at birth) and placental weight at birth using linear regression adjusting for 
main confounding factors.  
To our knowledge the present study represents the largest human investigation 
(n >800) in which non-targeted proton nuclear magnetic resonance spectroscopy 
has been used to understand the progression of normal fetal growth in two different 
Spanish populations. We identified 10 reproducible metabolic associations at week 
34 with estimated fetal weight, birth weight and placental weight. These signatures 
included pregnancy-related hormone breakdown products that were newly 
characterised in our study and branched-amino acids (BCAAs) isoleucine, valine 
and leucine with its catabolic intermediate 3-hyrdoxyisobutyrate. Overall metabolic 
phenotypes at week 12 could not predict fetal weight at week 34 or at birth, but only 
at weeks 12 and 20 and with little consistency across the two populations. Unique 
adverse metabolic signatures at week 12 of fetal growth were found in Sabadell 
related to mitochondrial oxidative stress, systemic inflammation and renal function. 
These findings captured the metabolic signatures of a myriad of physiological (both 
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maternal and fetal), environmental, and other lifestyle characteristics associated 
with fetal growth. Sensitive measures of environmental exposure to HAA toxins 
were also created using LC-MS, a non-volatile sub-type of water contaminants, 
using gold-standard urine biomarker (TCAA), in a case-control study for use in 
future epidemiological studies of fetal growth outcomes.  
 
This work provides ground breaking evidence of clinical relevance with the potential 
to personalise pre-natal care and ensure healthy fetal development.  
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Aims, objectives and scope of the thesis 
My primary purpose in this thesis was to (1) characterise the maternal urinary 
metabolome throughout pregnancy and its temporal variation and (2) demonstrate 
that maternal metabolic signatures can predict fetal growth. I then aimed to (3) 
identify sources of variation in metabolic profiles related to maternal lifestyle, 
exposures and clinical profiles that could be linked to their birth outcomes. Finally, I 
aimed (4) to accurately determine the level of individual exposure to a ubiquitous 
environmental chemical present in tap water for use future epidemiological studies. 
First, the concepts behind fetal growth determinants and justification for this thesis 
based on gaps in knowledge will be discussed; second the results based on two 
large independent mother-child cohorts will be presented; finally, what this thesis 
has added to the field of reproductive metabolomics and molecular epidemiology will 
be described, drawing on policy/clinical significance and what further research could 
be done using the thesis material and where should the future direction of this 
research field be. 
I will not attempt here to describe the genetic or particular molecular mechanisms 
involved in fetal development but rather focus upon the global metabolic phenotype 
in the mother associated with fetal growth. My intention is to provide convincing 
evidence for a novel analytical platform to describe the combined effect of genetic 
and environmental components at a population level for future use in pregnancy 
research.  
I have based my study on two large subcohorts of pregnant women in Spain from 
which extensive information on lifestyle, environmental exposures and clinical 
outcomes were available through the INMA study. To measure the metabolic 
phenotype I applied an untargeted 1H NMR metabolic profiling approach. This 
should enable the semi-quantification of major urinary metabolites for use in the 
next stage of the analysis with fetal growth outcomes. Then, using longitudinal fetal 
growth measures, I should characterise reproducible urinary biomarkers associated 
with fetal development.  This study will also use and extend the interpretation of 
these biomarker results by statistically identifying population metabolic variations 
explained by maternal lifestyle/clinical parameters, that are potentially modifiable. 
Finally, mass spectrometry-based measurement of a gold standard biomarker will 
allow accurate exposure assessment to chlorinated tap water by-products in our 
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pregnant population. This should be used to create a comprehensive exposure 
metric in combination with area-level data and frequency water use questionnaire. 
This study offers new proposals for profiling large pregnant population at the 
molecular level in relation to their fetal growth outcomes beyond established genetic 
and external teratogenic factors. Indeed, maternal intrauterine milieu has a 
dominant effect over genetic potential in determining foetal size and future chronic 
disease risk in the developing child. 
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 Introduction and Literature review Chapter 1 
This chapter introduces the concepts behind fetal growth determinants based on 
physiological and epidemiological evidences. It also describes how metabolic 
profiling can be applied in maternal-fetal research as a novel tool to identify 
underlying mechanisms for fetal growth failure but also as a tool in large-scale 
population studies to identify biomarkers of adverse outcomes and adverse 
environmental exposures. Justification for this thesis based on gaps in knowledge is 
also discussed.  
 Fetal growth and environmental factors 1.1
This section will introduce the stages of early life development from a single cell to a 
complex organism and the major physiological changes that women experience to 
support fetal growth. Cases when alterations in maternal physiology and 
environment lead to poor growth will be described, as well as, avoidable risk factors.  
 The stages of in utero development 1.1.1
The human development timetable is unique compared to other primates. Homo 
sapiens babies are born in a state of relative brain immaturity and therefore with 
some immature body functions. For example, communicative skills and independent 
ability to move arrive long after birth compared to other primates. A late brain 
development is necessary for humans in order to house a large skull and forebrain 
in adulthood while maintaining a narrow pelvic birth canal required for an upright 
posture for walking (Falk et al. 2012). 
 From the gametes to the embryo and functioning placenta 1.1.1.1
All information required to develop from a single fertilised cell (zygote) to an 
autonomous human being is contained in the 35 000 genes of this initial cell. During 
development, the genetic information is unfolded to control morphologic 
development. This set of genes consists of chromosomes coming half from the 
mother and half from the father. These chromosomes are combined during the 
fertilization stage, which is defined as the time when the spermatozoid and the 
secondary oocyte are in contact. 30 hours after fertilization the zygote undergoes a 
series of cleavage divisions maintaining the same total mass (Niakan et al. 2012). 
Further cellular division is accompanied by the formation of a small cavity between 
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the cells, forming the blastocyst. In the next days the blastocyst, which is at this 
stage only a ball of identical cells, starts to develop a polarity and different 
compartments are formed. The inner cell mass will form the embryo and the other 
components will constitute the placenta and other supporting tissues. The embryo 
must grow out of the conceptus (to ‘hatch’) to continue development and implants 
into the uterine lining. By that stage, the blastocyst would have travelled down the 
Fallopian tubes into the uterus.  
The placenta formation also requires the component of the blastocyst to grow out, 
the specialized epithelial cells form the outer layer of the blastocyst, and invade the 
maternal uterine wall. This process is called trophoblastic invasion. Once the 
invasion occurred the development of the utero-placental circulation system allows 
the circulatory system of the mother and of the embryo to exchange gases and 
nutrients through simple diffusion. At this stage the embryo is exposed to sudden 
high levels of oxygen and needs to produce anti-oxidant enzymes. Trophoblastic 
invasion and/or anti-oxidant reactions are believed to fail in hypertensive disorders 
such as gestational hypertension and pre-eclampsia which are the leading cause of 
maternal mortality in developed countries, accounting for 16% of deaths (Khan et al. 
2006). Oxidative stress can also affect the normal placental development and 
perturb nutrient availability later on during fetal growth. The placenta has an 
incredible range of functions which is described briefly below. Most importantly, it 
allows nutrient exchange between maternal and fetal blood but created an immune 
barrier between the fetus and genetically different mother by never allowing direct 
contact of the two circulatory systems. The placenta acts as the respiratory site for 
the fetus as well as a site of filtration for plasma nutrients and wastes. This 
exchange occurs such as the fetal blood flows through the umbilical arteries to the 
placenta, then into finer vessels, capillaries that go through a sponge-like material 
(chorionic villus, an alveolus-like structure) where exchange occurs between 
maternal uterine blood and fetal blood. Replenished fetal blood finally flows into one 
large umbilical vein that returns to the fetus. The placenta is also the site of 
hormone secretion that alters maternal physiology and support fetal growth. 
Placental size can vary greatly between pregnancies adapting to different 
environments. For example, at high altitude (>2,500m) where low oxygen levels are 
observed, pregnant women present larger placenta relative to fetal size. This is to 
benefit oxygen diffusion (Moore et al. 2011). The placenta is the most important 
determinant of the fetal environment.  
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During the embryonic period which lasts 8 weeks from the moment of implantation, 
most organ systems are established such as the heart, the gastrointestinal tract and 
the liver and this with an enormous rapidity. Therefore, it is also the most vulnerable 
time during pregnancy where most toxic exposures to teratogens result in an “all or 
none effect” (meaning any effect will be so profound as to cause a spontaneous 
abortion). By the end of the embryonic period, the incidence of malformations that 
lead to miscarriages decreases from more than 10% to 1% (Wilcox et al. 1988).  
 Fetal development  1.1.1.2
During the early fetal period (9 to 20 weeks), the body structures further develop 
with a gradual increase in functional ability. Because all the major organ precursors 
are in place, the fetus is less susceptible to environmental toxic exposure than the 
embryo, only physiological anomalies or minor congenital malformations may occur. 
During weeks 9-12 the body length doubles and the head is half of the body length. 
Head growth slows down thereafter. The fetus starts to swallow the amniotic fluid, 
which contains proteins, carbohydrates, lipids and phospholipids, and urea, all of 
which aid in the growth of the fetus. From week 13, external genitalia maturation 
allows sex prediction by obstetric ultrasonography. This is usually the time of the 
first ultrasound scan in the clinic to detect fetal anomalies. Between 17-20 weeks, 
growth slows down and muscle development allows fetal movement. By the end of 
20 weeks, the fetus reached 20% of its potential weight and 60% of its length at 
term. After 20 weeks, fetal weight gain increases substantially as can be seen in the 
fetal growth curve drawn in Figure 1-1. The central nervous system development 
from 26 weeks accelerates, enough to control some body functions. From 29 weeks 
to birth, muscle and fat tissues are laid down. By 38 to 40 weeks, fetal 
measurements averages 3000 to 3800g and 45 to 50 cm (Blackburn 2012). Fetal 
growth is assessed in the clinic through ultrasound measurements that are used to 
indirectly assess the growth, the gestational age and well-being of the fetus. 
Anthropometric measures include the biparietal diameter, head circumference, 
abdominal circumference and femur length from which the fetal weight can be 
estimated or the crowN-rump length (longest length of the embryo) which is used to 
estimate the gestational age in the first trimester of pregnancy. 




Figure 1-1 Fetal growth diagrams.  
At the top, fetal weight according to gestational age by gender using ultrasound 
measurements (from data in the Gipuzkoa cohort, personal communication from Carmen 
Iñiguez, CREAL, see methods 3.1.2.2). At the bottom, fetal crown-rump length according to 
gestational age which shows the enormous increase in size during the fetal period, in 




 weeks. The drawings of the fetus are highly schematic 
but the length is accurately redrawn from Schöni-Affolter, Dubuis-Grieder, & Strauch, 2008). 
 Maternal physiological changes during pregnancy 1.1.2
Pregnancy lasts for 40 weeks on average, after the first day of the last menstrual 
period (LMP). In obstetrics, the gestational weeks are normally calculated from the 
date of the LMP because this is a point in time that many women can easily 
remember but this is not the real start of pregnancy (fertilization). Normally the 
ovulation, and therefore the fertilization, occur 14 days after the beginning of 
menstruation, but can vary a lot temporally (timeframe shown in Figure 1-2). The 
pregnancy period, which is in reality 38 weeks, is characterised by dramatic 
anatomic, physiological and metabolic changes in women which ensure placental 
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and fetal growth. Most of these changes are the results of hormonal stimuli or 
physical alterations secondary to fetal volume.  
 
Figure 1-2 Stages of prenatal development (Schöni-Affolter et al. 2008) 
Maternal metabolism follows two phases during pregnancy characterised by an 
anabolic state with enhanced lipogenesis, glycogenesis and protein storage in a first 
period, followed by a catabolic state where fatty acids and glucose are increasingly 
released in the maternal blood. These two periods coincide with the development of 
the fetus and its increased need for nutrients. Indeed, the fetus gains 90% of its 
growth in the last half of gestation, the first half being reserved for maternal nutrient 
storage (King 2000; Blackburn 2012). As seen in Figure 1-3, maternal lipid storage 
and triglyceride synthesis greatly increase during the two first trimesters of 
gestation, before fetal energy demands culminate.  
 




Figure 1-3 Maternal metabolic changes and fetal weight during pregnancy 
Adapted from a publication (Rosso 1987). 
Some important maternal physiologic adaptations to pregnancy are mediated by the 
renal system. Pregnancy is characterised by increased intravascular and 
extracellular volumes (plasma and interstitial fluid) in order to maintain normal blood 
pressure, enhance maternal-fetal exchange of nutrients and oxygen and cope with 
potential blood loss during delivery. The renal system must undergo a variety of 
structural changes to handle maternal hypervolemia and to excrete an increased 
load of metabolic wastes from the fetus. The predominant renal adaptions are 
structural with the dilatation of the renal pelvis and ureters and functional with the 
increase in glomerular filtration rate. As a result, the urine output is greater and the 
renal excretion of proteins, glucose, urea, amino acids and vitamins increases. 
 Controls exerted over fetal growth 1.1.3
Understanding the factors related to normal, restricted, and excessive fetal growth is 
essential for clinical care of neonates and has been the subject of many studies. 
The fetus must develop not to be too large, potentially causing difficulties at delivery, 
not to be too small causing own risks to the fetus. Control over fetal growth is 
exerted by a complex interaction between maternal uterine constraint, nutrient 
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availability, fetal needs and placental capacity which renders it almost impossible to 
identify independent effects of these factors. Evidence on the role of these factors 
were collected from observational studies (in particular the Dutch famine cohort from 
1944-1945), inference from animal models (often from sheep models) and 
epidemiological studies. Maternal determinants over fetal growth regulation include 
genetic as well as environmental factors. Maternal height is of particular importance 
because it correlates to uterine capacity. Polymorphisms in maternal genes coding 
for proteins involved in extracellular matrix metabolism, placental growth and more 
were also found to be associated with IUGR incidence in genome-wide population 
studies (GWAS) (Edwards et al. 2011). However, both animal and human data 
suggest that the maternal intrauterine milieu has a dominant effect over genetic 
potential in determining fetal size, based on crossbreeding studies (Gluckman & 
Hanson 2005). It is well established that half siblings related through the mother 
have a higher correlation in birth weight than those whose the father is the common 
parent. 
Fetal genes, half inherited from the mother, are associated with size at birth to an 
extent such as each allele explain from 0.034 SD to 0.072 SD which equate 
approximately to changes in birth weight of 16 to 35g according to GWAS studies 
(Horikoshi et al. 2013). A portion of the genes involved (5 to 7 out of 21 strong 
associated genes to birth weight) were also related to adult traits (type 2 diabetes, 
blood pressure or height) which inform on the potential biological pathways involved. 
These genes included ADCY5 and CDKAL1 which are both strongly associated with 
insulin secretion or action and therefore of importance for fetal growth (Freathy et al. 
2010). Other genes such as HMGA2 and LCORL link prenatal growth with postnatal 
stature independently to maternal genome. Overall, fetal genes explain less than 
2% of variance in birth weight (Horikoshi et al. 2013). More importantly are the 
interactions between maternal and fetal genotype ensuring a delicate balance 
between maternal and fetal survival (Dunger et al. 2007). Regulation of expression 
of genes through epigenetic pathways and DNA methylation is particularly important 
to regulate fetal development. However, only few studies measured which CpGs 
were involved with birth weight in large population-based cohorts. A role for ARID5B 
in particular in fetal growth was found, using cord blood DNA, and revealed to be 
associated with postnatal growth and lipid accumulation in mice (Engel et al. 2014). 
Modification of epigenome pathways are believed to occur during pregnancy in 
response to events such as maternal smoking (Joubert et al. 2012) or depression 
(Liu et al. 2012), affecting pre- and post-natal growth. Beyond maternal genetic and 
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uterine constraints, fetal growth is largely determined by maternal nutrient 
availability. Nutrient availability to the fetus is controlled by maternal macro and 
micronutrient intake and their partitioning between maternal and fetal compartments. 
Increased total energy and protein intake are needed to cope with fetal growth 
acceleration in the second and third trimester of pregnancy (Kramer & Kakuma 
2003). First trimester dietary intake was also demonstrated to be important but 
conflicting results were presented on which period of pregnancy correlated the most 
to greater growth (Murphy et al. 2006). Evidence shows that the source of protein 
and the respective content in specific amino acids is also important. Blood glucose 
is another important determinant of fetal size where studies in diabetic women 
showed that too tight glycaemic controls led to higher risk of IUGR whereas high 
glucose levels led to excessive growth. Micronutrients are also crucial for healthy 
fetal growth and supplementation during pregnancy is often preconized. Folate is 
important for supplying methyl groups for DNA synthesis, Zinc is necessary for 
insulin secretion and storage, and vitamin E is an up-regulator of insulin sensitivity.  
Nutrient transport from maternal to fetal compartments depends on the adequate 
functioning of the placenta and production of certain maternal, placental, and fetal 
hormones. These include the insulin-like growth factor-1 (IGF-1) and IGF-2 which 
are produced by the placenta and the fetus and promote the development of the 
placenta and the fetal organs (Murphy et al. 2006). IGF-1 levels are responsive to 
changes in fetal insulin, which in turn are stimulated by glucose concentrations. 
Other hormones such as cortisol (glucocorticoid, produced in response to stress and 
low glucose), leptin and thyroxine (T4, thyroid hormone) also have an effect on IGF-
1 action and fetal growth (Sacks 2004). Less data are available for progesterone 
and oestrogen roles in fetal growth. 
To summarise, fetal growth is controlled by multiple interactions between maternal 
uterine constraints and fetal needs via the placenta, the site of oxygen, nutrient and 
hormonal exchange. Alterations in any of these pathways can have adverse 
consequences in the short-term, with abnormal weight at birth and increased 
perinatal morbidity, and in the long-term, via epigenetic modifications and increased 
risk for diseases in adult life. 
 Fetal growth outcomes: definitions and tools for characterisation 1.1.4
Fetal growth restriction (FGR) or intrauterine growth restriction (IUGR) occurs when 
fetuses fail to achieve their genetically determined weight and size. The ideal weight 
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and size for each individual is complex to determine in clinical settings. In clinical 
practice, FGR is diagnosed by comparing the birth weight and other length 
measurements, such as the abdominal or head circumferences at birth and/or 
during the fetal period (ultrasound measurements), to a population-based growth 
chart. Small for gestational age (SGA) is generally used as a surrogate for FGR, 
classically defined as a birth weight <10th percentile, using sex-adjusted centile 
charts. However, among neonates classified as SGA, only 25% may be 
constitutionally small according to different studies which determined constitutional 
variation due to maternal height, weight, paternal height, ethnic group and parity 
(McCowan & Horgan 2009; Mamelle et al. 2006; Wilcox 2001). Customised growth 
charts were found more likely to detect neonates at risk of perinatal morbidity and 
mortality than would be detected by a population chart (McCowan et al. 2005). The 
challenge for obstetricians is to differentiate constitutionally small fetuses to 
pathologically growth restricted and intervene with induced premature delivery if 
necessary. The diagnosis of abnormal fetal growth, and possibly prognostic would 
also for better postnatal care and provide closer clinical monitoring for subsequent 
pregnancies. However, 40-80% FGR cases remain undiagnosed before birth, 
contributing to high perinatal mortality (Chang et al. 1992). In epidemiological 
settings, simpler metrics have been used to study fetal growth determinants such as 
continuous birth weight or low birth weight (<2,500g, LBW) often restricted to term 
LBW, which need to be corrected for the gestational age directly or at the stage of 
the regression modelling with weight determinants by statistical adjustment (Slama 
et al. 2014). Although a consensus is lacking in the literature, in the rest of this 
thesis, the term FGR/IUGR will be employed for fetuses in the lower tail of the size 
distribution of newborn with the same gestational age, sex, parity, and maternal 
characteristics. Besides IUGR, fetal macrosomia, also defined as large for 
gestational age (LGA), is characterised by a birth weight above the 90th percentile or 
authors have variably defined it as a birthweight greater than 4000, greater than 
4500, or greater than 5000 g (Zhang et al. 2008). 
Common screening strategies for pre-natal outcomes include non-invasive tools 
such as ultrasonography and serum biomarker screening sometimes in 
combinations with invasive methods such as amniocentesis, for women at risk (>35 
years-old). For example, second-trimester measurements of α-fetoprotein, human 
chorionic gonadotropin (hCG), and estriol in maternal blood can help identify 60–
70% of cases of aneuploidy (abnormal number of chromosomes in a cell such as in 
Down syndrome). Novel tools to assess chromosomic disorders and alteration in 
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placentation might include analysis of fetal cell material in maternal blood (Fuks & 
Hsu, 2005). At the present time, no biomarkers were found clinically useful and 
urine biomarkers have remained largely unexplored (Conde-Agudelo et al. 2013). 
FGR can be classified into two types: asymmetric, which is the most common type, 
and symmetric. Asymmetric growth can take place if the fetus is subject to reduced 
oxygen or nutrient supply during the last trimester of pregnancy due to deficient 
vascular-placental functions. As a result body weight and sometimes length is 
reduced but the head circumference is maintained as normal. A symmetrical growth 
restriction consists of an equally distributed growth impairment of the head, weight 
and length occurring during early pregnancy (Wollmann 1998). FGR can have 
intrinsic origins stemming from fetal conditions such as genetic abnormalities or 
congenital infections. However, extrinsic aetiologies account for the majority of FGR 
cases including maternal and placental conditions. In fact, most of the pregnancy 
complications are believed to be the clinical manifestations of underlying placental 
ischemia (restriction of blood supply) and utero-placental deficiency (Ananth & 
Vintzileos 2006). The ischemic placental diseases comprise preeclampsia, FGR, 
placental abruption and fetal distress. In developing countries FGR is primarily the 
consequence of low energy intake associated with low BMI and low gestational 
weight gain. In contrast, in the developed world, FGR is prevalent among women 
with pregnancy-induced hypertension, smoking habits and poor nutritional status 
(Kramer 1987; Kramer 2003; McCowan & Horgan 2009). Recently published work 
has emphasised the importance of maternal diet, such as fruit intake and green 
leafy vegetable intake on the FGR incidence (Mitchell et al. 2004). It was also 
shown that the consumption of fish and the high adherence to a Mediterranean diet 
among women in the INMA cohort improved birth weight outcomes (Ramon et al. 
2009; Chatzi et al. 2012). In contrast, fetal macrosomia is strongly correlated to high 
maternal glucose levels and gestational diabetes (GDM) and often means that the 
delivery needs to occur through caesarean section.  
Advances in estimation of fetal adiposity via ultrasounds also allowed to better 
distinguish constitutional to pathological overgrown babies (Patrick M Catalano, 
Thomas, Huston-Presley, & Amini, 2003). Indeed fetal adiposity, which constitutes 
only 14% of birth weight, accounts for half of the weight variation observed across a 
population (Catalano et al. 1992). Animal studies also demonstrated that fat-free 
mass at birth displays high consistency across individuals (Catalano & Kirwan 
2001). Determinants of birth weight were shown to account for only 30% of the 
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population variation, and even less for fetal adiposity (17%) including maternal 
height, pre-gravid weight, weight gain during pregnancy, education, parity, paternal 
height and weight, neonatal sex, and gestational age.  
 Environmental determinants of abnormal fetal growth and long-term 1.1.5
consequences 
During prenatal and early postnatal life, i.e. during the time of cell differentiation and 
organ formation, the organism is highly sensitive to environmental constraints such 
as nutrients, environmental chemicals, drugs, infections and other stressors. This 
developmental period of plasticity may allow for adaptation to the changing 
environments in order to maintain or improve health and reproductive capability. 
However, this environment can also have adverse consequences on later life 
functions. The fetal origin of adult diseases is believed to play an important role in 
the progression of non-communicable diseases over the last 40 years such as 
cardio-vascular diseases, obesity and type 2 diabetes, dysfunctions of the 
reproductive, brain and the immune system; although, western lifestyle and genetic 
background are known to predispose to these diseases. However, the genetic 
component is believed to play only a small part, estimated to explain 20% of the 
variation observed in BMI, as based on a recent genome-wide study of 339,224 
individuals (Locke et al. 2015). In utero exposure to either toxic chemicals or to poor 
or over-nutrition can result in clinical manifestations, such as death, birth defects 
and low birth weight, or more subtle functional changes. Exposures to low doses of 
environmental chemicals during development, especially those with endocrine 
activity, can result in functional changes in gene expression, that have no phenotype 
at birth but that will lead to increased risk of disease and dysfunction later in life. 
This knowledge can have an impact on prenatal care, in the attempt to prevent 
perinatal outcomes, but also on the understanding and management of chronic 
diseases.  
Numerous European birth cohorts are currently set up to assess fetal and child 
development under environmental stressors (Vrijheid et al. 2011). More precisely 56 
pregnancy birth cohorts were set up since 1980 across 19 European countries with 
between 500 to 100,000 mother-child pairs recruited. The largest cohorts are 
present in Northern Europe. Noteworthy, the 1987 Finnish Birth Cohort which 
focused on the period from birth to adolescence and linked data for all births in 
Finland in 1987 (>60 000) to health registers and registers that provide information 
on induced abortions, criminality and state benefits. Most of these 56 cohorts 
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collected extensive data on maternal environmental exposure and on early-life 
developmental parameters, according to the CHICOS database project (Larsen et 
al. 2013).  
Evidence suggests that a number of environmental chemicals alter disease 
susceptibility as a result of pre-natal exposure. These include bisphenol A (from 
polycarbonate plastics), phthalates (softener in plastics) some organophosphate 
and organochlorine pesticides, nicotine (smoking), air pollution, mercury, 
perfluorooctanoic acids (stain and water repellents), and polybrominated diphenyl 
ethers (flame retardants) – all chemicals that are found in detectable concentrations 
in blood or urine samples from most people (CDC 2009). Adverse developmental 
effects from certain pollutants might be small, for instance drinking water 
contaminants, but the large number of women exposed means that the population 
attributable risk is potentially high and could be reduced by appropriate water 
treatment.  
The identification of environmental risk factors of FGR and early prognostic 
biomarkers (i.e. before clinical outcome manifests) would greatly improve obstetric 
counselling and decision making. 
 Metabolic Profiling 1.2
Metabolic profiling has great potential to serve environmental exposure sciences 
and pregnancy research as a tool to identify intermediate biomarkers linking 
exposure and outcomes. This original concept was defined previously as the ‘meet-
in-the-middle’ approach where preclinical biomarkers correlated to specific 
exposures in prospective studies could be elevated in cases and support the causal 
association between exposure and outcomes (Vineis & Perera 2007). Several 
studies served as a proof-of-concept where for instance, metabonomic signatures of 
colon cancer were related to dietary fibre intake in the EPIC study (Chadeau-Hyam 
et al. 2011).  
 General introduction to Metabolic Profiling/Metabonomics 1.2.1
Investigation of low molecular weight compounds (usually <1kDa in size), such as 
intermediate metabolites, hormones and other signalling molecules, as well as 
secondary metabolites including drug/toxicant metabolites provide information on 
the global perturbations of the organism. In fact, a pathophysiological process can 
1 . 2  M e t a b o l i c  P r o f i l i n g  | 35 
 
 35 
be mediated by interacting directly with genetic material and modifying gene 
expression or by interacting with proteins and perturb their activity. These 
perturbations can be measured by applying genomics or proteomics. However, a 
disease state is often the results of global perturbations of the organism, at multiple 
levels. Metabonomics, previously described as “the quantitative measurement of the 
dynamic multi-parametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification” (J K Nicholson, Lindon, & 
Holmes, 1999, page 1181), is able to measure the downstream products of 
transcriptional, posttranscriptional, translational, and posttranslational processes. 
Two approaches have been applied to measure metabolites: (1) the untargeted 
approach which aims to characterise in a comprehensive manner all the measurable 
identities in a sample including chemical unknown compounds and (2) the targeted 
approach which measures only a chemically defined group of metabolites with 
known identities that are hypothesised to be affected (lipids, bile acids, fatty acids, 
amino acids, etc…) (Want et al. 2010; Jäntti et al. 2013). High-throughput analytical 
instruments such as 1H nuclear magnetic resonance spectroscopy (NMR) or liquid 
chromatography coupled with mass spectrometry (LC-MS) have been used to 
simultaneously measure a broad range of metabolites (Bouatra et al. 2013; 
Psychogios et al. 2011). Thousands of metabolites have been well characterised 
and related to specific physiological factors and genetic status, which in turn may be 
linked to different lifestyle, environmental exposures, diet, diseases or interventions 
(Nicholson et al. 2011). 
 Applications of Metabolic Profiling 1.2.2
Metabolic profiling has been applied in various clinical settings, particularly recently 
in prenatal care, as well as in epidemiology of chronic diseases and environmental 
exposures which will all be discussed below. 
 Clinical research in prenatal care 1.2.2.1
Metabolic profiling applied to neonatal research has mainly emerged as a non-
targeted approach, to explore potential biomarkers of reproductive outcomes and 
identify underlying biological mechanisms. Human studies have focused on 
maternal plasma, amniotic fluid, urine and cervicovaginal excretions. Metabolic 
analyses of placenta and cord blood provided further information on the placental 
nutrient transfer especially of amino acids. Preeclampsia, which is characterized by 
high blood pressure and proteinuria, has been the main focus in metabolic profiling 
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applications to fetal-maternal research. Reports from Kenny et al. particularly 
focused on early prediction of late onset preeclampsia and was successful at 
identifying clinically relevant biomarkers (Kenny et al. 2010). Carnitines, amino acids 
(alanine, phenylalanine, glutamate and glycine), and increased total serum lipid 
content and low- and very-low density lipoproteins were highly predictive of 
preeclampsia, showing similarities with other cardio-vascular disorders. Graça et al. 
identified predictive metabolites of fetal malformations, gestational diabetes and 
preterm birth by applying both NMR and LC-MS to profile various biological samples 
such as maternal plasma, amniotic fluid and urine all in the 2nd trimester of 
pregnancy (Graca et al. 2009; Graca et al. 2010; Diaz et al. 2011; Graca et al. 
2012). The main findings suggest that fetal malformations, irrespective of the type of 
malformation, have the strongest impact on the amniotic fluid metabolome, while 
both preterm birth and fetal malformation cases displayed alterations in the 
placental transfer of amino acids. Women with malformed fetuses showed increased 
secretion of hypoxanthine, cis-acetonitate, acetone, stimulated gluconeogenesis 
pathways (amino acids involved in gluconeogenesis, Kreb’s cycle) possibly due to 
hypoxic metabolism (Diaz et al. 2011). Prediction of gestational diabetes (GDM) was 
also the subject of several reports where metabolic profiling was applied to study 
amniotic fluid. Disturbances in levels of lactate (increased) gluconeogenic amino 
acids and renal function related metabolites were observed (Fanos et al. 2013). 
Common metabolic signatures of prenatal outcomes, such as prediagnostic GDM, 
chromosomal disorders or preeclampsia, were found including  N-methyl-2-
pyridone-5-carboxamide and N-methylnicotinamide (products of abnormal 
nucleotide metabolism) most likely increasing due to the effects of stress (Diaz, 
Barros, Goodfellow, Duarte, Galhano, et al. 2013). 
Studies investigating fetal growth outcomes, including IUGR and fetal macrosomia, 
are sparser. A systematic search was conducted looking for studies published in 
peer-reviewed journals before June 2015 including “metabolic profiling”, 
“metabonomics”, “metabolomics” methods applied in humans during pregnancy only 
to assess “fetal growth”, “low birth weight“, “LBW”, “Intrauterine growth restriction”, 
“IUGR”, “birth weight” and is summarised in Table 1-1 (one study was added 
concerning pigs). Hogan et al. furnished a comprehensive work applying LC-MS 
based metabolic profiling in three different studies including in maternal plasma 
early in gestation and in venous cord plasma in association with SGA. The authors 
suggested a multifactorial origin of SGA and a potential for a pre-symptomatic 
screening test for SGA (Horgan et al. 2011). This study provided useful insights into 
1 . 2  M e t a b o l i c  P r o f i l i n g  | 37 
 
 37 
potential mechanisms of SGA across species, including general differential change 
in sphingolipids, phospholipids, carnitines and fatty acids. A general increase of 
these metabolites was measured in maternal plasma of SGA cases whereas they 
were decreased in cord blood, demonstrating a failure of the placenta to transfer 
essential nutrients to the fetus. However, the study size was limited and did not 
allow controlling for factors known to affect fetal growth such as gestational 
hypertension and smoking. Another study found similar metabolic signatures of poor 
pregnancy outcomes including SGA, preterm birth and neonatal intensive care 
admission in maternal serum in third trimester (Heazell et al. 2012). Mothers with 
poor pregnancy outcomes showed differences in plasma levels during the second 
trimester of pregnancy in lipids (sterols, glycerophospholipids, sphingolipids), steroid 
hormones (progesterone metabolites) and vitamin D metabolites compared to 
controls (n=40). Another recent study using LC-MS on maternal serum in early 
pregnancy (12-14th weeks) could predict the risk for birthweight >4000 g (n=20) but 
not LBW (n=19) (Ciborowski et al. 2014). Mechanistic insights were provided based 
on lower levels of phospholipids, lysophospholipids, and monoacylglycerols early in 
pregnancy in mothers with fetal macrosomia, suggesting an increased transport of 
lipids to the fetus (also supported by an indirect correlation between placental lipid 
transporters adipocyte fatty acid-binding protein (A-FABP) and maternal free lipids). 
These three studies were biased towards lipid species as a consequence of 
applying reversed-phase UPLC-MS, where the majority of polar species, including 
amino acids and organic acids, cannot be detected.  
To our knowledge, there is only one study reporting differences in maternal 1H NMR 
metabolic profiles from serum/plasma and urine where only 10 IUGR cases were 
available (Diaz, Barros, Goodfellow, Duarte, Galhano, et al. 2013). Another study 
analysed maternal blood and cord blood samples from very low birth weight infants 
by 1H NMR (n=8) and found metabolic signature of mothers delivering VLBW infants 
including decreased levels of acetate and increased levels of lipids, pyruvate, 
glutamine, valine and threonine (Tea et al. 2012) These studies highlighted potential 
differences in materno-fetal nutrient transfer using cord blood analysis and, 
probably, short-term changes associated with birth-related oxidative stress. 
Unfortunately, these studies showed a lack of consistent classification of SGA/IUGR 
and focus on single a disease. Indeed, Tea et al. (2012) compared mothers with 
VLBW infants to controls where 63% of the cases had hypertension in contrast to 0 
amongst controls. Besides IUGR, fetal macrosomia, defined as large for gestational 
age (LGA), was also the focus of a study using 1H NMR on first trimester maternal 
1 . 2  M e t a b o l i c  P r o f i l i n g  | 38 
 
 38 
urine in 50 participants (Walsh et al. 2014). They found that urinary metabolic 
profiles differed significantly according to fetal fat disposition in utero with increased 
levels of taurine, and histidine. The generalisability of the results is limited since only 
women with a previous uncomplicated delivery of an infant weighing >4,000 grams 
were included in the study.  
The principal limitation of all these studies is the small population size, with between 
5 to 60 subjects per group. This limits the transferability of the results to a general 
population with different ethnicities and/or diets. Small population size also did not 
allow targeting a single disease or a specific stage of disease. Indeed, clinical 
disparity between pregnancy outcomes such as FGR, preterm birth, pre-eclampsia 
and gestational diabetes should be recognised in studies applying metabolic 
profiling because of their different aetiologies (Fanos et al. 2013). In addition small 
sample size, prevented control for crucial confounding factors such as maternal 
smoking or maternal hypertension. Our recent work demonstrated the value of urine 
metabolomics in detecting early markers (approximately at 11 weeks) of preterm 
birth and FGR in a large nested case-control study with +400 participants (Maitre et 
al. 2014). We were able to distinguish between the metabolic signatures of 
‘medically indicated’/induced and ‘non-indicated’/spontaneous preterm birth, 
suggesting a range of aetiological metabolic factors contributing to preterm birth. We 
also showed specific urinary metabolic signatures of FGR associated with metabolic 
syndrome (i.e. decreased levels of tyrosine, acetate, trimethylamine and formate), 
improving our understanding of high BMI association with pregnancy outcomes. 
Metabolomics was proven useful also in neonatal medicine, although in small 
studies, with the ability to further understanding of pre-natal life, IUGR outcomes 
and subsequent development of metabolic diseases.  
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Table 1-1. Published work using metabonomics in human pregnancy research (fetal growth outcomes) in a hypothesis-generating approach 





Main findings Ref. 
Venous cord 
plasma (1), 
plasma from rat 




(1) case-control study 
(n=8/6) 
(2) Reduce uterine 
perfusion pressure rat 
model (n=23) 
(3) nested case-control 
study (n=40/40) 
LC-MS 
(1) within 20 
min after 
delivery (2) 





• Carnitine ↓ in (1) ↑ in (2) suggest a 
reduced activity of fatty acid oxidation at 
placental level 
• 19 metabolites signature of SGA across all 
3 studies (among them: sphingolipids and 
phospholipids) 
(Horgan et al. 
2011) 
Plasma SGA 
60 primigravid women 
who delivered a SGA 
baby within the SCOPE 
study and matched to 60 
controls 
LC-MS ~15 weeks 









Case-control study with 
40 controls and 40 
matched cases 
LC-MS 3rd trimester 
98 features significantly different including 
glyceroplipids, glycerophospholipids, fatty 
and organic acids, sterol lipids, 
progesterone hormone metabolites and 
vitamin D metabolites. 







FM n=35 vs controls=84; 
CD n=33; PB n=26; GDM 





VIP variable selection methods selected for 
IUGR: decreased amino acids (alanine, 
glycine, leucine, lysine, threonine and 
tyrosine), creatinine, 3-hydroisovalerate, 
choline, succinate and increased 4-
deoxyerythronic acid, trigonelline among 




Galhano, et al. 
2013) 






fold, birth weight, 
cord-C peptide) 






Mothers with GDM had ↑triglycerides, 3-
hydroxybutyrate, amino acids such as 
alanine, proline and BCAA - ↓ 1,5-
anhydrogluticol 
↑sum of skinfolds triglycerides, 
leucine/isoleucine and arginine 


















In the umbilical vein plasma of IUGR fetuses 
-reduced dodecanoylcarnitine,TG, and 
VLDL-C but elevated levels of carnitine, 
HDL-C, LDL-C, and TC 
- decreased glucose  
-decline in arginine, glutamine, and 
dodecanoylcarnitine but an increase in 5-
oxoproline between d 90 and 110 of 
gestation.  
- On day 90, concentrations of 2 aromatic 
amino acids [phenylalanine and tyrosine ], 3 
BCAA [valine ,leucine, and isoleucine ], and 
proline 
(Lin et al. 
2012) 
- Umbilical cord 
vein 




Very LBW and PB 
7 VLBW (GA<32 weeks 




-Increased butyryl-, isovaleryl-, hexanoyl- 
and octanoyl-carnitine in VLBW group 
-decrease in glutamine-glutamate in 
preterm arterial cord blood beside lower 
levels of amino acid precursors of Krebs 
cycle  
- Enhanced glutathione utilization is likely to 
account for the decrease in precursor amino 
acids (serine, betaine, glutamate and 
methionine) 
- increase in diacetylspermine and 
acetylputrescine (polyamines in their 
acetylated form) 
(Alexandre-
Gouabau et al. 
2013) 





measured with 34th 
week ultrasounds 
and at birth, insulin 
resistance 
50 women, second 
gravid, having 
uncomplicated history 
with infant >4000g 
NMR 13.2 weeks 
Significant association between urinary 
metabolites and fetal adiposity and maternal 
insulin resistance (within normal range, no 
gestational diabetes). 
Taurine, histidine and malonate increased 
wih increased adiposity. 








study: infant birth weight 
as follows: low, <2500 g; 
normal (n=19), 2500-






Lower levels of phospholipids, 
lysophospholipids, and monoacylglycerols; 
low vitamin D3 metabolites; and increased 
bilirubin level were associated with 
macrosomia.  
No significant association with LBW 
(Ciborowski et 
al. 2014) 
Abbreviations: IUGR, intrauterine growth restriction, GDM, gestational diabetes, LC-MS, liquid chromatography couple to mass spectrometry, 
LBW, low birth weight, NMR, nuclear magnetic resonnance,PB, preterm birth, SGA, small for gestational age, VLBW, very low birth weight 
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 Metabonomics application in Epidemiology of chronic diseases 1.2.2.2
Complexity in chronic disease risk factors cannot only be explained by genetic 
programming or single environmental exposure. Most chronic diseases are the 
results of gene-environment interactions operating at a population level and at the 
individual level. Application of metabonomics to investigate the source of phenotypic 
variations and chronic disease risk factors in large scale cohorts allow to 
simultaneously capture these levels of complexity. Metabolome-wide association 
studies (MWASs) have emerged as top-down approaches where metabolic 
phenotypes (the endpoint of physiological changes) are used to explore systematic 
statistical associations with disease risk factors, in order to generate hypotheses on 
disease aetiology and further test them in more controlled systems (cell assays, 
animal models or interventional studies) (Chadeau-Hyam et al. 2010; Nicholson et 
al. 2008). Concerns were raised on the clinically predictive potential of metabolic 
profiles because of its high temporal variability. However, it was shown that 60% 
(plasma) and 47% (urine) of biological variation in 1H NMR-detectable metabolite 
concentrations was stable and representative of familial and individual-
environmental factors (Nicholson et al. 2011). Other recent studies confirmed that 
the stable component of inter-individual variation or intraclass correlation (ICC), over 
a 4-month to a year interval was between 0.43 to 0.57 ((Sampson et al. 2013; 
Froese et al. 2002)). 
Modern epidemiological studies often include the collection of blood and urine 
samples, which are rich in a wide range of metabolites such as lipids, amino acids, 
small proteins, bile acids and other intermediate metabolites. Blood specimens 
represent a ‘snapshot’ of the global metabolism at the time of collection but can offer 
limited information on inter-individual metabolic variation since its metabolite content 
is under tight homeostatic control. In comparison, urine collection is non-invasive 
and more cost-effective and might be preferred in certain population (e.g. mother-
child cohort). Urine specimens supply a time-averaged view of the global 
metabolism including end-products of endogenous and exogenous metabolism. 
Additional non-invasive biological samples might be available such as hair, nails, 
saliva or placenta in prospective studies although their collection, storage and 
analytical procedures are less established when compared to urine and blood.  
Metabolic profiling and multivariate statistical modelling approaches have 
successfully been applied to large-scale epidemiological studies of chronic 
diseases, for example, in the metabolome wide association study (MWAS) of the 
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INTERMAP cohort (Holmes et al. 2008). This prospective study assessed the 
association between blood pressure and lifestyle factors by obtaining the metabolic 
phenotype of 4,630 people in 17 different population samples from China, Japan, 
United Kingdom and the United States. More than 10 biomarkers were discovered 
for blood pressure, related to diet, gut microbiota, drug use and host genetic 
influences. More recently, urinary metabolic signatures of BMI were found in the 
INTERMAP study (Elliott et al. 2015).  Metabolic profiles (LC-MS) can also predict 
the development of type 2 diabetes as shown in the Framingham Heart Study (T. J. 
Wang et al. 2011). A combination of three amino acids gave a >5-fold higher risk for 
individuals in top quartile, which included the branched-chain and aromatic amino 
acids isoleucine, leucine, valine, tyrosine, and phenylalanine. These findings were 
validated in multiple studies subsequently (Adams 2011). 
Other important metabonomic studies investigated successfully aging or all-cause 
mortality. The UK twin study applied to 6055 individuals found 22 metabolites which 
combined are strongly correlated with age (R2 = 59%) and with age-related clinical 
traits independently of age (Menni et al. 2013). This study also identified some key 
molecular mechanisms based on linkage of metabolic profiles with epigenome-wide 
association study that produce long-term physiological changes influencing human 
health and ageing. Another study identified four serum biomarkers by NMR 
metabolic profiling (blood—alpha-1-acid glycoprotein, albumin, VLDL particle size, 
and citrate) that could predict all-cause mortality within five years in an observational 
study of 17,345 persons (Fischer et al. 2014).  
Metabolic profiling applications were also proven useful in nutritional epidemiology. 
This approach often strengthen traditional self-reported dietary assessment 
methods that are subject to recall bias and measurement error and can offer 
mechanistic insights (Guertin et al. 2014). From a public health perspective 
metabonomics can help in identifying modifiable risk factors that contribute to 
changes in metabolite concentrations related to disease risk. Convincing evidence 
are coming from reports based on the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study conducted in 10 European countries to 
investigate the relationship between diet and risk of cancer. Meat intake and butter 
intake both found direct biomarker related to colon cancer risk (Floegel et al. 2013). 
However, the mean proportion of variation of serum metabolites (by LC-MS, 
Biocrates) that was explained by habitual diet was small, ranging from 3.6% for 
amino acids to 7.7% for a choline-containing phospholipid. Interventional nutritional 
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studies offered great validation using metabonomics to find intermediate pathways 
explaining dietary related cancer risks. This is best illustrated by the recent 2-week 
food exchange study in subjects from the same populations, where African 
Americans were fed a high-fibre, low-fat African-style diet and rural Africans a high-
fat, low-fibre western-style diet (O’Keefe et al. 2015). The food changes resulted in 
remarkable reciprocal changes in mucosal biomarkers of colon cancer risk and 
offered insights in aspects of the microbiota and metabolome known to affect cancer 
risk.  
 Applications in Environmental research 1.2.3
Environmental exposures are believed to account for about half of the 50 million 
global deaths in 2010 (chronic-disease mortality) based on data from the World 
Health Organization (Lim et al. 2012). A small set of exposures dominated including 
particulate air pollution (combined effects of ambient particles and household 
smoke), smoking (active and passive), and diet and half were unknowns. Hence, 
there is a growing interest into applying metabolic profiling to environmental 
epidemiology to understand and discover the unknown component of our exposome 
(Wild 2012). This field aims at (1) finding subtle metabolic disturbances resulting 
from chronic low-level exposure to multiple pollutants and (2) at finding novel 
biomarkers of exposure improving exposure assessment and classification. Only a 
few studies explored this field of research because metabolic changes expected 
with low-dose environmental exposures are believed to be minor in comparison with 
inter-individual variability that can be observed in a human population. As shown 
recently based on a comprehensive database/literature search, the blood 
metabolome may contain more exogenous metabolites arising from drugs, 
pollutants, diet-related compounds but a great dynamic range exits and pollutants 
were found to be 1000 times lower in concentrations than the rest of the 
endogenous metabolites, food chemicals and drugs (Rappaport et al. 2014). Until 
recently, one of the barriers in applying metabolic profiling to environmental 
epidemiology up to recently was the unavoidable instrumental drift when analysing 
samples from large cohorts as well as requiring wide metabolome coverage 
(problems with untargeted LC-MS methods). An untargeted LC-HRMS approach 
was applied in a small population of pregnant mothers (n=40) living in a French 
agricultural area (Brittany) as a proof of concept and found evidence of urinary 
metabolites resulting from exposure to pesticides (Jamin et al. 2014). Among 47 
pesticides initially selected for data mining, only two (azoxystrobin and 
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fenpropimorph) were found to discriminate among the sub-populations according to 
their levels of environmental exposure. 1H NMR based profiling was applied in the 
same population (n=83, 3 groups according to the surface of land dedicated to 
agricultural cereal activities in their town of residence) and urinary metabolites were 
found to discriminate the most exposed women (Bonvallot et al. 2013).  
 Conclusions on applications of Metabolic Profiling 1.2.4
Metabolic Profiling in the context of general human population, in contrast to 
controlled animal studies, can offer great insights into the actual impact of the 
environment and lifestyle on disease risks taking into account genetic and medical 
history diversity. Previous studies described above showed that although a 
reasonably high proportion of metabolites are associated with temporal variability, 
age, fasting status, and gender, disease risks and exposure stratification can still be 
distinguished within specific cohorts as proven by the plethora of markers found. 
Similarly, metabolic profiles can still be useful even when epidemiologic studies did 
not impose dietary restrictions (e.g., fasting) before blood drawn or urine collected. 
These biaises only slightly hinder detectable relative risks using biomarkers, and 
with still allow biomarkers to have far less measurement error than with standard 
epidemiologic questionnaires. 
Several limitations were identified in the literature in particular the presence of false-
positive findings in association studies that use data derived from high-throughput 
omics technologies. This was partially overcome by replicating the results in at least 
two independent cohorts and/or by validating the results in interventional studies or 
in animal experiments (Z. Wang et al. 2011). Another issue arise from the different 
analytical platforms (NMR, LC-MS, GC-MS, CE-MS, etc…), and even within the 
same platforms different protocols are used to identify and quantify (or semi-
quantify) metabolites, which make data harmonization difficult, though not 
impossible. 
 Example of an ubiquitous environmental exposure: the water 1.3
disinfection-by-products 
Most of the population is exposed to water disinfection-by-products (DBPs) which 
have been the subject of numerous toxicological and epidemiological studies. 
Exposure assessment tools to accurately quantify this exposure in large population 
and relate it to health outcomes are reviewed below. 
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 Formation of DBPs   1.3.1
Chlorine addition to drinking water prevents microbial contamination and its use 
since the 1900’s has considerably reduced waterborne disease progression (such 
as cholera and typhoid). In 1974, this disinfectant was also revealed to produce 
by-products by reacting with natural organic matter such as fulvic and humic acids 
that are primarily present in the surface water (water from lakes or rivers) (Rook 
1974). The presence and relative levels of DBPs depend on many factors varying 
seasonally and geographically relating to the quality of raw water, its origin, the 
conditions during chlorination treatment and its distribution (Bougeard 2009). Up to 
600 DBPs have been identified, differing in considerably in their physico-chemical 
proprieties (Richardson 1998; Richardson & Postigo 2012). The most prevalent 
classes are the volatile trihalomethanes (THMs), the non-volatile haloacetic acids 
(HAAs) as well as other halogenated and non-halogenated compounds. The HAAs 
include chlorinated species: trichloroacetic acid (TCAA) or dichloroacetic acid 
(DCAA) and the less abundant brominated species: mono-, di- and tri-bromoacetic 
acids. There are four species of THMs: chloroform, bromodichloromethane (BDCM), 
chlorodibromomethane (CDBM) and bromoform, the sum of which is referred to as 
total THM (THMs). In 1976, a National Cancer Institute study was released in which 
chloroform was classified as a suspected human carcinogen (NCI 1976). Since 
then, toxicological studies on laboratory animals and epidemiological studies have 
identified cancer and reproductive outcomes associated with different types of DBPs 
(Nieuwenhuijsen 2000). Regulations on maximum contaminant levels were 
established by the US Environmental Protection Agency (EPA) in 1998 following a 
report on human carcinogenicity of chlorinated DBPs (Agency 1998).  
 Toxicological evidence   1.3.2
Initial toxicological studies on health effect of DBPs linked THM exposure to cancers 
of the colon and the kidneys (Boorman 1999; Bull et al. 2002), whereas HAAs were 
associated with liver tumours (Bull et al. 1990). More recently, the research interest 
has focused on reproductive effects of DBPs (Nieuwenhuijsen et al. 2000). 
Reduction of body weight and survival in the offspring was observed after treatment 
with chloroform and several HAA and HAN (Graves et al. 2001; Tardiff et al. 2006; 
Christian et al. 2001). For instance two studies of DCAA and TCAA toxicity in rats 
resulted in reduced fetal growth as measured by birth weight and length, as well as 
fetal resorption and cardiovascular malformations (Smith et al. 1992; Smith et al. 
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1989). Despite a dose-response relationship reported in these toxicological studies, 
there are a number of issues which make it difficult to interpret the toxicological 
evidence and to translate to humans. Indeed, among the studies on DBPs’ effects 
on reproductive outcomes, the lowest-observable-effect level usually observed for 
developmental outcomes in rats is superior to 50 mg/kg (approximately 5000- to 
10,000-fold greater than the doses that would be consumed by humans drinking 
highly contaminated water) (Christian et al. 2001; Narotsky et al. 1997; Christian, 
York, Hoberman, Fisher, et al. 2002; Christian, York, Hoberman, Frazee, et al. 
2002). Furthermore, animal studies commonly assessed the toxic effects of one 
compound at a time and at high concentrations which produce obvious treatment-
related maternal adverse effects. A major problem for the translation of animal 
toxicological studies to humans is often the lack of consideration to mixture effects. 
Only a very small portion of DBPs are studied in animals or even regulated in 
drinking water. One important study by the U.S. Environmental Protection Agency 
(EPA) considered this issue by treating rats with concentrated chlorinated water 
(~130-fold) originating from treated surface water, in Ohio, which represented a 
complex whole-mixture of DBPs. No maternal toxicity in rats was observed, only a 
reduced gestational length was apparent in the ozonation/post-chlorination water 
group (Narotsky et al. 2008). In conclusion, toxicological results have been 
inconsistent and tend to be associated with high dose maternal toxicity. 
 Epidemiological evidence 1.3.3
Most of the population is exposed to DBPs by not only ingestion (the most studied), 
but also via inhalation and dermal contact to volatiles DBPs. A Spanish cohort 
determined a link between uptake of DBPs during showering, bathing and swimming 
and urinary bladder cancer (Villanueva et al. 2004). Evidences of cancer risk 
associated with DBPs exposure were reported mainly for bladder cancer and were 
much weaker for other cancers such as colorectal cancers (Nieuwenhuijsen et al. 
2009).  
Public health research has focused on the THMs as they are the only currently 
regulated DBPs in the UK with the maximum allowance level for total THMs set at 
100 µg/L. Even though THMs represent the largest proportion of DBPs in public 
drinking waters in the UK, there is current interest in HAA concentrations since the 
European Union’s Drinking Water Directive is currently considering a revision to 
include the regulation of the sum of the nine bromine- and chlorine-containing 
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species (HAA9) at 80 µg/L (DHI 2008). These compounds are already regulated in 
the USA. Various reviews and meta-analyses of the reproductive effects of DBPs 
have concluded that findings to date are inconsistent, suggesting that the actual 
risk, if any, would be small (Nieuwenhuijsen 2000; Tardiff et al. 2006; 
Nieuwenhuijsen et al. 2009; Grellier et al. 2010). Prenatal exposure to total THMs 
was studied in association with mainly fetal growth outcomes using as a surrogate 
LBW, SGA or IUGR, as well as congenital anomalies, still birth, spontaneous 
abortion, preterm birth (PB) and semen quality. A recent meta-analysis concluded 
from 37 epidemiological studies that THM exposure was not associated with LBW, 
PB, and only some evidence was found for SGA (meta-odds ratio per 10 µg/L of 
total THMs equal to 1.01, [1.00-1.02]) (Grellier et al. 2010). Interestingly, it was 
observed that neonates with a metabolic polymorphism of the CYP2E1 have a 
higher risk of IUGR when exposed to THMs (Infante-Rivard 2004). Different types of 
exposure assessment have been used, including studies which used as exposure 
indices, only water source and treatment, or routinely measured total THMs at a 
water-zone level with or without personal water consumption information, or 
individual THMs. The most recent studies preferred a personal exposure matrix 
where individual DPBs where measured at the water supply or at the residence and 
integrated personal characteristics such as showering/bathing timing, qualitative and 
quantitative water consumption. Only a few studies included in their analyses 
measures of HAAs in association with reproductive outcomes with inconsistent 
findings.  Three of them found a significant, but small, increased risk of fetal growth 
outcomes (IUGR and/or LBW or SGA) when prenatal exposure occur in third 
trimester for five HAAs, TCAA or DCAA (Hinckley et al. 2005; Porter et al. 2005; 
Levallois et al. 2012). Levallois et al. recently reported a monotonic dose-response 
association between HAAs and IUGR and an increased risk for IUGR during third 
trimester in the highest concentration quartile of THM and HAA (HAA5, OR = 1.4 
[95% CI   1.0 –1.8]) (Levallois et al. 2012). However, other studies did not find 
significant associations between HAA exposure and fetal growth outcomes maybe 
owing to limitations in their exposure assessment (Wright et al. 2003; Hoffman et al. 
2008; Horton et al. 2011). Few studies considered the actual personal exposure to 
DBPs by calculating the volume of ingested chlorinated water (Hoffman et al. 2008; 
Savitz et al. 2005). Only one study addressed multiple-routes of exposure with a 
pharmacokinetic model developed to predict the absorbed dose based on the 
physiological characteristics of the subjects (Levallois et al. 2012). Studies on 
preterm birth generally show no significant association with HAA exposure (Wright 
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et al. 2004; Hoffman et al. 2008; Horton et al. 2011). Studies addressing 
reproductive outcomes and including bio-monitoring of HAAs are discussed further 
below. 
 DBP exposure: biological monitoring  1.3.4
A promising complementary approach to semi-individual exposure metrics is the 
measurement of internal uptake or dose of specific DBPs via biomarker assays. 
Initial work form Weisel et al. focused on bio-monitoring of THMs and HAAs (Weisel 
et al. 1999). They could detect THMs in exhaled breath of individuals just after 
exposure through showering (dermal and inhalation exposure) which correlated to 
THM water levels but could not detect it in background exhaled breath samples. 
THMs are rapidly metabolized and eliminated in the body after uptake at 
environmental concentrations, thus it is inappropriate to profile THM measurements 
over a time-scale of multiple hours since exposure. Blood chloroform was also 
measured but this invasive procedure would be inappropriate in a large cohort and 
the compound half-life has also shown to be short (Ashley et al. 1994). Two 
biomarkers of HAA exposure, the TCAA and DCAA, were explored in blood and 
urine. Since HAAs are non-volatiles the major route of exposure is through oral 
ingestion. Dermal absorption of TCAA via bathing was only responsible for 0.005-
0.5% of the daily TCAA ingestion (Xu et al. 2002). An exhaustive systematic search 
was conducted looking for studies published in peer-reviewed journals before June 
2015 including monitoring of “trichloroacetic acid”, “TCAA” in urine specimen 
collected form humans. Initial studies validated the use of TCAA as a marker of HAA 
exposure with a significant correlation between urinary TCAA and estimated 
ingested TCAA (Weisel et al. 1999; Kim et al. 1999). Following studies confirmed 
the need to consider water consumption (volume, use of filter and type of beverage) 
to obtain a significant correlation between urinary TCAA and water THM or TCAA 
levels (Kim et al. 1999; Costet et al. 2012; Smith 2011). DCAA was found to be 
rapidly metabolised and that urine concentrations were similar between high and 
low HAA exposed groups. Consequently, TCAA has been validated as a biomarker 
of medium term ingestion exposure to HAA with a urinary elimination half-life of 2 to 
6 days (Froese et al. 2002; Bader et al. 2004). Urinary TCAA monitoring was 
employed in nine different studies on DBPs exposure situated mainly in US, 
Australia and Western Europe (see Table 1-2). For the majority, TCAA levels were 
measured in the drinking water and in the first morning urine. First morning urine 
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was preferred over spot urine, or time-of-visit urine, since it ensures a more constant 
time interval between an exposure and the sample collection as well as, it accounts 
for diurnal variation and preceding meals effects (Kim et al. 1999).  
It is only very recently that researchers have started to investigate biomarkers of 
DBP exposure in association with adverse birth outcomes in relatively large 
pregnant populations (Costet et al. 2012; Zhou et al. 2012). TCAA bio-monitoring 
was used in a French prospective birth cohort (PELAGIE cohort), to complement 
THM concentrations in water, primarily to identify occupational exposures to 
chlorinated solvents among pregnant women (Costet et al. 2012). They observed a 
higher risk of FGR for women with TCAA detected in their urine than women with 
TCAA levels below the analytical detection limit. The main limitation of this study 
was the high limit of detection (>0.01 mg/L) which allowed the TCAA detection of 
only 6.7% of the participants. A survey of a Chinese population demonstrated a 
decrease in the birth weight means of the participants in the third and top quartile of 
urinary TCAA levels (Zhou et al. 2012). Taken together these studies indicate that 
urinary TCAA might be correlated with a higher risk of fetal growth outcomes, 
although further studies with more detailed exposure data on DBP levels and other 
chemicals metabolised into TCAA present in chlorinated household products would 
be crucial to identify the responsible agents for such associations. In addition, the 
surveyed population with available urinary TCAA values was relatively small (n<360) 
and recruited in a limited number of areas with potentially small variation in DBP 
exposure levels. 
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max., 123.3 µg/L Cr 
(creatinine adjusted) 
mean, 7.7 µg/L; max., 
57.7 µg/L 




Abbreviations: FMU, First Morning Urine; NA, not available 
TCAA absorption, distribution, metabolism and excretion are critical information to 
understand the relationship between drinking water DBPs’ levels, inter-individual 
variability and urinary TCAA levels. TCAA from drinking water is believed to follow a 
dose-dependent absorption with a reduced absorption at higher doses (Chiu 2011). 
Once in the blood TCAA highly binds to plasma proteins with ~80% of bound 
fraction (Lumpkin et al. 2003). TCAA is largely (93%) eliminated unchanged through 
urine excretion. Only a small portion of TCAA (~10%) is metabolised to DCAA, CO2, 
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glyoxylic acid, oxalic acid and glycolic acid (Cancer 2004). Urinary TCAA can be the 
result of other chemical exposures than chlorinated water such as chlorinated 
cleaning agents or medication. Chlorinated solvents, containing trichloroethylene or 
tetrachloroethylene (also called perchloroethylene), can be used in dry cleaning 
agents, paintings or metal degreasing methods in industries (Cancer) 1997). These 
chemicals share common metabolites including TCAA and DCAA. Therefore, 
information collected via questionnaires on occupation and chemical exposure 
associated with chlorinated agents should be analysed to explore any confounding 
effects on the relation of urinary TCAA concentration to chlorinated water ingestion. 
Some medications including anxiolytics and hypnotics can contain chloral hydrate 
and be metabolised to TCAA (Cancer) 2004).  
The mode of action of DBP exposure in utero remains unclear. DCAA and TCAA 
might interfere with folate metabolism by inhibiting the vitamin B12-dependant 
methionine synthesis (Dow & Green 2000). Folate one-carbon metabolism is 
essential to nucleotide synthesis, cell proliferation and methylation reactions, which 
are all vital processes during fetal growth. In addition, TCAA and DCAA were found 
to induce lipid peroxidation in mouse and rat livers in vivo (Larson & Bull 1992). It 
has been hypothesised that these chemical species affect fetal development by 
inducing maternal oxidative stress (Nieuwenhuijsen et al. 2009).  
 Current gaps in literature and objectives of this thesis 1.4
The lack of understanding regarding aetiologies and risk factors of fetal growth 
outcomes was evidenced from the literature review. Placental dysfunction was 
recognised as one of the main mechanism behind FGR, whereas maternal 
metabolic dysfunction, such impaired glucose tolerance or hypertension, might be at 
the origin of fetal macrosomia. Therefore, the first trimester of pregnancy is a critical 
period for fetal growth prognostic because that is the time when placental 
vascularisation takes place via trophoblast and cytotrophoblast proliferation which is 
critical for an appropriate supply in nutrient and oxygen to the fetus for optimal 
growth. The third trimester of pregnancy is also a pertinent time window to study risk 
factors for fetal growth outcomes since this period is characterized by rapid fetal 
growth and important maternal metabolic adaptation (Hinckley, Bachand & Reif, 
2005, Owen et al., 1996). Metabolic profiling has a great potential to serve pre-natal 
research and identify prognostics and diagnostics biomarkers for non-invasive 
monitoring of pregnancies. However, research has suffered from the lack of multiple 
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time point collections throughout pregnancy to establish the standard for metabolic 
profiles associated with healthy pregnancy progression and its association with 
normal fetal growth. Once the norm is established, anomalies can be sought.  It is 
only in the past few years that the first research was published on changes in 
healthy pregnancy metabolic profiles (Pinto et al. 2014; Diaz, Barros, Goodfellow, 
Duarte, Carreira, et al. 2013; Sachse et al. 2012). These NMR-based metabolic 
profiling studies suffered from the lack of characterisation of pregnancy-related 
metabolites. Previous metabolic profiling applications also lacked replications and 
applications in large cohorts to find meaningful biomarkers for use in clinical 
settings. 
Chapter 4 of this thesis will present results to characterise the urine metabolome 
during pregnancy in the first trimester, at the time of placental development, and in 
the third trimester when most fetal growth occurs. Samples from two large 
independent cohorts will be analysed, as part of the INMA study (Spain, n=806 and 
886 for the 12th and 34th weeks), using an untargeted 1H NMR metabolic profiling 
approach. This should enable the semi-quantification of major urinary metabolites 
for use in the next stage of the analysis with fetal growth outcomes. The specific 
objectives were the following: 
a. To identify the main variation in the urine metabolome of this 
pregnant population which is attributable to the time of sampling 
during pregnancy (12th and 34th weeks of gestation). 
b. To assess the analytical stability of the NMR dataset. 
c. To assign novel urinary metabolites of pregnant women, in particular 
associated with the stage of pregnancy, using a multi-analytical 
platform. 
Little evidence on metabonomic signatures of abnormal fetal growth outcomes was 
found. This might be partially due to issues with outcome definition. There may be 
more potential of using in utero fetal growth instead of birthweight classifications. 
Assessing the relationship between maternal metabolic profiles and fetal biometrics, 
may aid in better understanding the mechanism by which maternal metabolism 
impacts growth and in identifying timeframes for interventions. Previous metabolic 
profiling applications and intrauterine fetal growth studies have been limited by small 
sample sizes and did not examine the changing dynamics between metabolic 
profiles and fetal growth across gestation. 
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Chapter 5 of this thesis will provide in-depth insights based on an epidemiological 
analysis of the association between NMR spectroscopic based maternal metabolic 
profiles with fetal growth outcomes using continuous longitudinal measures of fetal 
growth in utero and at birth.   
In addition, to improve understanding of the determinants of fetal growth outcomes, 
mediating factors, such as maternal lifestyle factors, should be considered in the 
associations between excreted metabolites and outcomes. Therefore, Chapter 6 of 
this thesis will present associations between metabolic signatures of fetal growth 
and maternal lifestyle, clinical parameters and nutrient intake. 
Finally, environmental exposure assessments are lacking in large cohorts of women 
during gestation, which is believed to be the most sensitive window during 
development. Most prior studies looking at exposure during pregnancy used crude 
exposure assessment (Bonvallot et al. 2013) and underused biomonitoring 
assessments. This is particularly true for water DBP research where inconsistent 
findings are believed to arise from exposure misclassification. A recent review on 
ongoing pregnancy-birth cohort in the EU illustrated that water contaminants 
received least attention among all other environmental risk factors considered 
(Makris & Andra 2014). 
Chapter 7 of this thesis will accurately quantify the exposure to adverse chemicals 
during pregnancy, specifically exposure to water DBPs (TCAA), from ingestion of 
chlorinated tap using urinary biomarker. 
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 Methodology and theory Chapter 2 
This chapter summarises the methodology employed in this thesis. Since the 
science and methods used originate from many disciplines such as epidemiology, 
analytical chemistry, statistics and clinical medicine, the basic concepts behind each 
of them are only described briefly. First, I describe the background of the mother-
child cohort used, the INMA study, in terms of the population recruitment, the type of 
data collected and the data and samples available for this PhD. Second, I describe 
the methods which correspond to the three main analyses. I provide the methods 
used for the metabonomic analysis of the urine samples from pregnant women 
(study 1), where I elaborate on the cohort study design, quality control strategy and 
the two analytical platforms (NMR and LC-MS) used to acquire the profile data and 
for metabolite identification. I also present the bioinformatics tools used for NMR 
data processing and multivariate data analysis. I then describe how the 
metabonomic data produced were incorporated in an epidemiological analysis 
(study 2). I define the fetal growth outcomes and confounders included in this 
analysis, the covariates used in a secondary analysis and the statistical methods. 
Finally, I explain the methods employed in a separate study of the TCAA exposure 
monitoring in urine from pregnant women (study 3) where I had recourse to a nested 
case-control study design and laboratory quantitative analysis using LC-MS/MS. 
 INMA cohort 2.1
This section describes the background of the study population: the INMA cohort.  
 Cohort Background: The INMA—INfancia y Medio Ambiente—2.1.1
(Environment and Childhood) Project 
The INMA [Infancia y Medio Ambiente (Environment and Childhood)] Project is a 
network of mother-child hospital-based cohort studies based in seven different 
Spanish cities. All these cohorts had the same aim, to study the role of 
environmental pollutants in air, water and diet during pregnancy and childhood in 
relation to child growth and development, from the fetal early stages to the 
adolescence. The first cohorts from Ribera d’Ebre (n = 102), from Menorca (n = 530) 
and from Granada (n = 668) recruited pregnant mothers between 1997 and 2002. 
New cohorts of pregnant women were designed between 2004-2008 in Valencia 
(n = 855), Sabadell (n = 657), Asturias (n = 494) and Gipuzkoa (n = 638) following a 
common protocol based on the experience from the existing cohorts (Ribas-Fito et 
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al. 2006). The eligibility criteria for enrolment were: an agreement to give birth at the 
study hospitals, the ability to communicate in at least one of the official languages, 
maternal age over 16 years, singleton pregnancy and not having followed an 
assisted reproduction program. The study subjects were excluded in case of 
miscarriage, fetal death, and those who withdrew or were lost (Guxens et al. 2011). 
Cohort participants were representative of the target population in terms of prenatal 
care attendance in the public health system (used by > 80% of the pregnant 
women). However, the educational level of the study participants was higher than 
the target population. 
In the four new cohorts, mothers were recruited in the first trimester of pregnancy 
and were followed up by surveys and sample collection during the third trimester. 
Information on the newborn and children were collected at birth, at 6 months (only 
for Sabadell and Asturias), at 1-1.5 years, at 2–2.5 years (except for Asturias), at 4–
5 years, at 6-7 years and 9-10 years (currently on-going, only in Sabadell and 
Valencia). Data were collected on the participants from various sources such as ad 
hoc administered questionnaires in face-to-face interviews conducted by trained 
INMA personnel, clinical data, physical examinations, ultrasound scans, biological 
samples (blood, urine, placenta, breast milk, saliva, hair and nails), biomarkers, 
cognitive and behavioural measurements, diet determinants and environmental 
measurements (air pollution, water pollution and persistent and semi-persistent 
pollutants). However, the data availability varied slightly between the cohorts 
depending on internal interest (e.g. specific environmental exposures). 
The INMA project was approved by the Ethical Committees of the participating 
centres, and all subjects gave written consent at enrolment and again after delivery 
of their babies.  
 Data and samples available for this PhD 2.1.2
The original main focus of my PhD was to accurately assess DBP exposure, to 
HAAs in particular, during pregnancy and to explore possible associations with birth 
outcomes, such as FGR. In addition, the PhD aimed to explore the global metabolic 
profiles of pregnant women who had been exposed to DBPs in order to provide 
insight on the underlying role of environmental exposures in the aetiology of birth 
outcomes. Therefore, additional criteria related to my PhD aims had to be applied to 
select the appropriate participants based on cohort characteristics and to select the 
appropriate sample type for NMR metabolic profiling and TCAA monitoring. 
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Decisions on sample size were also made for financial and logistical reasons. In 
addition, criteria based on my PhD aims were applied to select a subset from the 
plethora of epidemiological data collected through the INMA study. 
 Participant and biological sample selection 2.1.2.1
Among the seven cohorts in the INMA study, two cohorts were selected for this 
PhD: the Gipuzkoa cohort from the Atlantic area (Basque Country) and the Sabadell 
cohort from the Mediterranean area (Catalonia) as shown in Figure 2-1. They were 
both part of the second generation of INMA cohorts where urine and blood samples 
from pregnant women at week 12 and 34 of gestation were collected from July 2004 
to July 2006 in Sabadell and between April 2006 and January 2008 in Gipuzkoa 
using standardised protocols. We chose the most recent cohorts to avoid extensive 
sample degradation due to storage time. More specifically the Gipuzkoa cohort was 
selected since measured HAA concentrations in the public drinking water were 
available and the Sabadell cohort was selected because of the large number of 
SGA and FGR cases among recruited women, as well as the high concentration of 
THMs in the public water supply (Villanueva et al. 2011). Pregnant women in the 
Gipuzkoa cohort were recruited from the population visiting the Hospital of 
Zumarraga, which includes the municipalities of the Goierri and the Alto and Medio 
Urola. The other cohort was recruited from the Hospital of Sabadell (Corporació 
Sanitària Paric Taulí) which covers all the population in Sabadell, acting as a 
specialised consulting room and the reference hospital for births. Sabadell is a city 
of nearly 200,000 inhabitants situated in the metropolitan area of Barcelona, Spain. 
60% and 68% of the eligible pregnant women agreed to participate, in Sabadell and 
Gipuzkoa respectively.  




Figure 2-1. Geographic area of the seven cohorts included in the INMA study. Two 
cohorts were selected for this PhD project: the Gipuzkoa and Sabadell cohorts. 
Both maternal serum and urine were collected during the pre-natal period, but only 
urine was chosen for this study. The timing of urine collection during the day was 
not controlled in the INMA study therefore only spot urines were available, rather 
than 24 hours urine collection or first morning void. Among the 638 women initially 
recruited in the Gipuzkoa cohort and the 657 in the Sabadell cohort at the first 
prenatal visit (between weeks 10 and 13 of gestation), 611 and 620 were followed 
up until delivery and confirmed informed consent for themselves and their children 
to participate in the study. 9% and 30% of women in Sabadell and Gipuzkoa were 
further excluded because data were not available on personal water consumption 
from questionnaires and/or on THM measurements in drinking water which was 
relevant for study 3. Finally 402/479 and 418/418 urine samples were available from 
women in Sabadell and Gipuzkoa in their 1st /3rd trimesters. Samples included had 
sufficient urine available (2.5 mL) which was compromised in cases where the 
samples were required for other studies (other environmental biomonitoring) or the 
women did not provide sufficient urine. The flow chart below sets out the main 
stages in the selection of the samples (Figure 2-2). Further exclusion of samples 
occurred based on NMR spectral quality. 




Figure 2-2. Flow chart of inclusion/exclusion of subjects and urine samples from the 
Gipuzkoa (GM) and Sabadell (SB) cohorts 
 Data availability for this PhD  2.1.2.2
Fetal growth assessment 
Fetal growth was the outcome of interest for the epidemiological analyses in studies 
2 and 3 and was measured based on the estimated weight of the child in utero as 
well as at birth. Abdominal ultrasound examinations were routinely scheduled for 
gestational weeks 12, 20, and 34 and performed by obstetricians. Fetal measures 
were abdominal circumference (AC), biparietal diameter (BPD), femur length (FL), 
and estimated fetal weight (EFW). The latter was calculated using the Hadlock 
algorithm as shown below (Hadlock et al. 1985).  
 
The histogram in Figure 2-3 shows the distribution of the gestational week at which 
each ultrasound measurement was taken in the two selected cohorts. The timing for 
the ultrasound measurements was similar in both cohorts with the exception of the 
first ultrasound which happened slightly earlier in pregnancy in Sabadell compared 
to Gipuzkoa (respectively at week 12.1 and 12.4, median values).  




Figure 2-3. Histogram of gestational week distribution at the time of ultrasound 
measurement in the Gipuzkoa and Sabadell cohorts  
Preparation of the fetal growth variables was done in CREAL, Barcelona, by 
Dr. Carmen Iňiguez. Linear mixed models were used separately in each cohort to 
obtain longitudinal growth curves for the four fetal parameters (Pinheiro & Bates 
2000). Models were adjusted for maternal age, height, parity, pre-pregnancy weight, 
country of origin, father’s height, and fetal sex. Two types of z-scores were included 
in the epidemiological analysis of the association between NMR spectroscopic 
based maternal metabolic profiles with fetal growth outcomes (study 2): the 
unconditional z-scores at a certain time point which describe the size of a fetus at 
this time and conditional z-scores which describe the growth of a fetus during the 
respective time interval, i.e. 12th-20th, 20th-34th and 12th-34th weeks of gestation 
(Iñiguez et al. 2013). Anthropometric measures at birth included body weight and 
placental weight and were scaled to z-scores by subtracting the mean and dividing 
by the standard deviation. A positive z-score indicates a larger, and a negative value 
a smaller, than expected body weight. Fetal growth modelling for this population has 
been described elsewhere (Iñiguez et al. 2013). A summary of the outcomes 
selected for this thesis is represented in Table 2-1. 92% and 95% of women in 
Gipuzkoa and Sabadell respectively, had at least two ultrasound measurements 
taken during gestation at different time points. 
Table 2-1. Fetal growth variables used in study 2 (Chapter 4) 
Variable Type 
EFW at week 12 unconditional z-score, adjusted for 
confounders 
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EFW at week 20 unconditional z-score, adjusted for 
confounders 
Growth in EFW weeks 12-20 conditional z-score, adjusted for confounders 
EFW at week 34 unconditional z-score, adjusted for 
confounders 
Growth in EFW weeks 20-34 conditional z-score, adjusted for confounders 
Growth in EFW weeks 12-34 conditional z-score, adjusted for confounders 
Weight at birth z-score not adjusted 
Placental weight at birth z-score not adjusted 
BPD at week 12 unconditional z-score, adjusted for 
confounders 
BPD at week 20 unconditional z-score, adjusted for 
confounders 
Growth in BPD weeks 12-20 conditional z-score, adjusted for confounders 
BPD at week 34 unconditional z-score, adjusted for 
confounders 
Growth in BPD weeks 20-34 conditional z-score, adjusted for confounders 
Growth in BPD weeks 12-34 conditional z-score, adjusted for confounders 
HCC at birth z-score not adjusted 
Abbreviations: BPD, Biparietal diameter; EFW, estimated fetal weight; HCC, head 
circumference 
Covariates 
Mother weight pre-pregnancy, mother height, mother BMI pre-pregnancy, father 
height, father weight, father BMI, mother age at last menstrual period adjusted, 
parity, gestational age, newborn gender were considered as potential confounding 
factors for the epidemiological analysis of birth weight and placental weight with 
metabolic profiles. Gestational age was calculated from the date of the last 
menstrual period (LMP) which was self-reported and was confirmed using 
ultrasound examination in week 12 of gestation. When the date did not match the 
ultrasound measurement estimation by 7 days or more, the gestational age was 
corrected using its relationship to the crown-rump length. Maternal height was 
measured and pre-pregnancy weight reported by the mother at the first trimester 
visit; these were used to calculate pre-pregnancy BMI (kg/m2). Paternal weight and 
height were reported by the mother at the first trimester visit and used to calculate 
paternal BMI. Maternal and paternal BMI were grouped according to the World 
Health Organization categories for underweight (<18.5 kg/m2), normal (18.5–24.9 
kg/m2), overweight (25–29.9 kg/m2) and obese (≥30 kg/m2). All the variables were 
kept as continuous and untransformed (except for newborn gender which was 
categorical). 
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Variables representative of maternal lifestyle, socio-demographic status and clinical 
parameters were of interest for the identification of potential sources of metabolic 
variation associated with fetal growth. All the covariates selected are described in 
Table 2-2 as well as their categorisation or transformation type. Indeed, some of the 
continuous variables were transformed to better approximate the normal distribution, 
using different log or power transformations (0.25 or 0.50) or none, for use in linear 
regression models as described in 3.32 Data analysis. All the socio-demographic, 
lifestyle and dietary data were collected via questionnaires completed by trained 
interviewers during the first prenatal visit (around week 12) and this was repeated in 
the third trimester. Maternal social class was coded from the longest-held job during 
the pregnancy, using the four-digit Spanish classification , which is closely related to 
the International Standard Classification of Occupations (ISCO 88): Those in social 
class I are managers of companies with ≥ 10 employees, senior technical staff, 
higher-level professionals; social class II, managers of companies with < 10 
employees, intermediate-level professionals; social class III, administrative and 
financial management supporting personnel, other self-employed professionals, 
supervisors of manual workers, other skilled non-manual workers; IV, skilled and 
partly skilled manual workers; V, unskilled manual workers. Dietary information was 
collected through a semi-quantitative frequency food questionnaire which contained 
100 food items to assess usual food and nutrient intakes (available at: 
http://bibliodieta.umh.es/files/2011/07/CFA101.pdf). It asked how often, on average, 
women had consumed a particular amount of a specific type of food from the last 
menstrual period until the time of the first interview and between the second taking 
place at 28-32 weeks of gestation. The intake frequency for each food item was 
converted to the average daily intake for each woman (Vioque et al. 2013). 
Clinical biomarker variables were measured in non-fasting blood samples obtained 
from each woman during the first visit between weeks 10–13 of gestation. 
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Details (coding for categorical variables or transformation 
type for continuous variables) 
Socio-
demographic  
Mother age  12 Continuous No transformation 
  Mother ethnicity 12 Categorical Spain, Latin America or other 
  Country of birth 12 Categorical Spanish or foreign 
  
Maternal social class 12 Categorical 
3 categories: SC I+II,   SC III and SC IV+V  
based on CNO-94 
  Paternal social class 12 Categorical 3 categories: SC I+II,   SC III and SC IV+V based on CNO-94 
  
Maternal education level 12 Categorical 
4 categories: Without education or unfinished primary 
school, primary, secondary or university 
  
Paternal education 12 Categorical 
5 categories: Not able to read and write, Without education 
or unfinished primary school, primary, secondary or 
university 
Lifestyle Hours of sleep 12 and 34 Continuous No transformation 
  
Overall physical activity 12 and 34 Categorical 
3 categories: Little activity, Moderate activity, sufficient to 
intense activity 
  Night work 12 Categorical 2 categories: day or night shift 
  
Zone of residence (urban/sub-
urban/rural) 
12 Categorical 3 categories: Rural, suburban or urban area 
  
Total passive smoking 12 Categorical 
4 categories: No exposure, from 1 to 3 exposures between 
home/work/rest/leisure  
  Average daily intake of alcohol 12 Categorical 3 categories: None, 0.04-1g/day or >=1g/day 




Smoking before pregnancy 12 Categorical 
3 categories: No smoking, between 1 and 10 cig/day or more 
than 10 cig/day 
  
Smoking at the beginning of 
pregnancy 12 
Categorical 
3 categories: No smoking, between 1 and 10 cig/day or more 
than 10 cig/day 
  
Smoking at week 12 
12 
Categorical 
3 categories: No smoking, between 1 and 10 cig/day or more 
than 10 cig/day 
  
BMI before pregnancy 12 Categorical 
<18.5 (Underweight), 18.5-25 (Healthy), 25.1-30 
(Overweight) or >30 (Obese) 
Diet coffee/tea (g) 12 and 34 Continuous Log10 
  intake of calories (Kcal) 12 and 34 Continuous Log10 
  total fat (g) 12 and 34 Continuous Log10 
  consumption of dairy  (g) 12 and 34 Continuous 0.5 
  consumption of eggs  (g) 12 and 34 Continuous No transformation 
  meat  (g) 12 and 34 Continuous No transformation 
  fish (g) 12 and 34 Continuous 0.25 
  vegetables (g) 12 and 34 Continuous 0.5 
  fruits (g) 12 and 34 Continuous 0.25 
Clinical Cholesterol (mg/dl) 12 Continuous No transformation 
  Triglycerides (mg/dl) 12 Continuous Log10 
  Folic acid (micrograms/l) 12 Continuous Log10 
  Vitamin B12 (pg/l) 12 Continuous Log10 
  Vitamin D (ng/ml) 12 Continuous 0.5 
  TSH mother (µU/ml) 12 Continuous 0.5 
  T3 mother (nmol/L) 12 Continuous No transformation 
  T4 mother (pmol/l) 12 Continuous No transformation 
  C- reactive protein (mg/dl) 12 Continuous 0.25 
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  Iodine at week (micrograms/l) 12 Continuous Log10 
  Ferritin mother (micrograms/l) 12 Continuous Log10 
  
Total weight gain  
Birth 
Categorical 
3 categories: low, recommended or high total weight gain 
based on the body weight difference pre-pregnancy/at birth, 
recommended by IOM 
  
Rate of weight gain during 
pregnancy Birth 
Categorical 
3 categories: low, recommended or high rate of weight gain 
week 12-week 39, recommended by IOM 
  
Gestational diabetes 34 Categorical 
5 categories: none, impaired glucose tolerance (IGT), 
gestational diabetes mellitus (GDM); diabetes diagnosed 
prior to pregnancy (DM) or gestational diabetes mellitus 
(GDM2) 
Other Season of birth Birth Categorical 4 categories: spring, summer, fall or winter 
Abbreviations: SC=Social class 
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Water variables 
The water variables described below were used in the descriptive analysis of the 
exposure to water DBPs (TCAA) during pregnancy from ingestion of chlorinated tap 
water (study 3). These variables were prepared by our collaborator, Dr. Crisitna 
Villanueva at CREAL, Barcelona. Information on water use was drawn from the 
interview at week 32 of gestation which included questions on: source of drinking 
water (municipal, bottled, private well, other) at home and outside the home, use of 
a home water filter, changes in water ingestion since getting pregnant, and 
frequency and duration of showering, bathing, and swimming pool attendance 
(indoors and outdoors during winter and summer). Tap water ingestion was 
ascertained at weeks 12 and 32 using a food frequency questionnaire from which a 
continuous variable (litres per day) was computed using the midpoint of each 
category. Our collaborators also derived an estimate of daily THMs concentration in 
the bloodstream based on the modelled residential THM level, daily personal water 
use and uptake factors from the literature. This work is described in the article on 
prenatal THM exposure and birth outcomes (Villanueva et al. 2011). 
 Sample handling 2.1.2.3
Metabolic profiling and exposure biomonitoring applied to large-scale 
epidemiological studies requires the development of experimental protocols that 
ensure good analytical reproducibility, sensitivity, accuracy and that limit analytical 
drift (Bictash et al. 2010).  
A standard operating procedure was created to ensure the reproducibility of the 
sample handling and sample analysis across the two different cohorts and across 
time. The urine specimens stored in two centres across Spain were transferred into 
new vials and shipped (on dry ice) to the facilities in South Kensington, CSM, 
Department of Surgery and Cancer. In order, to minimise the number of freeze/thaw 
cycles applied to the urine samples, the 1 mL and 2mL needed for all analyses were 
split between two aliquots. At their arrival and until analysis, the samples were 
stored at -40°C.  
 Study 1: Cohort study- Metabonomic analysis 2.2
To characterise the urine metabolome during pregnancy at 12th and 34th weeks of 
gestation in the INMA study I used an untargeted 1H NMR metabolic profiling 
approach. This enabled the semi-quantification of major urinary metabolites for use 
in the next stage of the analysis. Even if the main focus of interest for this PhD was 
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fetal growth outcomes, specifically SGA and FGR, a cohort design was preferred 
over a nested case-control study with FGR cases matched with controls. By 
analysing global metabolomics data for all women in each cohort, the study design 
enables future epidemiological analysis to be carried out in relation to early-life 
outcomes in children, such as neurodevelopment outcomes. In addition, in a cohort 
design multiple outcomes can be modelled, such as for fetal growth as categorical 
or continuous variables. Furthermore, the platform elected for metabolic profiling, 
NMR, allowed a high-throughput of samples.  
 Study design and quality control strategy for NMR metabolic profiling 2.2.1
Samples from two time points during pregnancy, at 12th and 34th weeks, and two 
cohorts, Sabadell and Gipuzkoa, were analysed in order to explore two potential 
critical windows of exposure in two different regions of Spain. Urine samples which 
were too diluted or contained high concentrations of drug metabolites were excluded 
from the metabonomics analysis. 412/417 1st/3rd trimester samples were included in 
the Gipuzkoa and 394/469 for Sabadell.  
All the samples from Gipuzkoa and Sabadell were analysed on the same NMR 
instrument respectively in January 2012 and March 2013, forming two experiment 
batches. Pooled urine samples from the Sabadell cohort (approximately using 10% 
of the total sample batch) were used to monitor analytical stability and sample 
degradation over the NMR run as described in Figure 2-4. Pool sample aliquots 
were prepared and frozen in order to freshly prepare the quality control sample for 
each use. 





Figure 2-4 Quality control strategy applied to the NMR run of the Sabadell samples to 
assess batch effect, analytical stability and sample stability over the run time 
 Analytical methodology for sample profiling 2.2.2
To assess quantitatively and qualitatively the complex human urine metabolome, 
sophisticated analytical tools are required. A combination of two different analytical 
platforms was employed: 1H nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry coupled with liquid chromatography (LC-MS). Both methods 
were used in a non-selective manner or untargeted approach, favouring a broad 
metabolic coverage. NMR analysis provides a rapid insight into the metabolic 
content of the samples avoiding sample destruction and any preparation steps such 
as analyte separation or derivitisation. NMR spectroscopic analysis is also highly 
reproducible and has an inherent quantitative ability (Nicholson et al. 2005).  NMR 
spectroscopic methods provide detailed information on a broad range of metabolites 
from diverse chemical classes and on individual molecular structures in simple or 
complex sample mixtures. NMR is well adapted to large studies where typically over 
100 samples can be screened per day. However, the major limitation of 1H NMR is 
its low sensitivity compared to MS. The metabolite concentrations that could be 
reliably detected using NMR of human urine samples were recently shown to be at 
the low micromolar level and above (Dona et al. 2014) for compounds such as 
maleic acid alpha-ketoisovaleric acid and N-acetylputrescine (Bouatra et al. 2013). 
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MS is a widely used technique for identification and quantification of metabolites, 
and can detect metabolites at picomolar levels providing the substance of interest 
can be ionised. However, unlike NMR where the assignment of metabolite 
structures is relatively straightforward with homo-nuclear and hetero-nuclear 2-D 
experiments, metabolite identification by GC-MS or LC-MS analysis tends to be 
relatively incomplete. NMR was shown to detect approximately 8% of the known, 
quantifiable human urine metabolome whereas other techniques such GC-MS or 
LC-MS/MS detected less than 5%, therefore making NMR the best method at 
present for identifying and quantifying urinary compounds (Bouatra et al. 2013). 
However, LC-MS methods are still needed for full molecular characterisation of 
certain compounds when overlapped peaks occur in NMR spectra or when they are 
in low abundance. Significant differences appear also in metabolite coverage from 
one analytical platform to another due in part to their metabolite extraction or 
separation efficiency. 
This section describes the protocols for biochemical methods that were used to 
generate data from biological samples, further background on these methods is 
available in Biochemical methods: theory, Annexes.  
 1H NMR spectroscopy analysis 2.2.2.1
Urinary metabolic profiles were generated using  1H NMR spectroscopy (Beckonert 
et al. 2007). The different steps of the NMR experiment set up used in this thesis 
are summarised in Figure 2-5Error! Reference source not found..  




Figure 2-5. Workflow for standard NMR experiment used in this thesis 
Protocol for NMR experiments in this thesis 
Urine samples were thawed, vortexed, and allowed to stand for 10 min prior to 
mixing aliquots (400 μL) with phosphate buffer [200 μL, 0.2 M containing 99% 
deuterium oxide (D2O), 1 mM 3-(trimethylsilyl)-[2,2,3,3-2H4]-propionic acid sodium 
salt (TSP), and 3 mM sodium azide] and centrifuged at 15900g for 10 min. 
Supernatants (550 μL) were transferred into NMR tubes (507-HP-7, Norell, 
Landisville, NJ). The D2O provided a field frequency lock, and TSP provided a 
chemical shift reference (1H, δ 0). 1H NMR spectra were acquired on a Bruker 
Avance spectrometer (Bruker Biospin, Rheinstetten, Germany) operating at a 1H 
frequency of 600.13 MHz and a temperature of 300 K, using a Bruker TXI probe and 
an automated sample handling carousel (Bruker). NMR spectra were acquired using 
the standard one-dimensional solvent suppression pulse sequence (relaxation 
delay, 90° pulse, 4 μs delay, 90° pulse, mixing time, 90° pulse, acquire FID). For 
each sample, 128 transients were collected into 64K data points using a spectral 
width of 12000 Hz with a relaxation delay of 4 s, a mixing time of 100 ms, and an 
acquisition time of 2.73 s.  
• Probe tuning and matching
• Lock magnetic field on solvent
• Determine T1: 90° Pulse length
• Adjust O1: water suppression parameter





• Adjust receiver gain
• Acquire FID
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 Mass spectrometry (MS) coupled to liquid chromatography (LC-MS) 2.2.2.2
LC-MS was used in this thesis for two purposes through the use of different MS 
instruments. One LC-MS was employed for biomarker identification in parallel with 
NMR structural data through the use of tandem MS methods for fragment ion 
studies. The other type of LC-MS was selected for targeted analysis of TCAA 
through selective ionisation allowing high selectivity and sensitivity. Biomarker 
identification was done using LC-MS/MS in positive mode on a Xevo G2-S (Waters). 
 Metabolite identification 2.2.3
Metabolite identification is a crucial step that transforms raw spectral data into 
biological context, of potential use in a clinical setting and for exposure risk 
assessment. Structural information obtained from 1D 1H NMR experiments requires 
complementary tools to enhance and optimise data information recovery. Indeed, 
human urine spectra may contain more than a thousand peaks, characterised by 
partial overlap, rare peaks arising from specific diets or drug treatments, high peak 
shift due to varying pH and ionic strength, water peak interference and low signal-to-
noise ratio. In addition to employing sophisticated analytical tools such as 2D NMR 
to obtain further structural information, NMR peaks might need to be deconvolved in 
case of overlap using chemometric tools or further hyphenated approaches. Both 
will be described in this section. 
 Workflow for metabolite identification based on NMR data 2.2.3.1
1H NMR spectra of human urine have been extensively reported in the literature and 
reliable metabolite annotations are available. Recently, the Urine Metabolome 
project  identified 209 compounds and created a public online database with 1H 
NMR spectra and sometimes 13C NMR data for most metabolites reported in the 
literature (UMDB: http://www.urinemetabolome.ca)(Bouatra et al. 2013). A 
commercially available spectral library was also used, the chenomx suite, which 
allowed to match raw spectra to reference databases of metabolites, containing 
hundreds of pH sensitive compounds. Published studies on human urine were also 
used for peak annotations in this thesis (Yap et al. 2010; Salek et al. 2007). 
Previous NMR reports on the blood metabolome were relevant because many 
metabolites are found in both urine and plasma/serum samples (Foxall et al. 1993). 
As described in the workflow in  Figure 2-7, metabolites in this thesis were assigned 
firstly by noting the 1H chemical shift, peak multiplicity and J coupling-constant for 
peaks of interest, from the cohort sample 1D 1H NMR spectra. Cross peaks were 
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defined from independent 2D homonuclear experiments on a single representative 
sample from the cohort, such as a COSY. In addition to independent 2D 
experiments, pseudo-2D NMR spectra were computed based on the multicollinearity 
of the intensity variables in a batch of 1D spectra. Indeed statistically correlated 
intensities across the whole sample provided information on usual homonuclear 
coupling but were not restrained by bond length/spin systems or hetenuclei and 
could also provide information on metabolites belonging to the same pathway 
therefore having a similar excretion profile. This technique is termed statistical total 
correlation spectroscopy (STOCSY) (Cloarec et al. 2005). An improved version of 
the MATLAB script was used, called STORM, more appropriate for population 
studies, where only a subset of spectra (usually n=50) that contained specific 
spectroscopic signatures of a peak of interest were selected for the correlation 
analysis (Posma et al. 2012). 
If all the peak chemical shifts and multiplicities listed match the reference (from 
literature or commercial/public spectral library) the peak was identified. However, it 
occurred that no match was found and therefore steps 3 to 5 were required to obtain 
full annotation. Further structural information from 2D experiments such as 
heteronuclear HMDB NMR data were acquired. In the case of spectral overlap, lack 
of homo- heteronuclear couplings, or even too low compound abundance to obtain 
interpretable 2D spectra, separation techniques were used. Indeed SPE (cartridges) 
or HPLC can be used for simplifying a complex biological matrix such as urine, while 
concomitantly improving the concentration of analytes for NMR analysis (Appiah-
Amponsah et al. 2009).  




 Figure 2-7 Workflow for metabolite identification based on NMR metabolite profiling 
Further separation technique for annotation of metabolites 
For this thesis, a pooled urine sample representative of the Sabadell samples 
(quality control) was injected into a HPLC system in order to further metabolite 
annotation. This system was equipped with a photodiode array detector (PDA), 
which provided UV spectra of eluting peaks. The sample was injected 33 times with 
a partial loop injection of 20 µL. The column was a reversed-phase C18 Atlantis T3 
(3µm 4.6x150mm:  silica-based column). A linear gradient was used with the 
following solvents: (A) 0.1% (v/v) formic acid in water and (B) 0.1% (v/v) formic acid 
in Methanol with a flow rate of 1mL/min. The effluent from the HPLC system was 
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separated into 120 fractions after 1.5 minutes waiting time from the time of injection. 
Fractions were collected every 9 seconds. 
Fractions were automatically collected with a fraction collector III (Waters) and then 
evaporated using dry heat (37°C ) and nitrogen blow down TurboVap® LV, with an 
Automated Evaporation System (Biostage) which sped up evaporation of 50 
samples at the same time. The residue of each fraction was reconstituted in 
deuteriated water. 
 Bioinformatics 2.2.4
 NMR data pre-processing 2.2.4.1
Scaling and normalisation 
Before proceeding to the data analysis, the metabonomic dataset required pre-
processing to account for aspects that would hinder biological interpretation. 1H 
NMR and UPLC-MS data sets were subjected to slightly different treatments. NMR 
spectra were imported into MATLAB 7.12.0 (MathWorks) and digitalised into a table 
from the analytical measurements such that there are m rows (observations, 
samples) and n columns (variables, chemical shift) filled with spectral intensity 
values for each data point (n=32K). Using an automated method (in-house script 
developed by Rachel Cavill, Hector Keun and Tim Ebbels), the spectra were 
referenced and corrected for phase and baseline distortion. The spectral region, 
usually δ 4.0-6.0, containing residual water and urea resonances was removed prior 
to the normalisation.  
The data were normalised in order to account for different sample dilution states, 
influencing the concentrations of all metabolites, which can originate from biological 
variation. This was particularly important in the case of spot human urine specimens 
rather than 24 hour collections. Probabilistic quotient normalisation is particularly 
adapted to samples containing disproportionately concentrated metabolites, such as 
over-the-counter drug metabolites in human urine (Holmes et al. 2007). It assumes 
that the majority of signal intensities are a function of the dilution factor, but it does 
not consider the extreme rise of single metabolites in the calculation of dilution 
factors (Dieterle et al. 2006). Another common method not used in this thesis, called 
normalisation to total area, divides each data point by the total spectral integral. 
Scaling methods divide each variable by a factor, the scaling factor, which is 
different for each variable. Prior to multivariate projection methods (PCA and PLS-
DA),  we used unit variance scaling which allowed equal weighting to either small or 
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large peaks by dividing each value in the column by the standard deviation of the 
column and by converting the mean of each variable to zero, thus the data are 
scaled and centred. 
Peak alignment issues  
The effect of peak shifting due to natural variability in sample matrix composition 
such as pH, ionic strength, proteins or concentration of other metabolites, also 
called “positional noise”, can severely prevent pattern recognition analysis and 
quantification. Chemometric tools were developed to adjust the correspondence of 
peaks across spectra such as the alignment algorithm with recursive segment-wise 
peak alignment (RSPA) (Veselkov et al. 2009). This algorithm performed well 
enough to conduct subsequent pattern recognition analysis on full resolution data. 
However, as shown in Figure 2-8, artefacts were introduced in extreme cases of 
chemical shift differences such as for citrate and dimethylamine.  The algorithm 
failed when peaks crossed over in chemical shift between samples (i.e., when peak 
A appears upfield of peak B in spectrum 1, but downfield in spectrum 2). A study 
comparing different alignment methods was done recently by ordering spectra with 
respect to an internally varying peak (Liebeke et al. 2013). The authors concluded 
that artefacts are often introduced with alignment algorithm and cannot be visualised 
by simple spectral inspection, hence we did not align our NMR spectral datasets 
except when the statistical analysis was conducted on full resolution data. At the 
time of writing this thesis, peak fitting and targeted binning were the most 
appropriate methods to process this dataset.  




Figure 2-8 Alignment artefacts in representative 
1
H NMR spectra from urine of 
pregnant women in the Sabadell cohort (A. After and B. before alignment).  
The line colours in both windows correspond to an individual spectrum with 
and without alignment processing. The green spectrum for example present 
a doublet for citrate slightly shifted upfield, after alignment the first peak of 
the doublet is completely shifted downfield and an artificial line is created 
between the two peaks. 
Integration of selected spectral regions 
Biological variability and lack of control over time of sampling might hinder biological 
information retrieved from specific physiological signatures. In the case of urine 
samples, specific issues can arise from variation in drug intake (drug metabolites), 
urine ionic strength and dilution which can amplify the noise level in NMR spectra 
(peak shifting). This was partially addressed in our study by primary working on 
selected peak integrals (“targeted binning”) instead of full resolution spectra. 
Integration of selected peaks also allowed me to apply univariate statistics on 
individual metabolites and to limit the number of tests computed (problem of multiple 
testing and false positives).  
Integrals of single representative peaks were chosen on the basis of being present 
in a high proportion of spectra, having high signal-to-noise ratio, and exhibiting 
limited overlap with other peaks.  Certain metabolites with a low signal-to-noise ratio 
(specifically 0.58 (s), 0.63 (s), 0.92(s) and 0.93(s), see Figure 2-9) gave negative 
values for integrals, supposedly when the signal-to-noise intensity average was 
under 0.  
 
Intensity (UA) 




Figure 2-9. Low signal-to-noise (S/N) resonances from representative 
1
H NMR spectra 
from urine of pregnant women in the Sabadell cohort  
These signals were quantified using a Matlab peak fitting program for time-series 
signals (peakfit()), which uses an unconstrained non-linear optimization algorithm to 
deconvolve a complex, overlapping-peak signal into its component parts (O’Haver 
n.d.). Peak integrals obtained with manual integration and with the peak fitting 
algorithm were compared in Figure 2-10.  
 
Figure 2-10. Peak integral/area measured by two methods of signal at 0.56 (s) in 
1
H 
NMR spectra from urine of pregnant women in the Sabadell cohort  
Owing to high peak shift variability for these metabolites, the peak fitting function 
was modified so that 20 iterations for each signal of each spectrum were calculated 
Intensity (UA) 
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each time modifying the peak position (for example for the peak at δ0.63, a fit was 
calculated for the peak positions 0.6301, 0.6302, 0.6303 etc...). The peak fit that 
showed the lowest percentage error was selected for the final integral value. An 
example of the peak fitting performance can be visualised in Figure 2-11. The top 
graph represents a NMR spectrum zoomed in on the peak at δ0.63, where blue dots 
represent spectral data points and the red line: the Lorenzian peak fit. The bottom 
graph represents the residuals of the peak fit which related to spectral noise. 
 
 
Figure 2-11. Example of peak fitting for NMR signal at 0.63 (s) representing a low 
signal-to-noise ratio resonance using the function peakfit() in Matlab 
Precaution should be taken that, although NMR spectroscopy can be quantitative 
under appropriate acquisition conditions, routine metabonomic applications are only 
semi-quantitative. Integrals can be problematic in the case of  high inter-sample 
variations in term of turbidity and dilution, since parameters such as shimming and 
peak shape can be affected (Bauer et al. 1998). In addition, conducting data 
analysis on only selected metabolites will reduce the number of potential new 
biomarkers found. A list of the total 64 metabolites integrated and their integration 
window is summarised in Table 2-3. 
  







ipf 9.2 Linear autozero. Pan and Zoom to isolate peaks to be fit in upper window.
Vertical dotted lines indicate first guess peak positions. C to customize.
Peak #          Position        Height         Width             Area
1 0.6303 7.001e+040.004985489.9













Peaks = 1     Shape = Lorentzian     Error = 5.94% 
Intensity (UA) 
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1 Pregnanolone-3G Pn3-G 0.58 (s) 0.55 0.57 Fraction, spiked-in 
2 Pregnanediol-3G P3-G 0.63 (s) 0.6176 0.64 
Fraction, spiked-in, LC-
MS/MS 
3 UA 0.75(d) - 0.75 (d) 0.741 0.76 - 
4 Oestrogen metabolite - 0.78 (s) 0.7774 0.79 Fraction, Spiked-in 
5 UA 0.93(s) - 0.93 (s) 0.9311 0.94 - 
6 Leucine Leu 0.96 (t) 0.9503 0.97 2D NMR 
7 Isoleucine Iso 1.01 (d) 1.005 1.03 2D NMR 
8 Valine Val 1.05 (d) 1.034 1.06 2D NMR 
9 3-hydroxyisobutyrate 3-HB 1.08 (d) 1.063 1.09 2D NMR, fractions, spiked-in 
10 
4-deoxyerythronic 
acid 4-DEA 1.11 (d) 1.097 1.12 2D NMR 
11 UA 1.15 (d) - 1.15 (d) 1.132 1.16 
2D NMR (organic acid with 









(ov.) 1.17 1.21 2D NMR 
13 4-deoxythreonic acid 4-DTA 1.24 (d) 1.222 1.24 2D NMR 
14 UA 1.25 - 1.25 (d) 1.244 1.26 - 
15 3-hydroxyisovalerate 3-HV 1.27 (d) 1.264 1.28 2D NMR 
16 UA 1.29(s) - 
 
1.282 1.29 - 
17 Lactate Lac 1.33 (d) 1.32 1.35 2D NMR 
18 2-hydroxyisobutyrate 2-HB 1.36 (s) 1.355 1.37 2D NMR, spiked-in 
19 Alanine Ala 1.48 (d) 1.472 1.51 2D NMR 
20 UA 1.67(s) - 1.67 (s) 1.655 1.68 - 
21 Lysine Lys 1.73 (m) 1.701 1.76 2D NMR, Chenomx 
22 Acetate - 1.92 (s) 1.914 1.93 Literature 
23 UA 1.99(t) - 1.99(t) 1.97 2.00 - 
24 
N-acetyl glycoprotein 
fragments NAG 2.04 (s) 2.022 2.05 Literature 
25 
N-acetyl neuraminic 
acid NAC 2.06 (s) 2.054 2.09 Literature 
26 Acetone - 2.24 (s) 2.229 2.25 Literature 
27 P-cresol sulfate PCS 2.35 (s) 2.339 2.355 2D NMR 
28 
Pyroglutamate (5-
oxoproline) 5-OP 2.40 (m) 2.387 2.40 2D NMR, fractions, spiked-in 
29 Succinate - 2.41 (s) 2.4 2.42 Literature 
30 Glutamine Glu 2.45 (m) 2.43 2.47 2D NMR 
31 Citrate - 2.55 (d) 2.5 2.58 2D NMR 
32 3-aminoisobutyrate 3-AB 2.62 (m) 2.587 2.64 2D NMR 
33 Dimethylamine DMA 2.72 (s) 2.716 2.74 Literature 
34 UA 2.78(s) - 2.78 (s) 2.774 2.79 - 
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35 UA 2.83(s) - 2.83 (s) 2.818 2.85 - 
36 Trimethylamine TMA 2.87 (s) 2.861 2.88 Literature 
37 N-acetylserotonin NAS 2.90 (t) 2.9 2.91 2D NMR, spiked-in 
38 Dimethylglycine DMG 2.93 (s) 2.923 2.94 Spiked-in 
39 Creatinine+creatine Creat2 
3.05 (s) 
ov. 3.027 3.07 Literature 
40 Choline - 3.20 (s) 3.201 3.21 Literature 
41 Carnitine - 3.23 (s) 3.223 3.24 Literature 
42 Trimethylamine oxide TMAO 3.27 (s) 3.261 3.29 Literature 
43 Proline betaine PB 3.30 (s) 3.297 3.31 Literature 
44 Scyllo-inositol SIN 3.36 (s) 3.362 3.37 Literature 
45 Glycine Gly 3.57 (s) 3.561 3.58 Literature 
46 UA 3.8(s) - 3.8(s) 3.792 3.81 - 
47 UA 3.93(s) - 3.93(s) 3.927 3.94 - 
48 UA 3.95(s) - 3.95(s) 3.946 3.96 - 
49 UA 6.48(d) - 6.48(d) 6.477 6.49 - 
50 Fumarate - 6.52 (s) 6.521 6.53 Literature 
51 UA 6.59(s) - 6.59 (s) 6.585 6.61 - 
52 Furoylglycine FG 
6.64 
(dd) 6.636 6.66 2D NMR, fractions 
53 
N-methyl-2-pyridone-
5-carboxamide 2PY 6.66 (s) 6.657 6.67 2D NMR 
54 
p-
hydroxyphenylacetate HPA 6.87 (d) 6.851 6.88 2D NMR, STORM, spiked-in 
55 Tyrosine Tyr 6.90 (d) 6.89 6.92 2D NMR 
56 UA 7.32 - 7.32 7.306 7.34 - 
57 Phenylacetylglutamine PAG 7.37 (t) 7.343 7.38 2D NMR 
58 3-Indoxylsulfate 3-IS 7.51 (d) 7.494 7.52 2D NMR, spiked-in 
59 Hippurate - 7.55 (t) 7.527 7.58 2D NMR 
60 UA 7.68(s) - 7.68(s) 7.672 7.69 - 
61 Formate - 8.46 (s) 8.453 8.47 Literature 
62 UA 8.79(d) - 8.79(d) 8.772 8.81 - 
63 N-Methylnicotinic acid NMNA 9.13 (s) 9.113 9.14 2D NMR, spiked-in 
64 
N¹-Methyl-
nicotinamide NMN 9.28 (s) 9.269 9.30 2D NMR, spiked-in 
 
 Data analysis 2.2.4.2
The challenges of the application of metabonomics to large-scale epidemiological 
studies include the analysis of complex multi-dimensional data sets and potential 
false discovery associations. In addition, the abundance of phenotypic and exposure 
data provided by questionnaires add an extra layer of complexity to the data 
analysis. Consequently, typical statistical approaches such as multivariate projection 
methods (PLS-DA) developed on smaller-scale studies might not be adequate for 
1000s of metabolic observations in human studies where diet, age and diseases are 
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not controlled as in animal studies. Regression techniques are used in order to 
predict and/or explain the distribution of one response variable (i.e. fetal growth or 
metabolite levels) based on the status of multiple covariates (dietary information, 
timing of pregnancy, anthropometry, etc). Regression tools focusing on prediction 
such as multivariate projection methods (PCA and O-PLS) or machine learning tools 
(decision tree learning such as random forest regression) are excellent predictors 
and can handle a large number of covariates including ones that are inter-
correlated. Other more classical regression tools such as generalised linear models 
may give a better insight into the relevance of single covariates and therefore on the 
mechanism of the data generating process. Both sets of statistical tools are 
described in this section according to their applications and performed in the result 
chapters. 
Data mining techniques for spectral data overview: PCA and O-PLS 
To begin with, metabolic profiles, either as peak lists or digitised spectra were 
subjected to exploratory analysis where multivariate projection methods such as 
Principal Component Analysis (PCA) were applied to provide an overview of the 
data. The aim was to identify the main sources of variation and potential outliers that 
might arise from analytical variability or study design (1st/3rd trimesters) rather than 
biological information associated with the endpoint of interest: fetal growth. PCA 
narrows down the dimensionality of a multivariate set of observations by substituting 
the variables with a few derived axes called principal components (PC). These 
latent axes correspond to the maximum variance of the dataset with the first PC 
computed such as it minimises the square of the distance of each data point to that 
vector. Each following component has to be orthogonal and uncorrelated to the first 
PC, and maximises the secondary greatest source of variance in the dataset. To 
interpret the results, two projection plots are visualised the “scores plot” (T) and the 
“loading plot” (P). The scores correspond to the projections of each data point on 
the latent axes and allow the identification of inherent clusters between the 
observations and eventually facilitate the recognition of outliers. The loadings 
express the different variable weights in the construction of the PCs, and indicate 
which variables are responsible for the major variations in the dataset (Jolliffe 2002). 
PCA is an unsupervised technique as it builds a predictive model regardless of the 
‘a priori’ biological information relative to each sample class. PCA score plots were 
used in this thesis to identify sample clusters according to the stage of pregnancy 
(1st or 3rd trimester). 
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PLS (partial least square) regression analysis is a supervised technique equivalent 
to PCA, used to capture the linear relationship between the output variables, Y, and 
the input variables, X. In this thesis, Y was the stage of pregnancy (dummy variable 
coded 0/1 for visits in the 1st or 3rd trimesters) and variables X were the full 
resolution NMR digitised spectra from maternal urine samples. This method can be 
applied to produce pair-wise models in a discriminant analysis manner (PLS-DA) to 
compare two groups of samples according to their global metabolic profiles or to 
investigate relationships with continuous factors. PLS-DA methods compute latent 
axes accounting for the largest variance in the matrix X associated with the 
predictive Y(Trygg et al. 2007). O-PLS-DA is an extension to the PLS-DA method 
with an integrated Orthogonal Signal Correction (OSC) filter that removes variation 
from X that is orthogonal to Y and hence unrelated to the endpoint of interest. 
Orthogonal projection is a useful tool to remove unwanted noise from the matrices 
that could be associated with structured variance such as biological information (i.e. 
age, time, etc.) or analytical variability which happen to be orthogonal to the 
predictor of interest (Trygg 2001). The validity of the model against over fitting is 
tested by computing cross-validation parameters. The standard 7-fold cross 
validation method repeatedly leaves out a seventh of the sample and predicts them 
back into the model to check the robustness of the model. An O-PLS-DA 
coefficients plot (loadings) was calculated which highlighted the NMR variables 
involved in the discrimination of the classes using a correlation scale based on the 
squared Pearson correlation coefficient (R2). The coefficients plots are back-
projected as a pseudo-NMR spectrum to facilitate the interpretation. To interpret the 
O-PLS-DA model and to determine its validity we use two main parameters: R2X, 
the coefficient of determination, which shows how much of the variation in the 
dataset is explained by the model; Q2Y corresponds to the cross-validation 
parameter, it represents the predictability of the model and is related to its statistical 
variability (Trygg et al. 2007). 
PCA and O-PLS analyses were performed using MATLAB. 
Complementary univariate statistical tools 
To complement the above statistical tools, descriptive and targeted univariate 
statistics were conducted on individual metabolites.  For all the analyses, each 
metabolite integral was log-transformed (log base 10) to approximate a normal 
distribution and were modelled separately. To study the variability in metabolite 
measurements in the section assessing analytical stability based on NMR spectra 
2 . 2  S t u d y  1 :  C o h o r t  s t u d y -  M e t a b o n o m i c  a n a l y s i s  | 83 
 
 83 
from QCs (Chapter 4.2.2), two types of standard deviations (SD) were calculated. 
With n being the number of QCs, equal to 16 for each category (freshly prepared or 
sitting in the carrousel for the whole run), and xi and ?̅?  the log10-transformed 
measurement and mean, the SD for freshly prepared QCs was given by: 
 
With n being the number of data pairs, equal to 16, and x1 and x2 the log10-
transformed measurements acquired from the same QC aliquot, the SD for repeat 
QCs was given by: 
 
CV provided a dimensionless measure of the variability relative to the mean, also 
known as the relative standard deviation. In the case of log-normally 
distributed data, the CV is only relative to the standard deviation. Its value is given 
by the formula below (L. H. Koopmans 1964).  
 
In order to compare the metabolite levels at two stages of sampling during gestation 
(weeks 12 and 34) non-parametric tests such as Mann-Whitney test were used.  
The reported p-values, were corrected for multiple  testing. However,   methods  
such  as  Bonferroni  correction were judged  too  conservative since the  actual  
error  rate  was  inferior  to  the  p-value  cut-off  imposed  by  the  Bonferroni 
correction and the multiple comparisons were applied to adjacent metabolites 
possibly  correlated. Instead, multiple testing errors were considered by calculating 
the false discovery rate (Benjamini & Hochberg 1995).  
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 Study 2: Fetal growth and maternal urinary metabolites 2.3
In order to identify the metabolites associated with fetal growth measures, an 
epidemiological analysis was conducted. This section describes the regression 
models computed and the customised selection criteria for significant associations. 
Univariate regression analyses, as opposed to multivariate analyses such PCA and 
PLS, were needed to estimate metabolite-outcome associations whilst controlling for 
key potential confounders including parental anthropometry and fetal characteristics. 
However, there is no consensus on the most appropriate method to analyse 
metabonomic data in association with 100s of epidemiological variables (Bictash et 
al. 2010). In comparison with classic regression analyses, PLS methods do not 
directly provide p-values and therefore threshold for significance levels. P-values 
can be computed by applying a simple bootstrap procedure to estimate empirical P-
values for each variable in an O-PLS-DA model (Martens & Martens 2000), but this 
has not been widely employed. 
 Regression modelling and confounders selection for quantifying 2.3.1
outcome-metabolite associations 
Metabolite levels in urine of pregnant women were used to predict fetal growth in 
terms of weight and head size at different time points of pregnancy until birth. For 
each fetal growth outcome in each cohort, a linear regression analysis was 
computed to estimate metabolite-fetal growth associations whilst controlling for the 
time of sampling during gestation and further confounders in the case of measures 
taken at birth. Figure 2-12 depicts the time frame of the study variables. Metabolites 
detected in the urine at week 12 were used to predict fetal growth from week 12 until 
birth in terms of z-scores at all the time points available (n=4 + placental weight 
score) and in terms of growth score between these time points (n=3). Metabolites 
detected in the urine at week 34 were used to predict fetal growth at week 34 and at 
birth (body + placental weight) and in terms of growth in the 2nd and 3rd trimesters 
only. In total, 64 semi-quantified metabolites were available to predict fetal growth 
which led to the calculation of 3072 regression models (for both cohorts, both time 
points of pregnancy at which metabolites were measured and both types of 
outcomes). 
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Figure 2-12. Time frame and study design for the study on fetal growth and maternal 
urine metabolites. Fetal growth was assessed at four time points while maternal urine 
metabolic profiles were obtained at two time points. 
All regression analyses and data visualisation algorithm were performed using the R 
project software (http://www.R-project.org). 
Each metabolite integral was log-transformed (log base 10) and modelled 
separately. Prenatal fetal growth scores, the endpoints of this study, were already 
calculated adjusting for maternal age, height, parity, pre-pregnancy weight, country 
of origin, father’s height, and fetal sex. Therefore only the gestational week at the 
time of sampling was included in the regression models as confounding. Other 
models for growth outcomes measured at the time of birth including birth weight and 
placental weight needed to be adjusted for confounding. The following variables 
were selected as confounding factors for the models predicting birth weight and 
placental weight scores based on the literature and our prior analysis: mother’s 
weight pre-pregnancy, mother’s height, father’s height, parity, gestational age at 
birth, newborn gender and gestational week at the time of sampling. All these 
variables were significantly associated with birth outcomes in both cohorts, in linear 
regression models including individual metabolite levels. 
A series of metabolite selection criteria were applied in order to present only 
relevant and consistent metabolite-outcome associations. Significance was 
controlled at 5% level. The Benjamini and Hochberg method was also used to 
compute the false discovery rates (FDR) that were expected amongst the 
statistically significant metabolites (p-value<0.05). However FDR was not used for 
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metabolite selection. Instead, metabolites displaying significant associations to fetal 
growth data in both cohorts and in the same direction (positive or negative beta 
coefficient) were displayed in separate results tables to the metabolites which were 
unique for each cohort. Coefficients from the regression models were multiplied by 
the logarithm of 1.5 to derive an effect estimate for a 50% increase in metabolite 
levels (Glidden, Shiboski & McCulloch, 2011). Regression coefficients were 
presented as percent change in the z-score of the fetal growth measure. I 
specifically wrote an algorithm to automatically select the significant metabolic 
associations similar/dissimilar in both cohorts at each trimester and display the 
results as heat maps using the function ‘corrplot’ in the R package called the same 
name (Wei 2013). This function, developed for graphical display of a correlation 
matrix, was adapted to plot percent change only for selected associations. 
Metabolite correlation clusters were created using the complete linkage method for 
hierarchical clustering in order to present metabolite-outcome associations 
according to urinary metabolite clusters (heatmaps shown in annexes – chapter 5).  
 Identification of potential sources of variation in metabolic profiles 2.3.2
from epidemiological and clinical data 
 Variance decomposition of urinary metabolite according to between individual, 2.3.2.1
within-individual and epidemiological and clinical data 
For each metabolite concentration, the relative importance attributed to between 
individual and within-individual (1st-3rd trimester pregnancy) variations was estimated 
across all measurements based on variance decomposition. Using linear mixed 
effect regression models, random effects allows to account for an important source 
of variation by adding an additional source of random variation to the statistical 
model beyond that of residual error. In this study, the objective was to model 
variability in metabolite signals according to selected sources of variation among 
maternal lifestyle and exposures, where repeated measures were available (at week 
12 and 34). These two time points used in the study represent a random sample of 
a larger set of potential levels, therefore the time point of pregnancy was added as a 
random effect as well as by-subject random slopes for within-subject factors. Fixed 
effects tested were the cohort (Gipuzkoa or Sabadell) and a selected continuous 
epidemiological or clinical covariate. The regression model is summarized in the 
formula below. 
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This regression model was calculated for each metabolite and each continuous 
maternal parameter (from epidemiological and clinical covariates in Table 2-2) using 
the R package ‘lme4’ and the function lmer (Bates et al. 2014). To assess whether 
the covariates are significantly associated with the response and obtain P values, 
ANOVA was conducted on the mixed models. A descriptive summary of the 
explanatory power of epidemiological/clinical covariates for urinary metabolite levels 
was given by the coefficient of determination, also known as the proportion of 
explained variance, or multiple R2. The proportion of variance in metabolite 
according to the pregnancy time point, the maternal covariate and the cohort were 
calculated.  
 Sources of variation in metabolites specific to each cohort and each trimester of 2.3.2.2
pregnancy 
Generalised linear models were applied to predict metabolite levels using 
continuous and categorical variables representative of maternal lifestyle, socio-
demographic status and clinical parameters (n=41). Each metabolite integral was 
log-transformed (log base 10) and modelled separately (n=64). Continuous 
predictors were transformed in the case of non-normal distribution (see Table 2-2). 
Due to the highly correlated nature of the predictors, one model was computed for 
each predictor as well as for each cohort and each trimester separately. A total of 
10496 models were computed. P-values were computed when comparing two 
nested models, null model predicting metabolite levels and the model with one 
metadata as predictor, using an analysis of variance (function ‘anova’ in R). In order 
to compare the strength of the association metabolite/metadata, regardless of the 
categorical/continuous nature of the predictor, R2 values were extracted from the 
selected models, ordered and plotted in dot plots using the R package ggplot2 
(Wickham 2009). 




 The mediating role of maternal epidemiological and clinical data 2.3.2.3
A final set of analyses was performed in order to assess the importance of maternal 
lifestyle/clinical parameters in explaining the urinary metabolite-fetal growth 
associations.  Causality could not be determined but a change in estimated 
differences in body weight (z-scores) at week 20 of gestation or at birth per 50% 
increase in urinary metabolites after adjustment for clinical/lifestyle parameters 
pointed towards potential intermediate/confounder factors. Only metabolites at week 
34 that showed reproducible associations with fetal growth outcomes in terms of 
weight in each cohort (see Chapter 5 results) were reported. All the models with 
birth weight were adjusted at least for maternal weight, height, father’s height, parity, 
gestational week at urine collection and at birth and child’s gender. All the models 
with EFW at week 20 were adjusted at least for gestational week at urine collection. 
Beta estimates (1st column) without the intermediate variable in the model and 
adjusted estimates were computed. As a rule of thumb, if the betas estimate from 
the simple linear regression model changed by more than 10% (bold values in Table 
5-1), then the co-variable was considered as a potential intermediate factor.  
 Study 3: HAA risk assessment and birth outcome 2.4
In order to accurately quantify the exposure to water DBPs(specifically HAAs) from 
ingestion of chlorinated tap water during pregnancy a sub-study was design within 
our cohort of samples. This section describes the study design and the laboratory 
protocol. 
 Nested case-control design 2.4.1
A nested case-control design allowed increasing statistical power by analysing all 
cases of FGR and SGA from both Gipuzkoa and Sabadell cohorts (representing 
only 8-10% of the full cohort participants). By oversampling case samples we 
avoided the analysis of all the samples from pregnancies without signs of fetal 
growth restriction and avoided redundant information (Prentice 1986). In addition, 
only a subset of the samples available were analysed since TCAA analysis is also 
costly and labour intensive (35 samples analysed/week). A sub-group of controls 
were randomly matched to cases according to the child’s gender. No additional 
layers of matching were used to avoid the control series being less representative of 
the person-time experience of the total cohort. A nested case-control design was 
also favoured in order to insure that the quality of biomarker data was the same for 




case and control samples, avoiding batch effects during the analytical run that were 
correlated with either cases or controls (Rundle et al. 2005). Only 3rd trimester 
samples were selected for this analysis because this period represents the highest 
fetal growth rate during pregnancy. The numbers of cases and controls selected in 
the study are described in Table 2-4. 
Table 2-4.  Numbers for the nested case-control study 
 
Gipuzkoa Sabadell 
SGA 33 49 
FGR 26 43 
SGA ∩ FGR 17 34 
Low birth weight 10 20 
Total number of cases 41 58 
Matched controls 123 174 
 
 Quantitative analysis of TCAA using UPLC-MS/MS 2.4.2
Different methods have been developed in order to measure trichloroethylene (TCE) 
and its main metabolites DCAA and TCAA in biological samples. A detailed review 
describes the different techniques used (Delinsky et al. 2005). The ideal method 
would require a low volume of biological sample, be capable of high-throughput 
analyses, display a low limit-of-detection (LOD) to measure TCAA in the maximum 
number of samples and be cost-effective. Many published protocols do not fulfil 
these criteria with one of them requiring 12mL of urine for the TCAA analysis using 
static headspace coupled with GC/MS (Cardador & Gallego 2010) or the method 
applied to the PELAGIE cohort where the LOD was 10 µg/L and TCAA could be 
detected in only 6.7% of the pregnant population (Costet et al. 2012). In addition, 
derivatisation-free analytical methods are preferred in order to diminish artefactual 
degradation of TCAA (Kim et al. 2009).  
The method selected in this PhD could detect TCAA with a LOD of 0.5 µg/L using 
only 1 mL of urine. Urine samples were analysed for TCAA at the Health & Safety 
Laboratory, Buxton, UK, using solid phase extraction (SPE) followed by liquid-
chromatography-tandem mass spectrometry.  This analysis was performed in 
collaboration with Ms. Kate Jones. 
Urine (1mL) was dispensed into tubes and 50 µl of internal standard working 
solution (13C TCAA) and 2 ml milli-Q-water were added to each tube. Calibration 




standards were prepared in urine over the range 0 to 125 µg/l.  Quality control 
samples were prepared from an external occupational quality assurance standard 
(G-EQUAS, www.g-equas.de) and the laboratory used the official acceptance limits 
of this for their acceptance limits.  Extraction took place using Strata X-AW 
cartridges (30 mg; 1 ml), which are weak anion exchangers.  Cartridges were 
conditioned with 1 ml methanol and 1 ml pH7 buffer.  The samples were then loaded 
and washed with 1ml water then 1ml methanol.  The cartridges were dried and the 
TCAA eluted using 1ml 1% HCl in methanol.  Analysis was by LC-MS-MS (API3200, 
ABSciex) using electrospray ionisation with negative polarity.  Instrument conditions 
were as follows: curtain gas 40 psi, collision gas 6 psi, ion spray voltage –4500V, 
temperature 300oC, ion source gases 30 and 40 psi, declustering potential –15V, 
entrance potential –3V, collision energy –10V, collision cell exit potential –4V.  The 
HPLC column was 150 x 4.6 mm Hydro-RP (Phenomenex), flowrate 0.5 ml/min.  
Mobile phase was isocratic with 30% methanol and 70% 20mM ammonium acetate 
(pH5).  Injection volume was 25 µl.  Using multiple reaction monitoring (MRM), 
TCAA was monitored using the transition 160.8/116.8 and the internal standard 
transition was 161.8/117.7.  The limit of detection for TCAA was 3 nmol/L.  
Analytical precision was 15% (coefficient of variation).  
To adjust for concentration-dilution of spot urine samples, urinary TCAA results 
were corrected for specific gravity (each sample was multiplied by a correcting 
factor). I manually measured this variable using a handheld specific gravity 
refractometer.
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 Characterising the pregnant woman metabolome Chapter 3 
This chapter answers the first aim, which corresponds to study 1, to characterise the 
urinary metabolome during pregnancy at 12th and 34th weeks of gestation in a 
mother-child cohort, the INMA study (Gipuzkoa, n=417 and 412 for the 12th and 
34th weeks, Sabadell, n=394 and n=469), using an untargeted 1H NMR 
spectroscopic metabolic profiling approach. This enabled the semi-quantification of 
major urinary metabolites for use in the next stage of the analysis which focused on 
the statistical association of urinary metabolic profiles with birth outcomes (chapter 
5). This chapter describes the study population in Gipuzkoa and Sabadell in terms 
of maternal characteristics and pregnancy-related variables. NMR spectroscopic 
metabolic profiles of the urine samples of all pregnant women are presented and the 
analytical stability assessed together with variation related to the stage of gestation 
(biological). Finally, some urinary metabolites unique to pregnant women profiles 
required application of multiple analytical technologies to enable their structural 
identification.  
 Introduction 3.1
The pregnancy period is characterised by dramatic anatomic, physiological and 
metabolic changes in women which ensure placental and fetal growth. Previous 
studies lacked large enough sample size and repeated sample collection at different 
stages of pregnancy to allow detailed analysis of maternal physiology, lifestyle and 
medical history in combination with changing metabolic status during pregnancy. 
The present study benefited from the participation of pregnant women recruited in 
the Gipuzkoa and Sabadell cohorts at an early stage of gestation. They had their 
urine samples collected approximately at 12th and 34th weeks of gestation along with 
a plethora of other health and environmental determinants via questionnaires and 
biochemical analyses. Urine is a particularly useful biofluid for medical diagnostics 
because it is easy to obtain in large volumes, its collection is non-invasive and 
typically it contains a large number of hydrophilic metabolic breakdown products 
from a wide range of foods, drinks, drugs, environmental contaminants, endogenous 
waste metabolites and bacterial by-products. The urinary metabolic profile 
represents the accumulation of waste products since last urination, concentrated 
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from the blood by the kidneys, whereas serum metabolic levels are under 
homeostatic control and thus represent only a ‘snapshot’ of metabolic alterations in 
the biochemical pathways of the entire organism. The application of NMR based 
metabonomics to profiles pregnant women’s urine, 1,692 samples in total, allowed 
the acquisition of rich information on their metabolic profiles at two time points of 
pregnancy. These data represent the largest dataset to date characterising the 
pregnant woman’s urinary metabolome.  
 Results 3.2
 Study population 3.2.1
The characteristics of the women selected among the two cohorts are presented 
and compared in Tables 4-1 to 4-4 in terms of socio-demographic, lifestyle, diet and 
clinical parameters. The different columns allow the comparison of the 
characteristics in the four sub-cohorts corresponding to the women who gave 
samples at week 12 or week 34 and who were included in the final analysis (studies 
1 and 2). Since the population in Gipuzkoa sub-cohorts at weeks 12 and 34 were 
almost identical (only 5 women are different in the third trimester), characteristics 
are presented for the combined sub-cohorts at weeks 12 and 34 for a total of 419 
women. The two Sabadell sub-cohorts constituted 394 women who had urine 
samples collected at week 12 and 469 at week 34. The distribution of some 
population characteristics showed small differences between the full original cohorts 
and the population selected for this study (Population characteristics of the full 
cohorts presented in Annexe Table 9-1). In the Gipuzkoa analysis group, there was 
a higher proportion of women with tertiary education (53.2% vs. 49.8%) and with 
higher social class (both maternal and paternal), which may account for the slight 
decrease in the smoking and alcohol consumption compared to the full cohort (1-2% 
differences). This socio-demographic difference was inversed in the Sabadell 
population with only a slightly lower proportion of women with tertiary education in 
the subgroup (25.4%-26.5% versus 28.2% in full cohort). The Sabadell sub-
population which gave samples in the 3rd trimester of pregnancy was in general 
slightly more representative of the full cohort than the sub-cohort which gave 
samples in the 1st trimester, mainly due to their higher number. 
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Among the women included in this present metabonomic study, baseline 
characteristics were compared between the two cohorts as presented in Table 3-1. 
Mothers had a median age at the time of recruitment of 30 and 31 (respectively in 
Sabadell and Gipuzkoa), were in majority Spanish and born in Spain with a 
significantly larger proportion of women born abroad in Sabadell (11%) compared to 
Gipuzkoa (3%, p=4.83E-06). Parents were educated to a higher level and belonged 
to higher social class in Gipuzkoa compared to Sabadell (28% in Gipuzkoa versus 
20% of mothers in average in Sabadell belonged to a high socio-professional class, 
p-value=2.65E-03). Approximately half of the mothers were primiparous and 40% 
had given birth once before. There was a lower rate of birth outcomes in Gipuzkoa, 
although not significant, with 4% of LBW, 8% of SGA and 2% of preterm birth 
compared to Sabadell which had in average 5% of LBW, 11% of SGA and 3% of 
preterm birth. 
. 
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Table 3-1. Baseline characteristics of women in Gipuzkoa and Sabadell during pregnancy included in the analysis (different sub-cohorts exist for 
women who gave samples at week 12 or at week 34). P values were calculated using the Chi-squared
 
test (categorical variables) or Mann-Whitney test 
(continuous) between Sabadell women (week 34 sub-cohort) and Gipuzkoa women.  
  
Gipuzkoa* -  Included in 
the analysis (combined 
weeks 12 and 34, n=419) 
Sabadell - Included in the 
analysis (week 12, n=394) 
Sabadell - Included in 
the analysis (week 34, 

















Mother age  
 
31 29 - 34 30 28 - 33 30 28 - 33 1.14E-04 
Missing 
 
0 0.0 1 0.3 1 0.2 
 Mother ethnicity Spain 387 92.4 342 86.8 398 84.9 1.99E-05 
 
Latin America 9 2.1 29 7.4 36 7.7 
 
 
Others 2 0.5 14 3.6 13 2.8 
 Missing 
 
21 5.0 9 2.3 22 4.7 
 Country of birth Spanish 407 97.1 346 87.8 411 87.6 4.83E-06 
 
Foreign 12 2.9 43 10.9 51 10.9 
 Missing 
 
0 0.0 5 1.3 7 1.5 
 Maternal social class I+II (High) 119 28.4 84 21.3 91 19.4 2.65E-03 
 
III (Medium) 123 29.4 116 29.4 135 28.8 
 
 
IV+V (Low) 177 42.2 194 49.2 243 51.8 
 Missing 
 
0 0.0 0 0.0 0 0.0 
 Paternal social class I+II (High) 103 24.6 81 20.6 91 19.4 3.34E-01 




Gipuzkoa* -  Included in 
the analysis (combined 
weeks 12 and 34, n=419) 
Sabadell - Included in the 
analysis (week 12, n=394) 
Sabadell - Included in 
the analysis (week 34, 


















III (Medium) 60 14.3 62 15.7 72 15.4 
 
 
IV+V (Low) 251 59.9 225 57.1 274 58.4 
 Missing 
 
5 1.2 26 6.6 32 6.8 
 
Maternal education 
Without education or 
unfinished primary 
school 2 0.5 1 0.3 1 0.2 1.10E-12 
 
Primary 54 12.9 107 27.2 136 29.0 
 
 
Secondary 147 35.1 160 40.6 195 41.6 
 
 
University 216 51.6 123 31.2 135 28.8 
 Missing 
 
0 0 3 0.8 2 0.4 
 Paternal education Primary 107 25.5 141 35.8 166 35.4 1.91E-03 
 
Not able to read and 
write 6 1.4 1 0.3 0 0.0 
 
 
Without education or 
unfinished primary 
school 10 2.4 7 1.8 9 1.9 
 
 
Secondary 186 44.4 163 41.4 197 42.0 
 
 
University 101 24.1 78 19.8 92 19.6 
 




Gipuzkoa* -  Included in 
the analysis (combined 
weeks 12 and 34, n=419) 
Sabadell - Included in the 
analysis (week 12, n=394) 
Sabadell - Included in 
the analysis (week 34, 



















9 2.1 4 1.0 5 1.1 
 Low birth weight (<2.5kg) 
 
16 3.8 19 4.8 23 4.9 2.80E-01 
Missing 
 
3 0.7 2 0.5 1 0.2 
 Small for gestational age  
 
34 8.1 45 11.4 49 10.4 5.40E-01 
Missing 
 
7 1.7 7 1.8 7 1.5 
 Preterm birth (<37 weeks) 
 
8 1.9 11 2.8 15 3.2 3.10E-01 
Missing 
 
3 0.7 5 1.3 6 1.3 
 Season of birth Spring 121 28.9 113 28.7 129 27.5 2.20E-01 
 
Summer 122 29.1 98 24.9 152 32.4 
 
 
Fall 93 22.2 101 25.6 117 24.9 
 
 
Winter 83 19.8 82 20.8 71 15.1 
 Missing 
 
0 0 0 0 0 0 
 *Since the population characteristics in the Gipuzkoa cohort are almost identical between the first and third trimesters (only 5 women are 
different in the third trimester), the table is combined for 1st/3rd trimester samples for Gipuzkoa. 
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Lifestyle parameters during pregnancy, as described in Table 3-2, such as sleep 
duration and night work at week 12 were almost identical in both cohorts. Women 
slept on average 8 hours and only a small proportion of the population worked night 
shifts (<=5.5%). Other parameters such as physical activity showed different 
patterns in the two cohorts. As expected, physical activity was reduced in the two 
cohorts from week 12 to week 34 of gestation. However, women in Sabadell 
reduced their activity more dramatically at week 34 with the majority of women that 
kept little activity (45%) compared to Gipuzkoa (30%) with p<0.001. Another 
difference was that all the women in Sabadell lived in urban areas whereas only 
48% in Gipuzkoa did. Sabadell women were also more exposed to cigarette smoke 
via passive smoking and first-hand smoking. Indeed, 16% of Sabadell women were 
smoking more than 10 cigarettes a day at the beginning of pregnancy compared 
with 8% in Gipuzkoa (p=0.001). Self-reported alcohol consumption was relatively 
low in both cohorts with only 5-10% of women consuming more than 1g a day 
(corresponding to 1/10th of the recommended alcohol content of a standard drink in 
Spain, which means that most women reporting alcohol consumption had less than 
a drink a week). BMI values indicate that Sabadell women were more prone to being 
underweight or overweight and obese than Gipuzkoa women with only 67% of 
healthy BMI in Sabadell versus 76% in Gipuzkoa (p=0.003).
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Table 3-2. Lifestyle characteristics of women during pregnancy in Gipuzkoa and Sabadell included in the analysis (different sub-cohorts exist for 
women who gave samples at week 12 or at week 34). P values were calculated using the Chi-squared
 
test (categorical variables) or Mann-Whitney test 
(continuous) between Sabadell women (week 34 sub-cohort) and Gipuzkoa women.  
  
Gipuzkoa -  Included in 
the analysis (combined 
weeks 12 and 34, 
n=419) 
Sabadell - Included 
in the analysis 
(week 12, n=394) 
Sabadell - Included in 






















Hours of sleep at week 12 
 
8 7-8 8 7-8 8 7-8 6.42E-02 
Missing 
 
17 4.1 1 0.3 1 0.2 
 Overall physical activity at week 12 Moderate activity 149 35.6 181 45.9 210 44.8 3.19E-02 
 
Little activity 108 25.8 111 28.2 131 27.9 
 
 
Intense or sufficient activity 136 32.5 100 25.4 125 26.7 
 Missing 
 
26 6.2 2 0.5 3 0.6 
 Hours of sleep at week 34 
 
8 7-9 8.0 7-9 8 7-9 2.38E-06 
Missing 
 
2 0.5 0 0.0 1 0.2 
 Overall physical activity at week 34 Moderate activity 201 48.0 138 35.0 166 35.4 1.05E-05 
 
Little activity 126 30.1 178 45.2 213 45.4 
 
 
Intense or sufficient activity 90 21.5 78 19.8 89 19.0 
 Missing 
 
2 0.5 0 0.0 1 0.2 
 Night work Day shift 342 81.6 328 83.2 386 82.3 5.01E-01 
 
Night shift 23 5.5 20 5.1 20 4.3 
 




Gipuzkoa -  Included in 
the analysis (combined 
weeks 12 and 34, 
n=419) 
Sabadell - Included 
in the analysis 
(week 12, n=394) 
Sabadell - Included in 
























54 12.9 46 11.7 63 13.4 
 Zone of residence  Rural 50 11.9 0 0.0 0 0.0 7.88E-71 
 
Sub-urban 168 40.1 0 0.0 0 0.0 
 
 
Urban 201 48.0 393 99.7 468 99.8 
 Missing 
 
0 0.0 1 0.3 1 0.2 
 Passive smoking No exposure 161 38.4 142 36.0 174 37.1 4.11E-01 
 
At least in 1 place 185 44.2 167 42.4 193 41.2 
 
 
At least in 2 places  65 15.5 73 18.5 85 18.1 
 
 
At least in 3 places  8 1.9 12 3.0 15 3.2 
 Missing 
 
0 0.0 0 0.0 2 0.4 
 Average daily intake of alcohol (g) 0.04-1g/day 146 34.8 124 31.5 147 31.3 2.39E-01 
 
1g/day 25 6.0 38 9.6 40 8.5 
 
 
None 246 58.7 232 58.9 281 59.9 
 Missing 
 
2 0.5 0 0.0 1 0.2 
 Smoking before pregnancy (cig./day) between 1 and 10 cig/day 129 30.8 101 25.6 121 25.8 2.05E-01 
 
more than 10 cig/day 84 20.0 93 23.6 110 23.5 
 




Gipuzkoa -  Included in 
the analysis (combined 
weeks 12 and 34, 
n=419) 
Sabadell - Included 
in the analysis 
(week 12, n=394) 
Sabadell - Included in 























No smoking 204 48.7 197 50.0 233 49.7 
 Missing 
 
2 0.5 3 0.8 5 1.1 
 Smoking at the beginning of pregnancy  between 1 and 10 cig/day 48 11.5 53 13.5 64 13.6 1.40E-03 
 
more than 10 cig/day 35 8.4 64 16.2 73 15.6 
 
 
No smoking 336 80.2 276 70.1 330 70.4 
 Missing 
 
0 0.0 1 0.3 2 0.4 
 Smoking at week 12 (cig./day) between 1 and 10 cig/day 33 7.9 53 13.5 63 13.4 1.37E-02 
 
more than 10 cig/day 3 0.7 7 1.8 7 1.5 
 
 
No smoking 383 91.4 334 84.8 398 84.9 
 Missing 
 
0 0.0 0 0.0 1 0.2 
 BMI before pregnancy <18.5 (Underweight) 12 2.9 24 6.1 27 5.8 4.71E-03 
 
18.5-25 (Healthy) 320 76.4 268 68.0 310 66.1 
 
 
25.1-30 (Overweight) 57 13.6 72 18.3 93 19.8 
 
 
>30 (Obese) 30 7.2 30 7.6 39 8.3 
 Missing 
 
0 0.0 0 0.0 0 0.0 
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Dietary variables are described in Table 3- and are compared between stages of 
pregnancy (weeks 12 and 34) and between the two cohorts in  . Diet was measured 
as average daily consumption in grams of different product categories. A dramatic 
increase of dairy consumption was observed in both cohorts of more than 40% from 
week 12 to week 34 (from an average of 362g to 517g). Dairy products included 
milk, cream, yogurt, cottage cheese or fresh cheese, custard, pudding and ice 
cream. A significantly lower calorie intake was observed in Gipuzkoa compared to 
Sabadell consistently in both stages of pregnancy explained by a lower meat (91 to 
128g at week 12 and 91 to 125g at week 34, p<0.001) and fat intake (72 to 94g at 
week 12 and 68 to 91g at week 34, p<0.001). Eggs consumption was slightly lower 
in Sabadell with 95 women eating less than 10 grams a day versus 57 in Gipuzkoa 
at week 12. Average consumption in both cohorts was similar with around 20 grams 
of eggs consumed a day. Coffee and infusion consumptions were higher in 
Gipuzkoa 200 versus 186g in Sabadell at week 12 only. 




Figure 3-1. Dietary habits measured as average daily consumption of different 
products categories in grams in Gipuzkoa and Sabadell at week 12 and at week 34 P 
values were calculated using the Mann-Whitney test between Sabadell women (sub-cohort 
at week 34) and Gipuzkoa women. Significant p-values are labelled as following:  * P < 0.05, 
**P < 0.01 and ***P<0.001. 
All the clinical biomarkers presented in Table 3-4 were measured in maternal blood 
in the 1st trimester. Clinical measures indicate that Sabadell women had 
significantly higher triglycerides (100mg/dl versus 90mg/dl in Gipuzkoa, p<0.001) 
and C-reactive protein (4ng/dL versus 0.4ng/dL in Gipuzkoa, p<0.001) than in 
Gipuzkoa. They also had lower levels of vitamins and minerals such as vitamin B12, 
folic acid and iodine, except for vitamin D which was higher in Sabadell (73 versus 
28 ng/mL in Gipuzkoa, p<0.001). Other clinically measures during pregnancy 
indicated that women in Sabadell were more likely to have a gestational weight gain 
above the recommended level by IOM (41% in Sabadell versus 23% in Gipuzkoa) 
and also were more likely to have impaired glucose tolerance (17% in Sabadell 
versus 4% in Gipuzkoa, results of the oral glucose tolerance test (OGTT)). Other 
health outcome data not related to pregnancy (results not shown) indicate that 
women in the Gipuzkoa cohort were in general in good health with very few cases of 
heart, renal or thyroid gland disorders (respectively n=2, 3 and 12). However, 
Daily consumption (in grams) 
3 . 2  R e s u l t s  | 103 
103 
 
Sabadell women were showing a two to four-fold higher incidence than in Gipuzkoa 
for some of these conditions. Indeed, respectively for the 1st /3rd trimester sub-
cohorts, 16/19 women had heart disease, 15/19 renal or suprarenal diseases and 
27/27 disorders of the thyroid gland. 
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Table 3-3. Diet characteristics women during pregnancy in the Gipuzkoa and Sabadell included in the analysis presented as daily average 
consumption in grams (different sub-cohorts exist for women who gave samples at week 12 or at week 34). P values were calculated using the Mann-
Whitney test (continuous) between Sabadell women (week 34 sub-cohort) and Gipuzkoa women. P-values below 0.05 are bolded. 
  
Gipuzkoa -  Included in the 
analysis (combined weeks 
12 and 34, n=419) 
Sabadell - Included in the 
analysis (week 12, n=394) 
Sabadell - Included in the 



















At week 12 (data 
available for 403 
women in Gipuzkoa 
and 393/461 in 
Sabadell) 
coffee/tea  200 42 - 286 185.8 13 - 200 185.8 13 - 200 3.26E-04 
intake of calories(Kcal) 1934 1669 - 2175 2075 1785 - 2410 2075 1782 - 2412 2.06E-07 
total fat  73.85 60 - 89 94.05 77 - 109 94.05 77 - 110 3.36E-24 
consumption of dairy   375.9 282 - 619 356.7 254 - 596 356.7 248 - 604 6.17E-02 
consumption of eggs   21.62 22 - 22 21.62 22 - 22 21.62 22 - 22 2.48E-02 
meat   91.36 66 - 116 127.6 102 - 156 127.6 101 - 157 6.07E-36 
 
fish  68.6 48 - 92 65.49 43 - 92 65.49 43 - 92 1.24E-01 
 
vegetables  206 154 - 265 213.1 148 - 282 213.1 150 - 292 2.98E-01 
 
fruits  325.7 189 - 458 280.6 184 - 426 280.6 183 - 438 1.43E-01 
At week 34 (data 
available for 417 
women in Gipuzkoa 
and 394/468 in 
coffee/tea  200 86 - 286 200 46 - 279 200 29 - 286 4.78E-02 
intake of calories(Kcal) 1918 1662 - 2213 2092 1804 - 2460 2092 1818 - 2461 5.25E-11 
total fat  72.17 60 - 88 91.03 76 - 109 91.03 78 - 111 1.86E-35 
consumption of dairy   512.5 334 - 657 525.3 323 - 647 525.3 311 - 647 2.19E-01 
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Sabadell) consumption of eggs   21.62 22 - 22 21.62 22 - 22 21.62 22 - 22 1.67E-03 
meat   93.13 70 - 115 124.9 95 - 150 124.9 98 - 155 9.04E-30 
 
fish  70.59 53 - 92 63.37 44 - 91 63.37 43 - 91 8.09E-04 
 
vegetables  204.4 151 - 278 212.8 147 - 280 212.8 147 - 276 9.64E-01 
 
fruits  310.9 214 - 417 313.1 185 - 444 313.1 179 - 449 9.46E-01 
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Table 3-4. Clinical parameters of women at week 12 of pregnancy in the Gipuzkoa and Sabadell cohorts included in the analysis (different sub-
cohorts exist for women who gave samples at week 12 or at week 34). P values were calculated using the Chi-squared
 
test (categorical variables) or 
Mann-Whitney test (continuous) between Sabadell women (week 34 sub-cohort) and Gipuzkoa women. Abbreviation: TSH, thyroid stimulating hormone. 
  
Gipuzkoa -  Included 
in the analysis 
(combined weeks 12 
and 34, n=419) 
Sabadell - Included in 
the analysis (week 12, 
n=394) 
Sabadell - Included in 























 196 174 - 216 187 170 - 207 187 169 - 208 1.08E-03 
Missing 
 
3 0.7 13 3.3 11 2.3 
 Triglycerides (mg/dl) 
 
94 70 - 117 100 77 - 129 100 77 - 130 9.06E-04 
Missing 
 
3 0.7 13 3.3 11 2.3 
 Folic acid (micrograms/l) 
 
16.9 44866 11.2 8.5 - 16 11.2 8.4 - 17 1.25E-14 
Missing 
 
3 0.7 13 3.3 12 2.6 
 Vitamin B12 (pg/l) 
 
325 266 - 390 298 257 - 366 298 256 - 364 4.56E-04 
Missing 
 
1 0.2 7 1.8 6 1.3 
 Vitamin D (nanograms/ml) 
 
26.6 21 - 35 72.6 51 - 91 72.6 53 - 93 1.47E-106 
Missing 
 
1 0.2 7 1.8 9 1.9 
 TSH mother (microU/ml) 
 
1.27 0.8 - 1.9 1.21 0.8 - 1.8 1.21 0.8 - 1.7 2.44E-01 
Missing 
 
1 0.2 36 9.1 36 7.7 
 T3 mother (nmol/L) 
 
2.41 2.2 - 2.7 2.385 2.2 - 2.6 2.385 2.2 - 2.7 9.99E-01 
Missing 
 
1 0.2 36 9.1 37 7.9 
 T4 mother (pmol/l) 
 
9.96 9.1 - 11 10.7 9.8 - 12 10.7 9.8 - 12 4.50E-13 




Gipuzkoa -  Included 
in the analysis 
(combined weeks 12 
and 34, n=419) 
Sabadell - Included in 
the analysis (week 12, 
n=394) 
Sabadell - Included in 
























1 0.2 36 9.1 36 7.7 
 C- reactive protein (mg/dl) 
 
0.37 0.2 - 0.67 4 3-7 4 3 - 7.8 1.90E-123 
Missing 
 
3 0.7 78 19.8 91 19.4 
 Iodine (micrograms/l) 
 
175 114 - 272 101 62 - 160 101 55 - 154 3.58E-22 
Missing 
 
0 0.0 231 58.6 261 55.7 
 Ferritin mother (micrograms/l) 
 
25.28 15 - 46 26.89 15 - 44 26.89 15 - 45 5.19E-01 
Missing 
 
1 0.2 6 1.5 5 1.1 
 Total gestational weight gain Recommended 172 41.1 153 38.8 178 38.0 4.44E-09 
 
Low 126 30.1 74 18.8 88 18.8 
 
 
High 89 21.2 158 40.1 191 40.7 
 Missing 
 
32 7.6 9 2.3 12 2.6 
 Gestational diabetes none 367 87.6 132 33.5 159 33.9 3.64E-22 
 
impaired glucose tolerance (IGT) 13 3.1 62 15.7 79 16.8 
 
 
gestational diabetes mellitus (GDM) 14 3.3 9 2.3 10 2.1 
 
 
diabetes diagnosed prior to pregnancy 2 0.5 0 0.0 0 0.0 
 
 
gestational diabetes mellitus 0 0.0 1 0.3 2 0.4 
 Missing 
 
23 5.5 190 48.2 219 46.7 
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 Analytical and biological variability 3.2.2
An assessment of the analytical reproducibility and variability of NMR spectroscopic 
metabolic profiles of 1692 urine samples is presented in this section. Although NMR 
is recognized as a robust technique with limited analytical drift over time compared 
to LC-MS, possible variations within the NMR data due to technical biases were 
investigated in both cohorts separately. Analytical reproducibility is an important 
consideration for validation of NMR-based biomarkers. It was investigated in terms 
of analytical stability over the run time (sample order) in the first batch of samples 
(Gipuzkoa cohort) and in more detail in terms of analytical stability and sample 
degradation in the second batch of samples (Sabadell cohort) using a range of 
statistics including PCA, O-PLS regression techniques, univariate linear regression 
models and through calculation of coefficients of variation (CVs). 
 Gipuzkoa samples 3.2.2.1
The first batch of samples, the Gipuzkoa sub-cohort (n=412 for week 12 and n=417 
for week 34 of gestation), was analysed in March 2012 over 19 days with a small 
analytical drift over time which is described and explained below.  
The sample order for acquisition of the NMR experimental data was randomised 
across trimesters to enable subsequent separation of effects related to analytical 
variability (such as analytical drift) and to biological variations (such as time point of 
gestation). The urine samples were collected at the same time as the women were 
recruited at around 12 weeks of gestation, regardless of the woman’s health or 
lifestyle status. Therefore, the samples from Gipuzkoa were run in the same order 
that the women were recruited with the first and third trimester samples randomised 
(6 samples from 1st trimester/ 6 samples from third trimester/ 6 samples from 1st 
trimester/ etc). The first sample was collected in June 2006 and the last sample in 
August 2008. All the samples were stored at -20°C prior to shipment to Imperial. 
Two O-PLS models were computed to assess the effect of sample storage duration 
on the metabolic profiles. The dataset was split between first trimester and third 
trimester samples for the following statistical models. Using O-PLS regression 
analyses, an association was found between the spectral profiles with the time of 
sample collection (for 1st trimester: Q2Y=0.51, R2Y=0.88, R2X=0.12 and for 3rd 
trimester: Q2Y=0.31, R2Y=0.77, R2X=0.12). This association could be explained by a 
3 . 2  R e s u l t s  | 109 
109 
 
consistent biochemical degradation of the earliest collected samples which occurred 
over the course of two years of storage at -20°C. However, an O-PLS model also 
demonstrated a correlation between the NMR data and the run order (for 1st 
trimester: Q2Y=0.46, R2Y=0.82, R2X=0.10 and for 3rd trimester: Q2Y=0.41, 
R2Y=0.78, R2X=0.13). The effect of sample storage duration in the cohort centre 
and experimental run order on NMR measurements cannot be disentangled 




H-NMR mean spectra every 50 urine samples in the Gipuzkoa cohort 
display a decrease in creatinine peak at δ4.06 and an increase in triplet at δ4.04 
(inset). The spectral line colour corresponds to the run order (black corresponds to the 
beginning of the run, light blue corresponds to the end of the run)  
A systematic variation in spectral intensities, after data normalisation, was observed 
for each sequential NMR spectrum of the complete dataset. Figure 3-2 represents 
the mean spectra every 50 urine samples in the Gipuzkoa cohort coloured 
according to the sample position in the run. Abundant peaks such as lactate, citrate 
or alanine showed a signal reduction on spectral inspection. The CH2 creatinine 
peak at δ4.06 was particularly affected with a consistent signal reduction correlated 
to the increase in a multiplet at δ4.04 (inset Figure 3-2). The multiplet, with a J-
coupling constant of 1Hz, is believed to arise from the CHD group of creatinine after 
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exchange of a proton for deuterium (J ca. 1Hz for H-D coupling from the solvent 
D2O which was used for the spectrometer lock signal). 
The relationship between metabolite measurements and sample position in the run 
was quantified using linear and quadratic regression on log-transformed peak 
integrals. Unknown singlet at 0.93 (potentially pantothenic acid), 
3-hydroxyisobutyrate, 3-hydroxyisovalerate, overlapped 
3-hydroxybutyrate/3-aminoisobutyrate, citrate, pyroglutamate (5-oxoproline), 
leucine, valine, guanidinoacetate and fumarate, were particularly affected with a 
variance explained (R2) by the run order between 6 and 1 %. A couple of 
representative metabolite peaks were selected and displayed in Figure 3-3 to 
visualise potential patterns in the experimental drift over the course of the run. 
Based on the linear regression model the creatinine signal at δ4.06 experienced a 
0.02%-0.03% integral drop every incremental sample for data that normalised. 
TMAO experienced a smaller drop of 0.003%. This signal reduction followed an 
almost linear trend with a stronger decrease between the sample positions 500 and 
600 according to Figure 3-3. A. Scatter plots of raw integral data (before 
normalisation) in Figure 3-3. B. provided further evidence of the origin of the 
experimental drift. A clear pattern for creatinine and TMAO, as well as other peaks 
not represented here, was observed with a sharp decrease in peak integral values 
between the sample positions 290 and 558.  




Figure 3-3. Visualisation of experimental drift on NMR peak integrals in Gipuzkoa 
urine samples of the creatinine (δ 4.06) and TMAO (δ 3.27) peaks. A. Scatter plot and 
fitted linear and quadratic regression models of the peak integral of creatinine and TMAO 
(log-transformed) after probabilistic normalisations. B. Scatter plot and fitted linear (red) and 
smooth spline (blue) models of the peak integral of creatinine and TMAO (log-transformed) 
without any normalisation. 
Signal amplification is dependent on mainly one NMR experiment parameter: the rg 
value (receiver gain, see section 3.1.1.1.4 NMR experiment acquisition), which was 
automatically adjusted in this PhD for each sample given the variation in urinary 
osmoloality/dilution. A scatter plot of rg values against run order is given inFigure 
3-4. A (rg values were extracted for each NMR experiment) and provided evidences 
that rg values dramatically decreased (from a range of 100-600 to 0-100) between 
the sample positions 290 and 558. In addition, the water signal, which was 
integrated (4.76-4.88 ppm) from raw NMR spectra, also showed an almost two-fold 
increase between the samples 290 and 558 as displayed in Figure 3-4 B reflecting 
poorer water suppression in these samples. 




Figure 3-4 Evolution of the receiver gain (A.) and water signal (B.) in all 
1
H NMR 
spectra of urine samples from the Gipuzkoa cohort (n=829) across the run order 
To summarise, raw spectral data were affected by a change in water suppression in 
the middle of the run which returned to normal towards the end of the run. The 
consequence of this water suppression was a drop in rg values in the middle of the 
run (Figure 3-4) which affected the overall peak intensities. The signals surrounding 
the water area (4.00-6.00ppm) were more strongly affected. This bias was limited in 
the following analyses by cutting out the region 4-6ppm from all spectra. Overall the 
experimental drift was corrected by applying normalisation algorithms leaving a 
small residual bias: a general intensity decrease over the course of the run which 
was limited on average to a -0.2% decrease every 100 samples across all 
metabolites. In addition, the most abundant metabolite in urinary metabolic profiles, 
creatinine, was slightly affected by deuterium/proton exchange. 
4.0.1.1 Sabadell samples 
The second batch of samples, the Sabadell sub-cohort (n=394 for week 12 and 
n=469 for week 34 of gestation), was analysed over 22 days in January 2013 with 
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interspersed quality control samples, in order to better assess analytical variability 
based on the previous limitations identified in the Gipuzkoa NMR run. 
Urine samples from the Sabadell cohort were analysed based on the limitations of 
the Gipuzkoa sample analysis where sample storage time in the cohort centre was 
randomised and where additional measures were taken to assess sample 
degradation and analytical reproducibility. QCs issued from aliquots of the same 
pooled urine sample, representative of the Sabadell cohort samples, were added to 
the run in order to separate experimental biases from biological variations.  
Figure 3-5 Analytical stability of urine metabolites analysed by 
1
H NMR 
This is represented by coefficients of variation as a percentage (CV %) (n=32 
QCs across approximately 900 samples from the Sabadell cohort). represents 
the results of the two types of QCs which informed on variations due to the 
analytical/post-analytical variability and sample stability. Indeed, for each QC 
aliquot, two spectra were acquired: the first and last experiment out of batches of 60 
samples which corresponded to the sample holding capacity of the NMR carousel 
and to approximately 20 hours of analysis. The CVs, which provided a 
dimensionless measure of the variability, were calculated based on a formula using 
the standard deviation of the log10-transformed metabolite peak integrals. The CVs 
of the “Fresh” QCs represented the relative variation in peak integrals between 16 
identical aliquots whereas the CVs of repeat QCs represented the mean variation 
between the freshly prepared aliquot and the post-20-hour-repeat aliquot. 80% of 
the metabolite buckets had CVs inferior to 10% and 46% had even CVs inferior to 
5%, for both fresh QCs and repeat QCs. The other 20% of metabolites which 
presented relatively high CVs between 10-20%, included oestrogen metabolite, UA 
8.79(d), UA 6.48(d), 1-Methyl-nicotinamide and Fumarate with CVs above 20% and 
N-Methylnicotinic acid, Isoleucine, N-acetylserotonin, Valine, Progesterone 
metabolite, 2Py, Furoylglycine and UA 1.15 (mix). 




Figure 3-5 Analytical stability of urine metabolites analysed by 
1
H NMR 
This is represented by coefficients of variation as a percentage (CV %) (n=32 QCs across 
approximately 900 samples from the Sabadell cohort). 64 metabolites were semi-quantified 
and analysed for their variability in representative QCs from the Sabadell population in terms 
of analytical/post-analytical variability and sample stability. 
Visual inspection of the spectra acquired for the freshly prepared QCs in revealed 
systematic chemical shift variability in the case of a few peaks for three of the QCs. 
Signals with this variability included 3-hydroxyisobutyrate, unknown singlets at δ2.93 
and δ6.59, fumarate, N-methylnicotinic acid and 1-methyl-nicotinamide, i.e. the 
same metabolites with high CVs for fresh QCs in Figure 3-5. This consistent shift 
was not present for the majority of the signals. Lactate for example was not affected 
as observed in the inset of Figure 3-6. Signals with high CVs also had in common a 
low signal-to-noise ratio (SNR). This association was confirmed by measuring the 
SNR for all 64 metabolites in QC samples. The strong inverse relationship between 
CVs and SNRs is displayed in Figure 3-7 showing the reciprocal distribution for CVs 
for the four SNR ranges. 10 metabolites had a SNR inferior to 20 which included (in 
the increasing order of SNRs): UA 8.79(d), UA 6.48(d), fumarate, 1-methyl-
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nicotinamide, progesterone metabolite at δ0.58, furoylglycine, 2Py, UA 0.75(d), N-
methylnicotinic acid and isoleucine. Overlapped signals for creatinine and creatine 




H-NMR spectra of 16 quality controls from identical aliquots interspersed 
in the NMR run of 863 Sabadell cohort samples (22 days). The spectral line colour was 
assigned at random except for the red ones which correspond to spectra with systematic 
chemical shift variability. 
 




Figure 3-7. Boxplot showing the reciprocal distribution of CVs representative of the 
analytical stability of 64 metabolites across signal-to-noise ratio ranges. CVs and 
signal-to-noise ratios were calculated for measurements from the 
1
H NMR spectra of fresh 
urine QCs (n=16) 
Most metabolites showed good stability at room temperature based on the 
comparison of CVs from fresh and post 20 hours aliquots repeat QCs (red bars in 
Figure 3-5) and CVs of only freshly prepared aliquots. Few metabolites including 
fumarate, succinate, progesterone metabolite, UA 6.59(s) and N-methylnicotinic 
acid showed larger variation in CVs from fresh and post 20 hours aliquots than CVs 
of only freshly prepared aliquots, attributed to potential sample degradation (crude 
difference between CV analytical/post-analytical variability and CV for sample 
stability equal to 1.6-6%). 
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4.0.1.2 Coefficients of variation for Sabadell and Gipuzkoa samples 
In order to evaluate whether technical reproducibility may affect the interpretation of 
results from biological experiments, the following section investigates the total 
variation in metabolite measurements in both cohorts which represents biological 
and technical variance. 
The variability in urine metabolite measurements, represented by 64 metabolites 
selected based on their spectral quality (i.e. limited peak overlap and sufficient 
SNR), was assessed separately at the two time points in Sabadell and Gipuzkoa 
cohort samples. The total variability, as measured by CVs presented in Figure 3-8, 
is composed of analytical and biological variability. Similar metabolite variability was 
observed in both cohorts. CVs varied up to 240% for the unknown doublet at δ8.79 
to 11% for the unknown triplet at δ1.99. Trimester differences were especially 
marked for δ8.79 (d) which was highly variable at week 34. Metabolites such as 
steroid hormone derivates, N-methylnicotinic acid, 1-methyl-nicotinamide, 
furoylglycine, hippurate, fumarate, lactate, carnitine, TMAO, scyllo-inositol, 2Py, 
proline betaine showed a high variability with a CV superior to 50% in both cohorts. 
Conversely, metabolites such as leucine, 2-hydroxyisobutyrate, pyroglutamate (5-
oxoproline) and N-acetyl glycoprotein fragments showed lower variability with CVs 
inferior to 20%, in both cohorts. Few metabolites exhibited larger CVs in Gipuzkoa 
than in Sabadell samples including N-acetyl neuraminic acid and scyllo-inositol. In 
contrast, a larger proportion of metabolites had higher variability in Sabadell than in 
Gipuzkoa samples, including steroid derivates (oestrogen metabolites, progesterone 
metabolites and unknown doublet at δ0.75), which presented a CV of over 50% in 
the 1st trimester only. At this early stage of pregnancy (week 12), these signals were 
not easily detected and CVs represent mainly noise variation.  A large proportion of 
variance was biological (with 80% of metabolites with analytical CVs<10%), hence 
leaving potential for detecting effects/associations with health outcomes.




Figure 3-8. Variability of urine metabolites at two time points of pregnancy analysed in Sabadell (A.) and Gipuzkoa cohort (B.) represented with the 
coefficient of variation. 64 metabolites were semi-quantified and analysed for their variability in the population from both cohorts 
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 Metabolic shift from 1st to 3rd trimester 3.2.3
An overview of the NMR spectral data in the Sabadell and Gipuzkoa cohorts, using 
dimension reduction regression methods, provided a clear separation of the two 
times of sampling (Figure 3-9.A). The urine samples were collected in both cohorts 
during the first scan visit at the hospital approximately at the 12th week of pregnancy 
and again at the 34th week. PCA and O-PLS-DA models were performed on full-
resolution spectral data after normalisation and peak alignment. The separation 
between the first and third trimester samples was visible in the 1st and 2nd principal 
components as shown in Figure 3-9.A and B (in Sabadell, PC1: R2X = 13.5%, PC2: 
R2X = 5%, in Gipuzkoa, PC1: R2X = 5.8%, PC2: R2X = 3.9%). Discriminatory 
metabolites were identified from the O-PLS-DA coefficients on the basis of the 
regression coefficient strength. Consistently in both cohorts, creatinine, carnitine 
and scyllo-inositol were decreased in the 3rd trimester samples, whereas steroid 
hormone conjugates, alanine, 4-deoxyerythronic acid were increased in the 3rd 
trimester. Unique metabolite changes were observed for samples from the Gipuzkoa 
cohort with an unidentified singlet at 2.08 ppm only present in the 1st trimester 
samples.  




Figure 3-9. PCA and O-PLS-DA models discriminating 1st from 3rd trimester of 
pregnancy in urinary NMR spectral profiles.  
(A) PCA score plots for the Sabadell and (B) Gipuzkoa cohorts with 1st trimester (blue) and 
3rd trimester (red), (C) O-PLS-DA loadings coefficient plot in Sabadell cohort. The height of 
spectral peaks represents the covariance, and the colour code corresponds to the coefficient 
of determination, r2, Model statistics: R2Y = 0.89, R2X = 0.23, Q2Y = 0.86, (D) Same as (C) 
for Gipuzkoa cohort, R2Y = 0.91, R2X = 0.13, Q2Y = 0.86 




Subsequent univariate analysis on integrals from selected NMR peaks (n=64) 
revealed significant differences between early and late pregnancy, particularly for 
steroid hormone metabolites. Indeed, progesterone by-products, at 0.56 ppm (s), 
0.63 ppm (s), and 0.92 ppm (s) and oestrogens at 0.78 ppm (m) showed an average 
of 3-fold elevation in the third trimester samples with q-values (adjusted p-values for 
multiple testing) inferior to 1.10-50 (non-parametric Mann-Whitney test on paired 
data, results are shown in Annexe Tables 9-3 and 9-4). The challenging analytical 
assignment of structure to these signals is described in the following section.  
 Metabolite identification in pregnancy profiles 3.3
Metabolite identification is a crucial step that transforms raw spectral data into 
biologically meaningful data, of potential use in a clinical setting and for exposure 
risk assessment. Human urine presents a particular challenge because of its rich 
content in metabolites from varied chemical classes. Although many publications 
can be found, there are still unassigned or misassigned NMR spectra of biofluids in 
the literature. Based on chemometric tools, 2D NMR experiments and a further 
hyphenated platform approach, I revealed the identity of two new sets of metabolites 
in NMR urine spectra. 
 Steroid hormone assignments 3.3.1.1
Special attention was given to identifying the signals arising between 0.50-1ppm 
since they were unique to pregnant women’s urinary profiles (absent in non-
pregnant) and were associated with fetal growth outcomes (refer to chapter 5). Their 
assignments by 1H NMR presented particular difficulties because of their low 
abundance, overlap with multiple metabolites, the nature of the sterol skeleton and 
their similar chemical identities. Only the signals arising from the methyl protons 
attached to carbon 18 and 19 could be detected by 1H NMR, reflecting the NMR 
sensitivity. Their assignment was even more difficult owing to the absence of 
detectable neighbouring, spin-coupled protons with homonuclear 2D NMR spectra 
(COSY or TOCSY). Primary results from a statistical approach to recover metabolite 
structural information using peak correlation (method called STORM, see methods) 
indicated that 0.63 ppm (s) and 0.92 ppm (s) signals arose from the same molecule 
(r=0.92, p-value=1.9.10-6, N=50), whereas 0.56 (s) was only related to 0.63 (s), 




suggesting a correlated metabolic pathway rather than structural connectivity (r=0.6-
0.7). The resonance at 0.78 (s) was not correlated to any of the other resonances.  
Further NMR and LC-MS experiments were needed to characterise these peaks. 
Long-range heteronuclear 1H-13C 2D spectra (HMBC) of the urine samples 
confirmed the assignment of 0.63 (s) and 0.92 (s) to the methyl protons attached to 
the carbons 18 and 19 respectively on a steroid skeleton (spectra not shown, 
interpretation based on 13C chemical shift values in the literature). A potential 
candidate for the signals at 0.63 ppm and 0.92 ppm was 5β-Pregnane-3α,20α-diol-
3α-glucuronide (P3G) based on a literature review (this is the most abundant steroid 
hormone conjugate in pregnant women’s urine). The chemical standard was 
commercially available and acquired by 1H NMR using the same spectral acquisition 
parameters as for the acquisition of spectra from cohort urine samples. The 
chemical shifts matched the 0.63 ppm and 0.92 ppm peaks with a chemical shift 
difference of +/- 0.2ppm, as seen in Figure 3-10 .A. which might be due to different 
properties of the matrices (phosphate buffer alone and buffer plus human urine). 
Therefore, P3G was directly added to a representative 3rd trimester urine sample, in 
incremental spike-in experiments as can be seen in Figure 3-10.B, in order to 
validate the identity of the steroid. However, in order to confirm the identity of the 
newly assigned steroid and potentially other steroid peaks, sample fractionation and 
purification were needed, as well as further experiments to confirm structural 
information. Three urine fractions containing NMR signals between 0.5-1ppm were 
obtained using a HPLC gradient collecting 120 fractions in total from a pooled urine 
sample from Sabadell cohort (NMR spectra in Figure 3-10.C and D). To be noted, a 
mixture of pregnanes conjugated to a glucuronide group is likely to contribute to the 
signals arising at 0.56 (s), 0.63 (s), and 0.92 (s) according to the literature and LC-
MS/MS data we acquired (see next paragraph). However, these other molecules are 
less abundant than P3G and therefore harder to assign as they are at or below the 
limit of detection with NMR spectroscopy. Evidence of glucuronide conjugates in 
fraction 105 was based on the presence of a doublet between 4.6 ppm with a J-
coupling constant of 8Hz +/- 0.2Hz (see Figure 3-10 B’ and D’) which correspond to 
the anomeric proton on the glucuronide ring. However, this doublet could not be 
detected for other steroids potentially due to overlap with other signals in this region 
and its low intensity. 







H-NMR spectrum (800 MHz Bruker) of (A) 5β-Pregnane-3α,20α-diol-3α-
glucuronide (P3G) standard. (B) Spiked-in P3G in representative 3rd trimester urine 
sample (dark green: blank sample, light green: +1 unit P3G and yellow: +2 unit P3G). 
(C) pool urine from 1st and 3rd trimester urine samples used for HPLC fractionation. 
(D) Fractions 103rd, 104th and 105th containing resonances at 0.58 (s), 0.63(s), 0.78 
(m) and 0.92 (s) 
 
LC-MS/MS experiments were performed in order to obtain further information on the 
steroid structure based on m/z and fragmentation patterns. Figure 3-11 depicts the 




base ion chromatograms (BPI) of the P3G standard eluting at 2.74 min and of the 
other urine fractions containing different steroids. As expected, fraction 105th 
contains the same most abundant peak as in the P3G BPI. MS/MS experiments on 
the selected precursor ion [M + Na]+ responsible for the peak eluting at 2.74 min, 
allowed confirmation of the identity of the fragment ions produced by classical CID 
in the collision cell. The product ion mass spectra of P3G standard solution and the 
105th fraction in Figure 3-12 showed product ions formed by the loss of glucuronide 
moiety with a ppm error below 2. There were fragment ions characteristic of the 
steroid skeleton, such as 163.0013 m/z, which is useful for speciﬁc identiﬁcation of 
the analyte, and characteristic of the leaving glucuronide conjugated group such as 
199.02 and 217.03 m/z which correspond to [Glu+Na]+ with a ppm error <2. Sodium 
adducts are 23 Da higher than the expected molecular mass (175 m/z) and are 
quite common in electrospray ionisation. The interpretation of the fragments 
observed for P3G is presented in Figure 3-13. 
 
Figure 3-11. Base ion chromatogram (BPI, uses only the intensity of the most intense 
peak at a given retention time) for 5β-Pregnane-3α,20α-diol-3α-glucuronide (P3G) 
standard and urine fractions 103rd, 104th and 105th containing NMR resonances at 
0.58 (s), 0.63(s), 0.78 (m) and 0.92 (s) 










Figure 3-13. Fragment interpretation of ESI+MS/MS experiments of P3G  
Based on the interpretation of P3G MS/MS fragments, attempts were made to 
assign the steroids in fractions 103th and 104th.  There were likely to be other 
progesterone metabolites such as 5α/β-reduced-20-oxo- (allopregnanolone and 
isomers) or 5α/β-reduced-20α-hydroxy- (isomers of pregnanediol) metabolites of 
progesterone. However, the peaks assigned based on MS/MS fragment patterns 




and m/z values could not be matched with confidence to NMR signals observed in 
the 103th and 104th fractions due to the lack of correlation of the peak intensities 
between both platforms. In Annexe Table 9-5 can be found the MS/MS experiment 
results for the other abundant peaks present in 103rd, 104th and 105th fractions 
containing resonances at 0.56 (s), 0.63(s), and 0.92 (s) ppm in NMR spectra.





Figure 3-14 Stacked 
1
H-NMR spectra (600 MHz Bruker) of a representative 3rd 
trimester urine sample spiked-in consecutively with steroid hormone standards to 
assign resonances at 0.56 (s) and 0.78 (s). Hormone standards consecutively added to 
the unique urine sample are listed on the hand-right side of the spectra. 
Finally, additional spiked-in experiments allowed the assignment of the signals at 
0.56 (s) and 0.78 (s) to allopregnanolone (and isomers) and oestrogen metabolites. 
As observed in Figure 3-14, Estradiol and Estriol standards gave rise to peaks 
around 0.78 ppm when spiked-in a representative 3rd trimester urine sample. This 
sample only contained small amounts of the metabolites giving rise to the signal at 
0.78, which looked close to the noise level in Figure 3-14. Epipregnanolone and 
allopregnanolone standards both gave rise to a common singlet at 0.56 ppm and 
two different singlets at 0.98 ppm and 0.81 ppm respectively. These experiments do 
not completely confirm the metabolite IDs of the signals at 0.56 (s) and 0.78 (s) but 
inform on their steroid series, i.e. they are pregnanes and oestrogens, and also 
likely glucuronide conjugates based on previous studies (chemical standards of 
these steroid conjugates were not commercially available).  
 Assignments of 1.08 (d) and 1.15 (d) 3.3.1.2
NMR spectra of the urine fractions, acquired with a high-field spectrometer for 
higher resolution and sensitivity (800MHz Bruker), provided information for the 
assignment of numerous other metabolites with low abundance, such as 3-
Intensity (UA) 




hydroxyisobutyric acid. The doublet at 1.08 ppm is normally found in human urine 
spectra but has not been consistently assigned in previous studies or the literature. 
This metabolite was isolated in two urine fraction aliquots, n°28 and n°29, with 
signals arising at 2.49 (m), 3.55 (dd) and 3.72 (dd). COSY, TOCSY, 1H-13C HSQC 
and 1H-13C HMBC experiments were acquired on a representative third trimester 
urine sample from Sabadell in order to obtain further structural information. The 
doublet at δ1.08 was coupled to a CH-proton at δ 2.49 in the COSY spectrum, and 
with two non-equivalent CH2-protons δ 3.55, and δ 3.72 in the TOCSY spectrum. All 
resonances are reported in Table 3-5. Combination of the 1H and 13C resonances 
indicated the following structure: CH3 – CH (R1) – CH2 (R2). The carbon resonance 
at δ187 ppm (COOH) was correlated with the proton signal at 1.08(d) in the 1H-13C 
HSQC experiment. 3-ureido-isobutyrate and the chiral metabolites 
3-hydroxyisobutyric acid (HIBA) and 3-aminoisobutyric acid (AIBA), with respectively 
R2 as NHC(O)NH2 and R2 as OH, were considered as possible candidates. HIBA 
identity was confirmed using a series of spiked-in experiments in a third trimester 
urine sample of a pregnant woman as presented in Figure 3-15. These metabolites 
are intermediates in the pathways of l-valine and thymine.  
Table 3-5 3-hydroxyisobutyric acid (HIBA) NMR peak list 
Integral relative 
intensity 
1H Multiplicity J-coupling 
(Hz) 
13C Assignment 
3 1.08 d 7.1 - γCH3 
1 2.49 m  47.7 βCH 
2 3.55 m 6.4 68 1/2αCH2 
2 3.72 m 7.4 68 1/2αCH2 
    187.2 COOH 







H-NMR (800 MHz Bruker) spectrum of pure 3-hydroxyisobutyrate 
standard and stacked spectra of a representative 3rd trimester urine sample spiked-in 
consecutively with 3-hydroxyisobutyrate standard to assign the resonance at 1.08 (d). 
The doublet at 1.15 ppm is more rarely found in human urinary spectra. Because of 
its low abundance in the original urine samples, 2D spectra, COSY, TOCSY, were 
recorded from a fraction in which it was accumulated and purified. The doublet at 
1.15 (d) was coupled to two non-equivalent CH2-protons δ 3.45, and δ 3.54 in the 
TOCSY spectrum, therefore presenting the same spin system as HIBA/AIBA. 
However, further structural information could not be retrieved from the 1H-13C HSQC 
experiments because of the metabolites low abundance. 
 
  




This chapter presented the results of the first application of metabolic profiling to two 
independent large-scale pregnant populations with two time points. The quality of 
the NMR spectroscopic metabonomic data acquired from the urine samples of these 
pregnant mothers was assessed and improved by monitoring the analytical stability 
and sample degradation over the NMR run. Main analytical artefacts were identified 
to originate from chemical shift variability of 1H NMR signals, low signal-to-noise 
ratios for certain peaks, and varying water suppression quality across the run. The 
total variation in metabolite measurements in both cohorts was also quantified and 
indicated a great disparity between metabolites with CVs varying from 215 to 13%. I 
then demonstrated that the main metabolic variation observed originated from the 
impact of the pregnancy course on maternal urinary metabolic profiles. Finally, the 
identity of a number of metabolites in NMR urinary spectra was revealed, including 
pregnancy hormones and amino acid intermediates. 
 A representative pregnant population 3.4.1
Differences in terms of socio-demographic, clinical and lifestyle factors were noticed 
between the Spanish cohorts in the Mediterranean and Atlantic areas. Indeed the 
subgroup of subjects from Sabadell is from a lower socio-demographic background, 
less educated and less healthy than the one from Gipuzkoa. These two cohorts are 
representative of their respective regional population based on our comparison of 
the subgroups used in this study and the full cohort characteristics and knowing that 
the vast majority of mothers in these regions attended public hospitals, where they 
were recruited. Therefore, the differences observed are related to regional 
disparities. Among a multitude of aspects, one of the most striking variations 
between these two regions is the higher surrounding greenness in Gipuzkoa and an 
associated healthier lifestyle (Dadvand et al. 2012). In addition, large differences in 
iodine intake were observed with almost all the Gipuzkoa women supplemented and 
only 11% in Sabadell (Rebagliato et al. 2013). In addition, C-reactive protein (CRP), 
an established inflammatory biomarker, was 10-fold higher in Sabadell compared to 
Gipuzkoa.  This difference in CRP levels corresponds the one observed in a Finish 
pregnant population (n=677) between the lowest and highest quintiles (Brown et al. 
2013). In Sabadell, collaborators found higher maternal CRP levels to be associated 
with maternal age, parity (previous delivery), pre-pregnancy maternal obesity, and 
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lack of physical activity (Morales et al. 2011). All these parameters during pregnancy 
are associated with birth outcomes and infant development as shown in INMA-
related publications. A comparable mother-child cohort, also based in the 
Mediterranean region and used in a metabonomic study as part of my masters, the 
Rhea study based in Crete (Greece), showed similar cohort characteristics to the 
Sabadell women (Maitre et al. 2014). In conclusion, differences in terms of urinary 
metabolic profiles are expected to be seen between the two sub-cohorts. 
Differences between the beginning and the end of pregnancy in terms of food intake 
were seen, in particular an increase in dairy product consumption of 40% in the last 
trimester in both cohorts. Indeed, pregnant mothers are advised to increase their 
dairy intake by consuming milk and low-fat cheese for example. Higher dairy intake 
is associated with an increased infant weight at birth, in particular through increased 
protein intake, and potentially reduced maternal fasting glucose, incidence of GDM 
and pre-eclampsia rates and levels of C-reactive protein through intake of probiotics 
(Heppe et al. 2011; Lindsay et al. 2013). Increased dairy intake (+20%) was also 
previously observed throughout pregnancy in a study of 870 women with 
appropriate size for gestational age (AGA) infants in New- Zealand (Mitchell et al. 
2004). 
 Analytical variability in 1H-NMR metabolic profiling of human urine and 3.4.2
technical limitations 
Ideally for a metabolite to be validated as a clinical or exposure biomarker, the 
analytical variability, or CV, must be smaller than the effect size for diagnostic, i.e. 
the CV must be smaller than the smallest significant change in metabolite levels 
associated with the detection of a physiological status. As a first step in this study of 
pregnant women’s metabolome, variability in metabolite levels was assessed in 
relation to the measurement technique. Biological and technical variances were then 
compared to evaluate whether technical reproducibility might have affected the 
interpretation of results from biological experiments. 
Small biases emerged from the difficulty (1) in supressing the water signal with 
consistency from diluted spot urine samples, (2) to accurately measure low 
abundant metabolites with NMR and (3) account for variations in chemical shift for 
the same metabolites across different samples. Analytical variability was accurately 
quantified based on repeat QC samples and CVs on 64 well-characterised 
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metabolites. 80% of the metabolite buckets had CVs inferior to 10% and 46% had 
even CVs inferior to 5%, which is considered as a good quality factor in previous 
investigations. As expected the highest technical variation was observed for low 
abundant metabolites, which were close to the noise level. This finding agrees with 
recent work on synthetic urine which shows that the majority of CVs for 1H NMR 
signals fell in the range of 1 – 15% (Wang et al. 2013). They also demonstrate the 
influence of post-analytical methods, such as normalisation, on technical variation. 
The authors validated the choice towards the probabilistic normalisation, as used in 
this PhD, which exerted a minimal influence on the CVs of strong peaks in the 
dataset but tends to increase the reproducibility of small peaks.  
In addition, sample stability was assessed based on the length of storage time in 
cohort centres at 20°C and based on repeat aliquots held at room temperature for 
approximately 20 hours. Storage time differences between the first and last urine 
samples collected (approximately over 2 years) did not affect metabolic profiles 
(results not shown). The time between sample preparation and NMR acquisition at 
room temperature also did not significantly affect sample stability except for 
fumarate which might have been converted to succinate within the samples (explain 
20-30% of total technical variation in these two metabolites). Numerous studies 
demonstrated the rise of lactate and decrease of citrate in case of bacterial 
contamination of urine samples at 4 C° after 30 days (Schreier et al. 2013) or at 
room temperature over 4 weeks (Saude & Skykes D. 2007). These artefacts were 
not observed in our samples: addition of the bacteriostatic preservative sodium 
azide in urine samples was therefore effective in our study. 
The relevance of technical variability in comparison to biological variability was 
tested. For biological variability, we tested inter-individual variance within each sub-
cohort and each time point (Sabadell at week 12, Sabadell at week 34, Gipuzkoa at 
week 12 and Gipuzkoa at week 34). Intra-individual stability was not measured here 
since the difference of physiological status between the two participant visits at 
weeks 12 and 34 of pregnancy was predominant and do not relate to normal within-
individual longitudinal fluctuations (see next section). The inter-individual variability 
measured here also reflects intra-individual variability due to potential changes in for 
example dietary patterns or recent vigorous activity. However, effects from the 
diurnal dilution of urine were excluded by data normalization. We showed that the 
biological variance clearly exceeds the technical variance. Metabolite variability 
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between the two profiled populations of Sabadell and Gipuzkoa was surprisingly 
similar. Our results are in line with a study which analysed 40 urine samples from 22 
healthy individuals (11 males and 11 females) over a period of 3 months (Assfalg et 
al. 2008). NMR signals arising from urinary dimethylamine and lactate showed a 
high sporadic temporal variability and other metabolites such as hippurate and N1-
methylnicotinamide showed a high but stable intra-individual variability. Isoleucine, 
leucine and valine all showed a low inter- and intra-individual variability in line with 
our results. A previous study quantified 24 metabolites by 1H NMR to assess 
variability in normal subjects (27 females and 30 males) and identified also large 
coefficients of variation (i.e., up to 270 for lactate and down to 40% for alanine) for 
normalized metabolite concentrations (Saude et al. 2007). Interestingly, this study in 
a second part, measured daily concentrations of 10 urine metabolites in 6 women 
over 30 days by 1H NMR and found significant within-individual longitudinal 
fluctuations (specifically, for citrate and tyrosine in a subset of individuals). This 
study suggested that a single individual metabolome is capable of varying greatly 
over periods of time and is able to span the same metabolite range as that for an 
entire group. Based on these results, another study decomposed the biological 
variance of 1H NMR spectra of plasma and urine samples into familial (genetic and 
common environmental), individual environmental, and longitudinally unstable 
components (Nicholson et al. 2011). They found that the mean proportion of stable 
biological variation across annotated metabolites in urine (n=27) was 53% which 
comprise the clinically predictive potential of metabolic variation. Methylnicotinic acid 
(trigonelline) and hippurate which showed a high inter-individual variability in our 
study were also the ones explained by a strong individual environment component in 
Nicholson et al. study. This was a stable biological variation over a 4 month period. 
In contrast, lactate and TMAO which also had high CVs in our study were the ones 
with the highest biological temporal variability.  
Based on the variability assessment, precautions had to be taken when interpreting 
the biological effect of the following metabolites: unknown signal at 0.75(d), 
oestrogen metabolites, isoleucine, valine and N-acetylserotonine; which presented 
similar technical and biological variance. In our study, steroid hormone by-products 
presented both high analytical CVs (20-38%) due to their low concentration and high 
biological variations (37-85%). In the case of oestrogens this is partially explained 
because their levels are close to the limit of detection in QC samples (mixed 1st and 
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3rd trimester samples), as seen in blank urine spectrum in Figure 3-15. Only 3rd 
trimester samples contained oestrogen metabolites and even within this time point, 
a high variability was observed with complete absence or presence of the signals. 
Progesterone metabolites could be detected with more ease, especially P3G. Other 
metabolites such as niacin breakdown products had a larger difference between 
technical and biological variance which gave more confidence in their future 
biological interpretation.  
Based on this accumulating knowledge on sources of variability in metabolite 
measurements in large human population over time, guidelines were erected to 
determine the effect sizes and study sizes for a given statistical power. In animal 
studies, a study advocated to use dozens of subjects for borderline significant 
biomarkers measured by 1H NMR (corresponded to an effect size of 1.55 calculated 
for each NMR bucket using the smallest mean difference between the controls and 
the cases for a significant result and standard deviation) (Goodpaster et al. 2010). 
However, in epidemiological studies, effect sizes are usually expected between 0-1 
and therefore require larger sample sizes. Another study computed sample sizes 
based on within-individual variability in metabolite levels (measured by LC/MS and 
GC/MS in plasma samples) for typical moderate effect sizes observed in 
epidemiological studies (Sampson et al. 2013). Even with a slightly lower inter-
individual variability, the authors reached similar conclusion on sample sizes as 
Nicholson and colleagues that epidemiological studies require more than 1,000 
subjects to detect metabonomic associations (Nicholson et al. 2011). My PhD 
utilised approximately 430 individuals per group and therefore is below these 
recommendations. However, in order to minimise the number of false negative 
results while also minimising false positives from multiple testing, a loose significant 
threshold was chosen, p-value>0.05. We chose to not control multiple testing, using 
Bonferoni correction for example, as presented in these previous studies above, but 
rather indicate the false discovery rate for each significant results in study 2 
(Benjamini & Hochberg 1995). Reliable inferences were still made based on the 
comparison of the two cohort results and multiple time points to identify biomarker of 
fetal growth. In study 2 of this thesis, where associations between metabolite levels 
and fetal growth outcomes were sought, effect size was interpreted for a 50% 
change in metabolite integral values. Such statistical significance testing and 
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inferences should facilitate the translation of NMR-based metabonomics discovery 
of biomarkers to epidemiological setting and eventually clinical use. 
 Characterisation of metabolic variations related to the time course of 3.4.3
pregnancy 
The significant metabolic changes observed in pregnant women’s urine samples 
between the two study time points, in early and late pregnancy, were highly 
consistent in both cohorts. Our observations also strongly agree with previous 
findings on NMR metabolic profiles of repeat urine samples during pregnancy (Diaz, 
Barros, Goodfellow, Duarte, Carreira, et al. 2013; Sachse et al. 2012; Pinto et al. 
2014), as well as with existing knowledge of the biochemical phenomena 
accompanying pregnancy further outlined below.  
A large proportion of the metabolites measured were affected by the time of 
gestation but steroid by-products of progesterone and oestrogens were particularly 
increased between week 12 and 34 (by three-fold). Surprisingly, our study was the 
first to confirm the identity of these metabolites via 1H NMR even if there were 
previously identified as important urinary markers during pregnancy (Diaz, Barros, 
Goodfellow, Duarte, Carreira, et al. 2013; Sachse et al. 2012; Pinto et al. 2014). 
Only one publication refers to steroid hormone resonances in 1H NMR urinary 
metabolic profiles which were observed in female rat samples (Stanley et al. 2005). 
The authors assigned 0.56 (s), 0.58 (s), 0.61 (s) to CH3 at C18 of progesterone 
metabolites and 0.75 (s), 0.77 (s), 0.78 (s) to CH3 at C18 of oestrogen metabolites, 
by analysis of urine samples spiked with small amounts of standard compounds 
dissolved in methanol. I took the assignment of signals at 0.63 (s) and 0.92 (s) 
further by fractionating a representative pooled urine sample from mixed 1st/3rd 
trimester pregnant women’s urine and analysed it by both high resolution (800MHz) 
1H NMR and LC-MS/MS. This allowed to assign this metabolite to 5β-Pregnane-
3α,20α-diol-3α-glucuronide with confidence. According to previous publications, 
22% of progesterone metabolites are excreted in the urine as 5β-Pregnane-3α,20α-
diol-3α-glucuronide which corroborate our LC-MS/MS and NMR results (Hill et al. 
2011; Meng et al. 1997). This metabolite is the product of the metabolic interaction 
of the maternal-fetal-placental unit (Pasqualini, 1970). Indeed, steroid hormone 
production, i.e. steroidogenesis, takes place mainly in the trophoblast during 
pregnancy. In concert with placental development, the trophoblast mass and steroid 
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hormone levels increase during the pregnancy course. However, the placenta lacks 
or has reduced level of several enzymes necessary for the de novo steroidogenesis 
and depends on maternal or fetal precursors such as cholesterol via low-density 
protein (LDL). The association between excreted P3G and allopregnanolone 
isomers (solely annotated as δ 0.63 and δ 0.55) with blood HDL and LDL was 
evidenced by Pinto et al. in a recent metabonomic study (Pinto et al. 2014).  
Circulating amino acids are known to decrease during pregnancy partially due to 
hormonal changes, a high demand in essential amino acids by the fetus and 
predominantly due to renal changes. Renal adaptations to pregnancy, notably to 
handle maternal hypervolemia and excretion of fetal waste, require an increased 
glomerular filtration rate. As a result, the urine output is greater and the renal 
excretion of proteins, glucose, urea, amino acids and vitamins increases (Blackburn, 
2007). This phenomenon has also been observed in our study, with the exception of 
lysine and glutamine, which decrease by 10-20 % in late pregnancy, as observed in 
a previous report (Wertz et al., 1959). Increased amino acids in the third trimester 
included alanine and glycine. Branched amino acids such as isoleucine and leucine 
increased by 10-20% in the third trimester urine compared to early pregnancy, which 
could be explained by a decreased maternal BCAA oxidation during pregnancy in 
order to improve BCAA availability for the fetus (Fitch & King, 1987). Valine and 
tyrosine levels are not changed between the first and third trimesters. 
Other urinary metabolites associated to threonine and its degradation products, 
possibly in the context of ketogenesis, were increased in the third trimester 
compared to the first trimester such as 4-deoxyerythronic acid and 4-deoxythreonic 
acid (Appiah-Amponsah et al., 2009). Alternatively, carnitine levels were 2-fold lower 
later in gestation which is consistent with characteristic enhanced lipid oxidation 
later in pregnancy, agreeing with previous reports (Diaz et al., 2013, Cho & Cha, 
2005). Finally, a 3-fold decrease of scyllo-inositol is observed in the third trimester 
but this has not yet been interpreted. 
 Metabolite identification 3.4.4
Even for previously characterised metabolites, which were the majority in this 
present NMR dataset, matching one chemical value (for example one peak chemical 
shift) was not sufficient in part due to differences in spectral acquisition parameters 
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and sample preparation. Recurrent identification mistakes can be found in the 
literature such as for phenylacetylglutamine which is often instead assigned to 
phenylacetylglycine (which is found only in rats and mice) and N-acetylglutamic 
acid, due to chemical shift similarity of partial sets of resonances. A minimum of two 
independent and orthogonal data relative to an authentic compound analysed under 
identical experimental conditions was required for validated identification as 
proposed by the Metabolomics Standard Initiative (MSI) (Sumner et al. 2007). The 
same authors in a recent report suggested a new quantitative scoring system for 
summarizing a metabolite identification confidence, summing of all the data types 
supporting the identification (Sumner et al. 2014). For example confidence is 
building upon multiple types of data, one dimensional 1H NMR, 2D dimensional 1H-
13C NMR and match of two signals to spectral library or literature. An even more 
quantitative approach was suggested this year, judging authentic reference standard 
for confident metabolite identification unnecessary for NMR-based metabolite 
identifications as long as the seven recommendations in this report were met 
(Everett 2015). Such recommendations were based on the high precision of spectral 
matching to a library or the high number of bits of information for each metabolite 
calculated upon the number of chemical shifts, multiplicities, coupling constants, 
COSY and HSQC cross-peaks. In this thesis, P3G is assigned for the first time in 
urine 1H NMR spectra. This assignment required multiple data and platforms due to 
the absence of matches to spectral libraries or literature and the absence of 
detectable neighbouring, spin-coupled protons with homonuclear 2D NMR spectra. 
Other steroid signals including oestrogen derivates and allopregnanolone isomers 
were assigned with less confidence due to their low abundance and the absence of 
commercially available sulphate and glucuronide conjugates. 
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 Maternal metabolic predictors of fetal growth Chapter 4 
This chapter aims to conduct an epidemiological analysis of the association between 
NMR spectroscopic based maternal metabolic profiles and fetal growth outcomes 
using estimated fetal weight and head size (aim n# 2). Maternal metabolite profiles 
were represented by 64 NMR spectroscopic buckets well described in Chapter 4. 
Information on each of the 64 NMR variables was collected such as their variation 
according to the time of gestation, technical variability, population variability and 
chemical ID, enabling biological interpretation of their association with fetal growth.  
 Introduction 4.1
Detecting early fetal growth failure is crucial for infant health and survival. Fetal 
growth restriction (FGR) or intrauterine growth restriction (IUGR) affects 7-10% of all 
pregnancies, and is also associated with growth failure and accelerated weight gain 
during childhood, which predisposes the fetus to metabolic and cardiovascular 
disorders later in life. Recent national incentives, such as in the UK, aim for risk-
adjusted prenatal care by defining women at risk at the beginning of pregnancy 
(NICE, 2008). This risk assessment is currently based on maternal lifestyle factors 
(i.e. smoking, BMI and diet), medical history and a panel of serum biomarkers. 
However, none of these methods provide high enough accuracy to detect FGR 
(Conde-Agudelo et al. 2013). To date, no prophylactic treatment for FGR is available 
with the main clinical strategies being timing of delivery and fetal assessment. The 
lack of understanding regarding FGR has been recognised and an increasing body 
of research is investigating non-invasive tools to monitor pregnancies with 
prognostic and diagnostic biomarkers.  
The advancements in metabolomics, in particular high sample throughput, offer a 
unique opportunity to discover a combination of biomarkers for reproductive 
outcomes. Metabolomics was previously proven useful in the diagnostic of adverse 
pregnancy outcomes (Graca et al. 2009; Horgan et al. 2011; Graca et al. 2012) in 
particular for pre-eclampsia where the first commercial blood test is being developed 
based on metabolomic studies (Kenny et al. 2010). Recent work has demonstrated 
the value of urinary metabolomics in detecting early markers (approximately at 11 
weeks of gestation) of preterm birth and FGR in a nested case-control study (Maitre 
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et al. 2014). Specific urinary metabolic signature of FGR were shown to be 
associated with metabolic syndrome (i.e. decreased levels of tyrosine, acetate, 
trimethylamine and formate), which improved our understanding of high BMI 
association with preterm birth. However, to find biomarkers of FGR with potential 
public health applications, studies with larger sample size and repeat sample 
collection are needed to study temporal metabolic profiles during pregnancy.  
To our knowledge the present study represents the largest human investigation 
(n >800) in which urinary metabolomics has been applied to study fetal growth 
outcomes. This study aimed (i) to elucidate the urinary metabolic signatures 
associated with fetal biometry in two Spanish cohorts using longitudinal ultrasound 
measurements and (ii) to identify potential sources of variation in metabolic profiles 
associated with epidemiological and clinical data. 
 Results 4.2
 Fetal growth in Sabadell and Gipuzkoa 4.2.1
Fetal growth was the outcome of interest for this PhD and was measured based on 
the estimated body weight and head size of the child in utero (approximately at 
gestational weeks 12, 20, and 34) and at birth. Ultrasound biometry was available at 
three time points during pregnancy for more than 87% of women. Growth patterns in 
terms of body weight and head circumference were notably different based on EFW 
and birth weight charts in Figure 4-1. In both charts, fetuses which belonged to 
Sabadell (blue dots) compared to Gipuzkoa (pink dots) sub-cohorts (included in this 
study) showed a slightly enhanced growth up to the week 34 of gestation but a 
smaller weight and head size at birth, based on LOESS Curve Fitting (Local 
Polynomial Regression, span=0.75). Based on Table 5-1, EFW was similar in both 
cohorts in the first two trimesters with values equal to 61 grams at week 12 and 412 
grams at week 20. At 34 weeks of gestation, a significantly higher EFW is observed 
for Sabadell women with fetuses weighting 2400 grams whereas in Gipuzkoa the 
median weight was 2344 grams (p-value=0.000016). At birth, this gap between the 
cohorts was inversed but not statistically significant, with Sabadell babies weighting 
(median values) 3290/3300 grams and in Gipuzkoa 3313 grams. The BPD, i.e. the 
transverse diameter of the head, was similar in both cohorts at week 12 equal to 
20mm, however a higher variability was observed at week 20 with values around 
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50mm and at week 34 85mm. At birth HC was larger in Gipuzkoa with a median 
value of 35.0 mm versus 34.4 mm in Sabadell (p-value=5.5*10-8).  
It is important to note that early fetal size at week 12 of gestation and growth 
between weeks 12 and 20 were only correlated with birth weight as shown in Figure 
4-2 in both cohorts.  
In the analysis of metabolic associations with fetal growth in the next section, BPD 
was used for approximation of head size in utero, instead of head circumference, 
due to data availability. In order to compare EFW and BPD for the same gestational 
week, fetal growth scores or standard deviation scores (z-scores) were obtained 
using longitudinal growth curves calculated for each individual adjusting for 
constitutional factors known to affect fetal growth (i.e. maternal age, height, parity, 
pre-pregnancy weight, country of origin, father's height and fetal sex). Two types of 
z-scores were used in the metabolic association analysis: unconditional z-scores at 
a certain time point which describe the size of a fetus at this time and conditional z-
score which describe the growth of a fetus during the respective time interval, i.e. 
12th-20th, 20th-34th and 12th-34th weeks of gestation (see Chapter 3.1.2.2 Data 
availability for this PhD - Fetal growth assessment methods and Iñiguez et al., 
2013). Z-scores were missing only for 32 women in Gipuzkoa sub-cohort, 6 women 
in Sabadell 1st trimester sub-cohort and 20 women in Sabadell 3rd trimester sub-
cohort. The distribution of the z-scores in respective cohorts followed a normal 
distribution, ranging between -3 and +3, averaging at 0 and was not statistically 
different between the two cohorts (using t-test). In annexe can be found histograms 
of the distribution of z-scores for EFW and BPD in the Sabadell and Gipuzkoa 
population. 




Figure 4-1. Estimated fetal weight (EFW, left) and Head circumference charts (right), constructed from the sub-cohorts of the Gipuzkoa and 
Sabadell population of more than 800 fetuses 
 




Figure 4-2 Inter-correlation between fetal growth z-scores in terms of weight and head size in Sabadell (A.) and Gipuzkoa (B.) at week 12, 20, 34 of 
gestation and at birth




Table 4-1. Description of fetal and birth anthropometric measures in the Sabadell and Gipuzkoa cohorts.  
 
Gipuzkoa -  Included in the 
analysis (combined weeks 12 
and 34, n=419) 
Sabadell - Included in the 
analysis (week 12, n=394) 
Sabadell - Included in the 
analysis (week 34, n=469) 
 
Outcome Median 
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  P-values were calculated using Mann-Whitney test to compare anthropometric measures across the two cohorts for the women included at week 34. Abbreviation: EFW, 
Estimated fetal weight; BPD, Biparietal Diameter; HC, Head Circumference. 




 Maternal urine metabolites are associated with fetal growth 4.2.2
measurements 
A panel of maternal urinary metabolites, semi-quantified from 1H NMR spectra of 
pregnant mothers’ urine samples, were predictive of fetal growth. Each metabolite 
was modelled separately for both the Sabadell and Gipuzkoa cohorts. In addition, 
urine metabolites were modelled for each time point of sampling, in the first (week 
12) and third trimesters (week 34) of pregnancy.  
 Overview of the metabolite-outcome associations 4.2.2.1
In total, 64 semi-quantified metabolites were available to predict fetal growth 
outcomes which led to the calculation of 3072 regression models (for each cohort, 
each time point during pregnancy at which metabolites were measured and each 
fetal growth outcome). Statistical significance was determined for metabolites with p-
values<0.05. Only significant associations between maternal urinary metabolites (at 
weeks 12 and 34) and fetal growth scores (fetal weight and head size) in the 
Gipuzkoa and Sabadell cohorts are presented in Figure 4-3 and Figure 4-4 (at 
weeks 12 and 34 respectively). The complete list of results from the linear 
regression models in terms of regression coefficients, confidence interval and 
statistical significance in document can be provided on demand (not included in this 
thesis). 
In Figure 4-3 and Figure 4-4, results are given for each category of fetal biometric 
measurement (1), time point of sampling during pregnancy (2), time point of fetal 
growth outcome measurement (3) and cohort (4). Each row corresponds to 
metabolites which are ordered with respect to their metabolic class, origin or 
pathway (i.e. amino acids, energy metabolism, steroid hormones or bacterial origin). 
This classification was based on metabolite inter-correlation in urine samples, as 
presented in heat maps in annexes.  
Overall, BW was the fetal growth outcome with the most significant associations with 
maternal urine metabolites. Indeed, 16 metabolites out of 64 were found associated 
with birth weight at week 34 of gestation in each cohort. As expected, metabolites 
measured at week 34 of pregnancy showed twice more significant associations with 
fetal growth outcomes than at week 12, since the third trimester of pregnancy 
presents the highest growth rate. Metabolite associations at week 34 also showed 
more consistency between cohorts than at week 12. Indeed, the Sabadell women 




showed dramatically different metabolite signatures at week 12 with fetal growth, 
with a greater number of associations with metabolites measured at week 12 than in 
Gipuzkoa, mostly negative. Comparison of associations between maternal urinary 
metabolites and fetal growth in terms of weight and head growth were also of 
interest in order to identify differential metabolism effect on bone development or 
peripheral tissues and on fetal body volume or central organs. When comparing the 
time windows of metabolite associations at week 12 with head or weight, head size 
associations appeared for the majority to be concentrated over week 34 and growth 
between weeks 20-34 and weeks 12-34 compared to associations with weight which 
were more varied across the stage of pregnancy, in both cohorts.  
A subtype of amino acids: BCAAs (valine, leucine and isoleucine) presented the 
greatest number of significant associations with fetal growth outcomes across all 
outcomes, cohorts and time points during pregnancy (on average 20 associations). 
In second position, steroid hormones represented by P3G, Oestrogens and 
Progesterone metabolites (conjugates of allopregnanolone and isomers), were also 
frequently associated with fetal growth outcomes (in average 11 associations across 
the three hormone metabolites). Fifteen metabolites presented no significant 
associations or only one association and are not shown in Figure 4-3 and Figure 
4-4. 
In order to compare the magnitude of the associations across different outcomes, all 
measures of association between maternal metabolites and fetal growth outcomes 
were expressed as percent changes in standard deviation of outcome scores for an 
increase of 50% in the metabolite spectral integral (log10). Percent changes ranged 
from +3% (dark red) to -3% (dark blue) in weight/head size or growth scores. The 
magnitude of this relationship of 3% should be interpreted, as a 3% change in 
standard deviation which is equal to 440g for example for BW and is equivalent to a 
13 gram deviation from the expected mean weight. Expected fetal growth measures 
were based on individualized rather than a population-based growth standards, 
adjusting for constitutional factors such as maternal age, height, parity, pre-
pregnancy weight, and country of origin; father's height; and fetal sex. 
  





(1). Glycoprotein breakdown products (related to renal function and/or inflammation) 
Figure 4-3. Associations between maternal urinary metabolites at weeks 12 and fetal growth 
scores (weight and head size) in the Gipuzkoa and Sabadell cohorts.  
Percent of change in the standard deviation scores are presented as a heat map where the colour 
scale corresponds the strength of the change for an increase of 50% in the metabolite spectral integral 
(log10). Only metabolites which were significantly associated with fetal growth in both cohorts and with 
a p-value<5% are presented. 
Abbreviations: 2Py, N-methyl-2-pyridone-5-carboxamide; 3-HBA/3-ABA : 3-hydroxybutyrate/3-aminoisobutyrate; 3-
HIB, 3-hydroxyisobutyrate; 3-HIV, 3-hydroxyisovalerate; UA: unassigned. s, singlet; d, doublet, dd, doublet of 
doublets; t, triplet; m, multiplet ; Pregnanediol-3-G, 5β-Pregnane-3α,20α-diol-3α-glucuronide; NAC, N-acetyl 
neuraminic acid; NAG, N-acetyl glycoproteins; TMAO, Trimethylamine oxide. Numbers 12, 20, 34 stand for the 
gestational week at which the fetal growth outcome was calculated or the conditional growth between these weeks.  





(1). Glycoprotein breakdown products (related to renal function and/or inflammation) 
Figure 4-4. Associations between maternal urinary metabolites at weeks 34 and fetal growth 
scores (weight and head size) in the Gipuzkoa and Sabadell cohorts.  
Percent of change in the standard deviation scores are presented as a heat map where the colour 
scale corresponds the strength of the change for an increase of 50% in the metabolite spectral integral 
(log10). Only metabolites which were significantly associated with fetal growth in both cohorts and with 
a p-value<5% are presented. Abbreviations: see figure 5-3 




 Common associations are found between each cohorts 4.2.2.2
At the 12th week of gestation, one metabolite reached a significant level of 
association with fetal growth in both cohorts, in terms of weight and head growth 
Figure 4-3. The overlapped signal arising from creatinine and creatine at δ3.05 ppm, 
which are a breakdown product of creatine phosphate in muscles, was associated 
consistently in both cohorts with -1.2% change in weight at week 12 (p=0.027 and 
0.011 in Gipuzkoa and Sabadell respectively). It was also associated with -1.1% 
change in z 12 BPD (z-score of the BPD measured by ultrasound at the 12th 
gestational week) in Gipuzkoa and with -1.2% in z 20 BDP in Sabadell. 
Progesterone derivates (including P3G and allopregnanolone conjugates, pathway 
in pink) at week 12 showed also common pattern of association, although weak, 
between each cohorts with head biometry, as displayed Figure 4-3. In Gipuzkoa 
associations were found with head growth as reflected between 12-34 and 20–34 
weeks of gestation and head size at week 34 (+0.5% for P3G and +0.3% for other 
progesterone metabolite). Weak positive metabolite associations were found in 
Sabadell for P3G with +0.41% associated change in birth weight (CI: 0.071;0.75) 
and progesterone metabolites.  
At the 34th week of gestation, a panel of maternal metabolites present in urine were 
consistently associated in both cohorts with greater fetal growth, as reflected 
between 12-34 and 20–34 weeks of gestation, leading to increased body weight and 
head circumference at week 34 and at birth (results presented in Figure 4-4). In 
addition to body weight, placental weight at birth was included in the analysis which 
was strongly correlated to body weight but did not always show consistent 
associations with all the metabolites. Similarly to week 12, steroid hormones 
including mixed signals arising from oestrogen metabolites were consistently 
associated with weight growth between 12-34 and 20–34 weeks and weight at week 
34 and birth, with a +0.9% increase in weight at week 34 in both cohorts (p-values= 
7.10-3 in Gipuzkoa and 3.10-5 in Sabadell) and up to 1.3% increase in placental 
weight in Gipuzkoa (p-value=5.10-4). Progesterone derivates, i.e. pregnanediol-3-
glucuronide and allopregnanolone conjugates, were associated solely with 
anthropometric measures a birth in contrast to oestrogens, with 0.3-0.6% associated 
increase in birth weight for a 50% in metabolite levels (p-values between 0.001-
0.02).  




BCAAs leucine, valine, and isoleucine, pathway coloured in green in Figure 4-4, along 
with 3-HIB which is a degradation intermediate of valine, showed the strongest 
associations with fetal growth outcomes in terms of consistency across fetal 
development stages and strength of effect (dark red squares in Figure 4-4, 
corresponding to a large percent of change), in particular in Gipuzkoa samples. 
Indeed, Isoleucine, Valine and Leucine were associated with weight increase at 
week 34 of up to 2.4% in Gipuzkoa (p-values: 0.0009; 0.002; 0.0008 respectively) 
and +1% in Sabadell (p-values 0.003, 0.01, 0.03 respectively). Fetal head growth, in 
terms of BPD at week 34 and HCC at birth, was also strongly associated with 
BCAAs, as represented with Leucine and Valine, with a positive growth of up to 
2.8% in Gipuzkoa and 1.2% in Sabadell associated with these metabolites at week 
34. Increased organic acids, including 3-HIB, were significantly associated with 
increased 12-20 growth or body and placental weight at birth (+0.5-1%). 3-HIB was 
associated solely with greater HCC at birth, in both cohorts (+0.8% in Gipuzkoa and 
+0.5% in Sabadell). Overlapped signal from 3-hydroxybutyrate/3-aminoisobutyrate 
was significantly associated in both cohorts only with decreased placental weight 
(+0.93%).  BCAAs and oestrogen metabolites were found to be consistently 
correlated to each other across both cohorts suggesting a common source of 
variation (Spearman’s correlation coefficient ρ(BCAAs-Oestrogen metabolite)=0.5 and 0.25 in 
Gipuzkoa and Sabadell respectively). 
Positive associations with fetal weight and head size consistent between each 
cohort also included other amino acids such as alanine and glycine, which 
participate to glucose metabolism (pathway in orange in Figure 4-4), as well as 
choline, which was linked to glucose metabolism in diabetes patients. Choline, 3-
HIB, glutamine and alanine were found to correlate to each other suggesting a 
common source of variation (ρ(alanine-choline)=0.3-0.4, ρ(alanine-3-HIB)=0.5-06 
and ρ(alanine-glutamine)=0.7-0.7 in Gipuzkoa and Sabadell respectively). 
Significant negative associations with 3-Indoxylsulfate, a metabolite arising from the 
microbial-host co-metabolism (brown colour-coded pathway) and furoylglycine, 
appeared inconsistently associated with BPD growth in the third trimester or HCC at 
birth. However, although not significant, negative associations were observed in 
both cohorts at all fetal development stages for these metabolites.  




 Unique associations in each cohort 4.2.2.3
Unique metabolite-fetal growth associations were observed in each cohort, however 
less confidence can be given to these results due to their non-repeatability in both 
cohorts. Nonetheless, confidence in the results can be given in case the metabolite-
outcome associations are repeated over several time windows in pregnancy, over 
several metabolites belonging to the same pathway or over two types of 
anthropometric measurements, body weight and head size.  
Unique metabolite associations in each cohort at week 12 
Specific metabolite associations at week 12 in the Sabadell cohort can be compared 
to the Gipuzkoa cohort in Figure 4-3 for body weight and for head size. Sabadell 
women exhibited mainly negative metabolic associations at week 12 with fetal 
growth in terms of weight and head size (70% of total significant metabolites showed 
negative percent change). Metabolites associated with decreased weight at week 20 
in Sabadell included amino acids and derivates such as isoleucine -0.8% (CI -1.4;-
0.15), valine -0.8% (CI -1.6;-0.048) and N-acetylserotonin -1.0% (CI: -1.8; -0.21). 
Other metabolites associated with mitochondrial processes such as energy 
production through TCA cycle or lipid metabolism showed similar patterns including 
for succinate (-1.5%), citrate (-1.5%) and carnitine (-0.64%) or related to oxidative 
stress such as for 5-oxoproline -1.7% (-2.7;-0.63). In Sabadell, all the BCAAs were 
associated with head growth measures in the third trimester of pregnancy (i.e. BPD 
at week 34 and growth between week 12-34 and 20-34). Glycoprotein breakdown 
products (often related in the urine to renal function and/or inflammation) displayed 
the strongest negative associations with early growth in Sabadell at week 12 and 20, 
with -1.2% and -1.5% changes in fetal weight for N-acetyl glycoproteins and -1.6% 
and -2.9% for N-acetyl neuraminic acid, respectively for weight at week 12 and 20. 
Interestingly, some of these metabolites at week 12 were also associated with birth 
weight without reaching p<0.05 but only p<0.1 such as isoleucine, valine, N-
acetylserotonin and N-acetyl neuraminic acid (results not shown in the heatmap for 
a p<0.1). Only few metabolites were significantly associated with decreased birth 
weight such as Valine and 4-deoxythreonic acid.  
Only a few interesting associations unique to Gipuzkoa appeared such as for 4-
deoxyerythronic acid and p-cresol sulfate, which displayed the most repeated 
associations across weight outcomes at different time point of pregnancy. Some of 
these metabolites showed opposite associations with fetal growth in both cohorts 




including p-cresol sulfate, N-acetyl glycoproteins and unknown at δ1.67 (s). In 
Gipuzkoa strong positive associations between Valine and BPD growth with +1.7% 
(CI: 0.58;2.9) in BPD at week 34 were observed, whereas valine was negatively 
associated with BPD in Sabadell at week 34 with -1.1%(CI: -1.7;-0.44). As has been 
noted in the previous section on commonness in both cohorts, valine at week 34 
was positively associated with weight and head growth in both cohorts. 
Overall, commonness between head size and weight associations within each 
cohort was observed, giving more confidence into unique associations in each 
cohort. In Sabadell, eight metabolites at week 12 were associated with impaired 
fetal growth both in terms of weight and head. In particular, amino acids including 5-
oxoproline, isoleucine, valine and leucine (although not reaching significance for 
weight) were all associated with BPD at week 34 and with weight at week 12 or at 
birth. Carnitine and N-acetyl glycoproteins were both associated with growth in 
terms of body weight and head size at week 12; however they did not correlate with 
growth at later time points. 4-deoxythreonic acid was associated with head growth in 
the third trimester and with placental weight at birth. Interestingly, these associations 
did not always appear at the same stages of pregnancy depending on the fetal body 
parts considered. For example, succinate, 5-oxoproline and isoleucine were 
associated with BPD growth in the third trimester, whereas they were significant only 
with fetal weight growth in the first/second trimesters. Overall associations with head 
growth occurred across the whole pregnancy period but metabolites at week 12 
seemed to be always associated with either growth in the second trimester or in the 
third trimester but not in both, suggesting different effect for different time windows.  
In Gipuzkoa, five metabolites presented common associations with head and weight 
growth, including repeated positive associations with microbial-host co-metabolite: 
p-cresol sulfate. Although not reaching significance with fetal growth in weight, 
phenylacetylglutamine and 3-indoxylsulfate, also microbial-host co-metabolites, 
showed the same association pattern with head growth.  
Unique metabolite associations in each cohort at week 34 
Different metabolic associations at week 34 with fetal growth in Gipuzkoa and 
Sabadell were also found. Based on Figure 4-4, Gipuzkoa cohort presented the 
greatest number of unique associations, common between weight and head size, 
including for metabolites belonging to the nicotinamide metabolism: 1-methyl-
nicotinamide and N-methylnicotinic acid. A specifically strong positive association 




was observed for Lysine (+1.5% (CI: 0.41;2.5) for weight at week 34). Interestingly 
lactate, another substrate for energy production when glucose or oxygen is lacking, 
was positively associated in Gipuzkoa with both weight and head growth. In 
addition, metabolites of bacterial origin including hippurate, 3-indoxylsulfate and 4-
hydroxyphenylacetate, all presented negative associations with fetal growth in terms 
of weight. In Sabadell, unique signatures at week 34, common between weight and 
head size, included carnitine (also common at week 12), 2Py and unknown steroid 
hormone derivate at δ0.75. In addition, N-acetylserotonin, a derivate of tryptophan 
metabolism, was positively associated with weight in the third trimester.  
 Potential mediating effect of glucose intolerance 4.2.3
Glucose tolerance test (OGTT) results, which measure blood glucose after a meal 
reflecting a potential resistance to insulin, were of interest after interpreting results 
on significant associations between BCAAs and fetal growth. A secondary set of 
analyses allowed stratifying the population according to their results at the OGTT 
such as the urinary BCAA levels of women with gestational diabetes (GDM), 
impaired glucose tolerance but not GDM, or normal OGTT results were analysed 
separately. Simple linear regression models were computed in each cohort and 
each time point separately but we chose to focus on results for Sabadell women at 
week 12, presented in Figure 4-5, which indicates that all three BCAAs levels at 
week 12 showed an inverse relationship with BDP measured at week 34 which is 
particularly pronounced in women with GDM in the second trimester of pregnancy 
(blue line, R2(isoleucine) =25%, R2(leucine) =35%, R2(valine)=19%).  
 Discussion 4.3
This study represents the first application of metabolic profiling to understand 
metabolic predictors of fetal growth in a large-scale pregnant population with 
extensive information on maternal demographic, clinical and lifestyle parameters, as 
well as fetal anthropometry. After understanding the metabolic variations related to 
the time course of pregnancy in Chapter 4, fetal measurements were examined and 
co-analysed with metabolic data in order to identify a maternal metabolic phenotype 
of improved fetal growth. This study showed the ability of a panel of maternal urinary 
metabolites to predict fetal growth at a late stage of pregnancy. These metabolic 
associations were validated between the two cohorts while adjusting for 




constitutional factors contributing to fetal growth. Discussion will be focused on (1), 
metabolic pathways involved with greater fetal growth in the third trimester of 
pregnancy,(2) interpretation of unique metabolic signatures at week 12 in the 
Sabadell cohort and (3) on the strength and limitations of this study. 
 Maternal urinary markers of fetal growth  4.3.1
After understanding the metabolic variations related to the time course of 
pregnancy, fetal measurements were examined and co-analysed with metabolic 
data in order to identify a maternal metabolic phenotype of greater fetal growth. 
Overall, associations between maternal urinary metabolites and fetal growth 
measures, consistent between the two cohorts, are primarily present in the third 
trimester urine.  
 Specific metabolic adaptations based on BCAA catabolism during the third 4.3.1.1
trimester of pregnancy are related to greater fetal growth 
Interpretation of metabolic signatures in maternal urine at week 34 associated with 
greater fetal growth according to metabolic pathways are summarised in Figure 4-6. 
Higher urinary levels of BCAAs at week 34 of pregnancy were particularly 
associated with greater fetal growth both in terms of weight and head size. BCAAs 
are essential nutrients that cannot be synthesized de novo in humans. Their 
homeostasis is therefore maintained by degradation and dietary intake only. BCAAs 
are potentially particularly important during gestation as an energy source, or utilized 
for biosynthetic purposes. They can be oxidised to keto-acids which are in turn 
decarboxylated to form acetyl-CoA and succinyl-coA which eventually enter the 
Krebbs cycle (TCA cycle) and produce ATP. BCAA oxidation is particularly 
important in cases of fasting or even in patients with Type 2 diabetes and obesity 
where there is a switch from glucose to other substrates such as ketone bodies, 
glucogenic amino acids and fatty acids for energy production (Adams 2011). Some 
studies using metabolomics have also demonstrated elevated levels of BCAAs in 
pregnant mothers with gestational diabetes compared to normal pregnancies 
(Scholtens et al. 2014; Cetin et al. 2005). 
During the third trimester of pregnancy, mothers would tend to rely more heavily on 
BCAA catabolism and other substrates for gluconeogenesis to ensure the 
availability of glucose in maternal blood for fetal demand. In our study, further 
metabolic signatures in the 3rd trimester samples associated with increased fetal 




growth supported this hypothesis. In particular increased excretion of 3-HIB, which 
is a degradation intermediate of valine (Nyhan et al. 2005). In our data, this keto-
acid was strongly correlated to an intermediate of the TCA cycle capable of donating 
electrons to the mitochondrial electron transfer chain, succinate, suggesting a 
concomitant adaptation of the mitochondrial respiratory chain complex I-III 
(anaerobic conditions) and energy production via BCAA oxidation. It was also shown 
previously that 3-HIB inhibits the function of the respiratory chain complex I-III and 
mitochondrial creatine kinase (Viegas et al. 2008). 5-oxoproline a key metabolite of 
the γ-glutamyl cycle (glutathione synthesis) and a known marker of mitochondrial 
oxidative stress was correlated to succinate levels and with to a certain extent to 
greater fetal growth (Wu et al. 2004).  These results resemble to a reduced use of 
mitochondrial respiratory chain pathway and an up-regulation of oxidative pathway 
which might increase the level of mitochondrial reactive oxygen species (ROS) 
formation and detoxification via the glutathione pathway. Another supporting 
evidence for the hypothesis of a maternal switch from glucose to other substrates for 
energy production between the first and the third trimester of pregnancy are 
increased alanine and lactate (only significant in Gipuzkoa) also associated with 
increased fetal growth. This may suggest that energy production is being conducted 
preferentially through glycolysis under anaerobic conditions. Choline also showed 
consistent positive associations with fetal growth and high inter-correlation with 
urinary alanine and glutamine, suggesting its involvement in glucose and energy 
metabolism during pregnancy beyond its main role in lipid metabolism. Overall, the 
observed metabolic signatures in mother’s urine associated with greater fetal growth 
suggest an up-regulation of the early steps of BCAA catabolism for energy 
production. However, the influx of acetyl-CoA substrates seems to exceed the 
capacity for incorporation in Krebs cycle and as a result BCAA intermediates 
accumulate, which can be exported out of the mitochondria into the blood and urine. 
Metabolic adaptations in mitochondrial oxidative pathways, evidenced by application 
of metabolomics on urine samples, were well described in previous studies of obese 
rat models (Boulangé et al. 2013) and human studies of diabetic and obese patients 
(Du et al. 2013). Unfortunately little evidence is available from feto-maternal 
research. 
Taken together our results indicate that pregnant women showing greater fetal 
growth tend to rely on BCAA catabolism to produce energy, in response to 
increased glucose demand by the fetus. In previous studies, BCAAs were shown to 




promote fetal growth by stimulating fetal insulin secretion, muscle protein synthesis, 
and also regulates pancreatic β-cell mass (insulin-producing cells). Previous 
metabonomic studies of maternal urine corroborate our results, where a general 
decrease of amino acids such as alanine, glutamine, glycine, leucine, lysine were 
observed at gestational weeks 14-26 in mothers with fetal growth below the 5% 
percentile (n=10) compared to controls (n=84) (Diaz, Barros, Goodfellow, Duarte, 
Galhano, et al. 2013). Cord blood studies of IUGR babies (n=22) showed that 
BCAAs were increased compared to controls (n=21), as well as other amino acids 
such as proline, glutamate and phenylalanine. These same amino acids were also 
found in lower concentrations in IUGR fetal plasma compared to controls (Horgan et 
al. 2011; Lin et al. 2012). These differential changes were suggested to reflect 
placental dysfunction, which reduced essential metabolites passing through to the 
fetus and which are required for fetal growth and development. However, it currently 
remains unclear whether elevated BCAAs in cord blood result from alteration in 
peripheral metabolism of BCAA, increased proteolysis associated with insulin 
resistance, or gut-derived factors. Urinary levels of amino acids are even more 
difficult to interpret in relation to placental transport and metabolism since they also 
summarise renal functional changes. 
 Hormonal milieu and fetal growth 4.3.1.2
Urinary metabolites of steroid hormones were positively associated with fetal growth 
in the late stages of pregnancy in our study, which corroborate previous findings. 
Steroid hormones detected in this study included two metabolites of progesterone, 
P3G and derivates of allopregnanolone (and isomers), unidentified soluble 
metabolites of oestrogens and an unknown peak at 0.75 ppm. Although steroid 
hormone metabolites were close to the noise levels by NMR, consistent 
associations in both cohorts were found in urine at week 34 with greater birth weight 
and placental weight and to a lesser extent with greater EFW in the third trimester of 
pregnancy. Progesterone metabolites at week 12 were also associated with greater 
fetal growth however it showed less consistency across cohorts and outcomes 
probably due to low steroid hormone concentration and a high measurement error at 
week 12. However, these associations at week 12 were biologically significant. 
Indeed, the crucial importance of endogenous oestrogens and progestogens during 
pregnancy is widely known, to maintain and control the course of normal pregnancy. 
Starting at the third month of pregnancy, these hormones are mainly produced by 
the placenta and then metabolised by fetal and maternal adrenal, placenta, fetal and 




maternal liver (Hill et al. 2010). Therefore the hormone by-products measurable in 
the urine, usually the steroid soluble fraction, are the products of the interaction of 
the maternal-fetal-placental unit (Pasqualini, 1970). Previous reports which 
corroborate our results, found that progesterone and oestrogens were reduced in 
FGR cases (hence increased for neonates with greater birth weight, as observed in 
our study) when measured in maternal blood in the third trimester (Salas et al., 
2006). By-products of progesterone were also found decreased in metabonomics 
studies of poor perinatal outcomes using a LC-MS platform (Heazell et al., 2012, 
Horgan et al., 2011). It was also shown via NMR metabonomics on maternal urine 
and plasma collected at different time point of pregnancy that urine signals arising 
from progesterone metabolites (0.63 and 0.56ppm) were correlated with increases 
in plasma HDL and LDL + VLDL throughout pregnancy (│r│=0.60-0.70), confirming 
the role of these steroid metabolites in lipoprotein/protein metabolism during 
pregnancy (Pinto et al. 2014). 
Despite extensive research on the steroid hormone role in maintaining pregnancy, 
the role of particular isoforms of oestrogens and progesterone metabolites and the 
balance between free steroids and their conjugates, on fetal growth remains 
unanswered. Indeed balance between active and inactive forms of steroids may be 
crucial for the regulation of their biological activity and consequently for sustaining 
the pregnancy and fetal programming (Hill et al. 2014). Further investigations are 
needed to fully understand the association between progesterone metabolism, fetal 
growth and variation across individuals. It also seems that males and females are 
not equal regarding placental growth response to progesterone levels in the first 
trimester. In our study, infant gender modified the association between certain 
maternal urinary metabolites and birth measurements (results not shown). It was 
previously demonstrated that male fetuses are more likely to experience adverse 
perinatal outcomes with higher mortality rates for male fetuses that females (Di 
Renzo et al. 2007).  
 Independent metabolic predictions for early fetal growth patterns and size at 4.3.1.3
birth 
Based on the results in our study that fetal growth measurements at week 12 and 
growth 12-20 weeks of gestation did not correlate to the measurements at birth, we 
suggest that early fetal growth patterns may be affected independently to size at 
birth. Previous research report different findings where smaller than expected 




fetuses in the first trimester are at higher risk of  SGA (Smith et al. 1998; Thorsell et 
al. 2010). However, these studies are likely to present significant misclassification of 
appropriate fetal size in the first trimester due to the challenging nature of accurately 
defining the time of conception or implantation. Indeed, current practice is to simply 
re-evaluate gestational age when the predicted value from LMP does not 
correspond to the ultrasound dating (based on crown–rump length) which does not 
take into account individual variations resulting from pathological or physiological 
processes. A more accurate assessment of early fetal growth requires multiple 
measures such as performed by Habayeb et al. which actually found that size at 
birth does not correspond to fetal growth rate (Habayeb et al. 2010). However, it is 
important to keep in mind the difference between fetal growth, which is a dynamic 
process and fetal size, which represents a single measurement point. Fetal size can 
be appropriate despite restricted/accelerated growth, and appropriate fetal growth 
can be associated with abnormal size. In this study, we presented fetal size at a 
certain time point, from single measurements, and the growth during time interval, 
i.e. 12th-20th. Therefore, when both size at week 12 and growth 12th-20th weeks are 
predicted by urinary metabolites at week 12 but not size at birth, this implies that 
early fetal growth is impaired while catch-up growth might occur later during 
gestation. Understanding of the impact of early fetal growth impairment or 
acceleration on childhood outcomes requires further investigations. Evidence 
suggest already that first trimester growth correlates with cardiovascular risk factors 
in school age children even after adjusting for birth weight (Jaddoe et al. 2014).  
Surprisingly different time periods were associated with metabolic profiles for the 
two types of fetal body measurements suggesting that first trimester urinary profiles 
affected more strongly early fetal growth in terms of body weight and more strongly 
head growth in the second/third trimesters. Growth velocity was shown to be 
relatively constant for body weight from the end of the first trimester and onwards 
based upon high-frequency longitudinal ultrasound data from normally growing 
human fetuses (Milani et al. 2005; Lampl & Jeanty 2003). This indicates that despite 
fetal growth velocity reaches its peak at around week 22 of gestation; growth also 
occurs early on and might be affected by a favourable or unfavourable environment 
(e.g. nutritional, hormonal). Technical considerations in the interpretation of these 
findings include the possible misclassification arising from ultrasound measurement 
error while estimating fetal size in utero compared to the more accurate measure of 
birth weight.  




 Unique metabolic signatures in the first trimester of pregnancy in each cohort 4.3.1.4
Sabadell women presented unique adverse associations between urinary 
metabolites at week 12 and fetal growth related to BCAA catabolism and 
mitochondrial energy and oxidative metabolism as summarised in Figure 4-7. These 
metabolic associations included all three BCAAs, isoleucine, leucine and valine, 
which direction of association with fetal growth is even opposite to the one observed 
when metabolites were measured at week 34. Other markers showing inverse 
associations with fetal size at weeks 12, 20 of gestation are consistently related to 
mitochondrial processes such as (1) energy production through TCA cycle or lipid 
metabolism also including for succinate, citrate and carnitine or (2) related to 
oxidative stress and protective mechanisms such as for N-acetylserotonin and 5-
oxoproline. Finally, glycoprotein breakdown products (N-acetyl glycoproteins and N-
acetyl neuraminic acid) showed the strongest magnitude of negative association. 
Interestingly, some of these metabolites at week 12 were also associated with birth 
weight without reaching p<0.05 but only p<0.1 such as isoleucine, valine, N-
acetylserotonin and N-acetyl neuraminic acid. Metabolic associations in the first 
trimester were found to correlate with early fetal growth despite previous research 
suggesting that maternal metabolism during early pregnancy remains mostly 
unaffected in terms of glucose and protein metabolism (King 2000).  
This relationship might be driven by women with subsequent gestational diabetes 
(n=10) or who presented early signs of impaired glucose tolerance (n=62), as 
revealed by a stratified analysis based on the results from the OGTT test in the 
second trimester of pregnancy. This would mean that already at week 12 women 
excrete metabolites predicting glucose intolerance appearing later during pregnancy 
and which is related to changes in fetal growth patterns. These results are very 
important for obstetricians to adapt their clinical practice for mothers with potential 
macrosomia. Similar results were found in a metabolomics study of maternal 
hyperglycemia at ∼28 weeks' gestation from 67 Northern European ancestry 
mothers from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO). 
Indeed, isoleucine, leucine and alanine were predictive of fetal adiposity (newborn 
sum of skinfold) but these associations disappeared once adjusted for maternal 
glycaemic status (supplementary data). Carnitine, an obligatory cofactor for the 
transport of long-chain fatty acids into mitochondria for subsequent β-oxidation, was 
related consistently at weeks 12 and 34 of pregnancy to a subsequent smaller 
child’s weight and head; however this association occurred only in Sabadell. 




Carnitine has an important role during pregnancy in particular in the placenta where 
fatty acid oxidation enzymes have a high activity. Defects in long-chain fatty acid 
oxidation, as noted in placental insufficiency studies, lead to a high frequency of 
SGA newborns (Tyni et al. 1998). A previous metabolomic study of an animal model 
of placental insufficiency corroborate our results where increased plasma carnitines 
early in pregnancy were associated with placental insufficiency (Horgan et al. 2011).  
Renal changes and inflammation may be at the origin of some of the markers of 
early fetal growth impairment observed such as excreted creatine/creatinine 
(validated in both cohorts), N-acetyl neuraminic acid and N-acetyl glycoproteins. 
Creatinine is the breakdown product of creatine and creatine phosphate, which are 
amino acid derivatives involved with cellular energy production, principally in 
muscles. Creatinine excretion during pregnancy was shown to decrease, as also 
observed in this PhD (Chapter 4 - 3.2.3), as well as levels in serum due to increased 
glomerular filtration rate (GFR) (Blackburn 2007). Interestingly, creatine 
supplementation during pregnancy was recently proposed to have benefits for the 
fetus and neonate whenever oxidative stress or feto-placental hypoxia arise 
(Dickinson et al. 2014). N-acetyl-containing metabolites detectable in urine samples 
represented mainly by N-acetyl neuraminic acid and N-acetyl glycoproteins are 
composite markers that reflect the integrated concentrations of several of the most 
abundant glycoproteins in urine (Engelke et al. 2004; Bell et al. 1987). Urinary 
glycoproteins are believed to mainly originate from the serum acute-phase proteins 
following inflammation episodes or directly excreted by the kidney. During 
pregnancy, plasma level of N-acetyl neuraminic acid (also called sialic acid) were 
found strongly correlated to CRP and slightly higher in women with SGA (without 
pre-eclampsia, non-significant) (von Versen-Hoeynck et al. 2009). 
In contrast, Gipuzkoa women at week 12 presented positive metabolic associations 
with fetal growth in line with the ones observed at week 34 such as for alanine, 
lactate, glycine and valine. In addition, metabolites related to gut microbial 
metabolism including increased p-cresol sulfate, phenylacetylglutamine, 
3-indoxylsulfate and decreased 4-hydroxyphenylacetate were solely associated with 
head growth in Gipuzkoa. Gut microbial metabolism during pregnancy was recently 
proven to be of high importance during healthy pregnancy, promoting insulin-
resistance and fat deposition necessary to answer to fetal nutrient demand (Koren et 
al. 2012).  




To our knowledge three metabonomic studies used maternal biofluid (blood or urine) 
in the first trimester to predict fetal growth outcomes. One study identified urinary 
metabolites by NMR at 13th week of gestation associated with fetal adiposity such as 
taurine, histidine and malonate. However, the cohort of pregnant mothers analysed 
might not be representative of the general population since all these women 
delivered overweight babies (>4,000g) (Walsh et al. 2014). Another study conducted 
in Crete, Greece presented urinary markers of FGR at week 12 including decreased 
lactate, alanine, citrate, acetate, trimethylamine and glycine which corroborate 
results in Gipuzkoa at week 12 (Maitre et al. 2014). Finally, the study by Horgan et 
al. using LC-MS, found plasma markers such as sphingolipids, phospholipid and 
P3G but the little overlap in metabolite coverage between their study and our study 
render comparison of results difficult (Horgan et al. 2011).  
In conclusion, metabolic predictors of fetal growth at week 12 are more cohort-
dependant than at week 34 and might be affected by different lifestyle and 
environments which will be explored in the next chapter. 
 Strengths and limitations of this study 4.3.2
 A novel approach to measure fetal growth 4.3.2.1
Most studies on risk factors of fetal growth outcomes have used anthropometric 
measures at birth and rarely outcomes such as small-for-gestational-age using 
customized growth charts as proxy measures of in utero growth. These approaches 
are limited as they assess fetal growth restriction after delivery where different 
patterns of growth during pregnancy might be missed. Studies suggest that birth 
weight poorly reflects fetal growth during the first two trimesters of pregnancy 
(Hemachandra & Klebanoff 2006). Birth size might not fully capture neither the 
timing during gestation in which fetal growth fails nor transient effects during 
intrauterine life. Indeed, fetuses can grow disproportionally with a reduced weight 
and sometimes length but to a normal head circumference in case of reduced 
oxygen or nutrient supply during the last trimester of pregnancy as result of deficient 
vascular-placental functions. On the contrary, fetal growth restriction with equally 
distributed growth restriction of the head, weight and length will occur early during 
the pregnancy (Wollmann 1998).  
Assessing the impact of maternal metabolic profiles on fetal biometry using 
longitudinal ultrasound measurements was useful for identifying potential specific 




periods of vulnerability. Furthermore, several biometric measures were used to 
differentiate greater head growth to the rest of the fetal body. EFW, which was 
based on abdominal circumference (AC), biparietal diameter (BPD), femur length 
(FL), might represent more fetal body volume or central organ development whereas 
head size, more precisely BPD, informs on brain development. Head circumference 
at birth has been reported to be an indicator of brain size, and both head 
circumference and brain size may be predictive of IQ and cognitive ability in 
childhood (Fisch et al. 1976; Gale et al. 2006). However the choice of BPD in this 
study might raise some concerns since head circumference may be a more reliable 
measurement if there is variant head shape. Other measures of fetal growth were 
used in previous metabonomic studies, such as the anterior abdominal wall width, a 
marker of fetal adiposity (Walsh et al. 2014). This measure may better differentiate 
fetuses that are constitutional large to the ones pathologically overgrown and at risk 
of later metabolic diseases in adult life. In addition to using multiple measures of 
fetal growth, this study used a novel approach to obtain an individualized rather than 
a population-based growth standard. Therefore, measured variations in fetal sizes 
described in this study correspond to deviation of individuals in regards to their 
expected growth curves based on their constitutional factors. In clinical settings, it 
remains difficult to define abnormal fetal growth, IUGR or SGA, owing to healthy 
biological variability in human size. However, detecting small infants at risk of 
perinatal morbidity and mortality is crucial for pre-natal screening and prevention. 
This PhD considered to the most recent recommendations given by a group of 
expert epidemiologists in reproductive outcomes to better characterize 
environmental effects on human reproduction (Slama et al. 2014). In our analysis, 
particular attention was given to consider different individual growth potentials, 
adjustment for the gestational timing, respective contributions of the different body 
parts in fetal growth, and most importantly fetal growth was considered as a 
continuous phenomenon using serial measures of fetal parameters.  
Finally, limitations on outcome measurements may include the lack of ultrasound 
measurements performed from week 35 onward, which prevented investigation of 
associations between maternal metabolic profiles and fetal growth during late 
pregnancy (i.e., weeks 32–38), when most of the constitutional variation in fetal 
parameters occurs. The fact that we also analysed parameters at birth partially 
inform on late fetal growth. Another concern about using ultrasound measurements 




to measure metabolic associations with fetal growth is measurement error. Indeed, 
errors arising in clinical settings from intra and inter-observer variability was 
estimated to be equal to up 11% in z-scores (Sarris et al. 2012). In our study, this 
error might have been minimised since the ultrasound measurements were 
performed in only two centres in Sabadell and one centre in Gipuzkoa, which limited 
the number of ultrasound units and ecographists performing the measurements.  
Linear regression models played an important role in epidemiology and are still the 
reference statistics because of their ease of interpretation, their simple 
implementation in different software packages and their solid theoretical foundation. 
Applying this type of univariate statistics instead of multivariate projection methods 
such as PCA, allowed quantification of these novel metabolite-outcome 
relationships, showing that a 50% increase in isoleucine, leucine and valine is each 
associated with a 1 to 2.4% change in birth weight, which corresponds to a 13 gram 
deviation from the expected mean weight. However, multiple comparisons between 
urinary metabolites and outcomes can lead to false positive findings. Replication of 
the findings in the third trimester urine with parameters at birth, however gave 
greater weight to our findings. 
 Biological interpretations 4.3.2.2
This approach made no assumptions as to whether metabolite-outcome 
associations were causally related or were the consequence of fetal size. Rather, 
these findings captured the metabolic signatures of a myriad of physiological (both 
maternal and fetal), environmental, and other lifestyle characteristics associated with 
fetal growth. Caution should be taken in the interpretation of the metabolic pathways 
involved since the metabolites measured only represent the excreted fraction of the 
maternal-placental-fetal metabolism. Conflicting results on the role of amino acids in 
fetal growth and their transfer through the placental barrier are often presented in 
the literature due notably to the species differences in feto-maternal metabolism of 
amino acids and the different timing of biofluid collection during pregnancy (Cowett 
2012). Indeed, the significance of circulating amino acids in maternal blood remains 
unclear partially due to the placental retention of amino acids and the high rate of 
fetal amino acid catabolism. However, the importance of BCAAs for fetal tissue 
accretion in late gestation is well known (King 2000).  






Figure 4-5. Relationship between urinary branched amino acids (BCAAs) at week 12 and head growth (z-score Biparietal diameter, BPD) at 
gestational week 34 according to the diabetic status of pregnant mother in Sabadell cohort. Linear regression equation and R
2
 are plotted. 
  





Figure 4-6 Summary of metabolic signatures in maternal urine at week 34 associated with greater fetal growth. Metabolites with a yellow box were 
significantly associated with fetal growth (head and/or weight) in both cohorts, unless when marked with a star.  





Figure 4-7 Summary of metabolic signatures in maternal urine at week 12 associated with greater fetal growth in Sabadell. Metabolites with a yellow 
box were significantly associated with fetal growth (head and/or weight). 




 Lifestyle and clinical factors associated with Chapter 5 
maternal metabolic signatures of fetal growth 
This chapter aimed to identify potential sources of variation in metabolite signatures 
of fetal growth from epidemiological data such as lifestyle and clinical parameters 
(aim n#3). This information aids interpretation of observed fetal growth-metabolite 
associations (Chapter 5). However, this approach made no assumptions as to 
whether lifestyle/clinical associations with urinary metabolites were causally related 
or were the consequence of these maternal parameters. Three sets of analyses 
were undertaken: (1) mixed effect regression models to identify the sources of 
variation in metabolites in the whole dataset assigned to the sampling time during 
pregnancy (two repeat measurements), the cohort or maternal parameters using 
only continuous covariates, (2) simple linear and logistic regression models where 
specific sources of variation in metabolites were identified in each cohort and each 
trimester of pregnancy separately using continuous and categorical covariates, (3) 
multivariate regression models to estimate the metabolite-outcome associations 
after adjustment for lifestyle/clinical, potentially on the causal pathway. These three 
sets of analyses provided evidence on the relationship between maternal urinary 
metabolites, lifestyle/clinical parameters and fetal growth outcomes as presented on 
a causal diagram in Figure 5-1. 
 
Figure 5-1 Causal diagram of metabolite-outcome associations and potential 
intermediate factors on causal pathway    





 Sources of variation in metabolites in the whole dataset 5.1.1
Based on the significant associations observed with metabolites at week 12 and 34 
with fetal growth in term of weight and head size, a panel of metabolites was 
selected and further analysed. For each metabolite concentration, the variance was 
apportioned (variance decomposition) according to the time of measurement during 
pregnancy, the cohort membership and a maternal co-variable (epidemiological or 
clinical, modelled one-a-time). Beyond geographical variability, the proportion of 
variation attributed to the cohort membership might be representative of other 
variation in the protocol between the two cohorts or experimental batch effect 
(samples analysed with one year interval on the same spectrometer). As seen in 
Figure 5-2, the percentage of variance attributed to the time point of pregnancy (in 
pink) was over 50% for the steroid hormones, creatine/creatinine and carnitine. This 
result confirmed the observations on trimester differences in Chapter 4. Some 
metabolites showed a proportion of variance <1% attributed to the time point such 
as 5-oxoproline or valine, indicating a high stability in urine of pregnant mothers over 
time. The membership to Sabadell or Gipuzkoa cohorts (in blue) was generally of 
lesser importance than the time point. Metabolites with the largest proportion of 
variance attributed to cohort membership were leucine, valine and N-
acetylneuraminic acid (σ>35%). Leucine was 30% higher in Sabadell at both time 
points, Valine was 20% lower in Sabadell and N-acetylneuraminic acid was 440% 
lower in Sabadell in the 1st trimester than in Gipuzkoa.  Interestingly, these 
metabolites at week 12 also showed unique associations with fetal growth in each 
cohort, even opposite patterns of associations were observed in the case of valine.  
The proportions of variance explained by individual epidemiological and clinical 
covariates were summed across the different models for each individual metabolite 
and were plotted in green in Figure 5-2. These sums need to be interpreted with 
caution since co-variables were not all analysed in one model. Indeed, some of the 
variances explained might be overlapping with different covariates and therefore 
their explanatory power might be overestimated here. However, these sums 
provided helpful insight, showing the proportion of variance in metabolite levels 
attributed to maternal co-variables was equal to 8% on average, which was much 
smaller than the variation explained by time of measurement (week of gestation) or 




the cohort. The largest proportion of variance attributed to these co-variables was 
between 20-25% for 3-hydroxyisovalerate and N-methylnicotinic acid. By-products 
from steroid hormones showed the smallest proportion of the variance explained by 
co-variables with a sum between 1.3%-2.3%. 
 
Figure 5-2 Proportion of variance explained in metabolite measurements according to 
the pregnancy time point, the cohort and epidemiological or clinical variables. 
Abbreviations: 2Py, N-methyl-2-pyridone-5-carboxamide; 3-HBA/3-ABA: 3-
hydroxybutyrate/3-aminoisobutyrate; 3-HIB, 3-hydroxyisobutyrate; 3-HIV, 3-
hydroxyisovalerate; UA: unassigned; d, doublet; P3G, 5β-Pregnane-3α,20α-diol-3α-
glucuronide; Pn3G, Allopregnanenolone and isomers. 
In Figure 5-3 and Figure 5-4, further insights into the individual importance of 
maternal lifestyle, clinical parameters (6-2 A & 6-3 A.) and diet intake (6-2 A & 6-3 
B.) in the proportion of variance explained in urinary metabolite levels during 
pregnancy. Metabolites involved in BCAA, glucose or lipid metabolism, in Figure 




5-3, were all related to vitamin D levels (2-4% of variance explained, in blue). 
Vitamin D levels were monitored in the first trimester by measuring circulating levels 
in maternal blood of 25-hydroxyvitamin D (25(OH)D). Other biomarkers measured in 
the first trimester were associated with metabolites related to BCAA, glucose or lipid 
metabolism such as CRP (in green), a marker of inflammation and stress and 
thyroid hormones (triiodothyronine (T3) and its prohormone, thyroxine (T4)). Part of 
the variation in isoleucine, leucine, alanine, lactate, choline and 3-
hydroxyisobutyrate was also explained by circulating triglyceride levels, which 
enable the bidirectional transference of adipose fat and blood glucose from the liver. 
Only glycine was associated with cholesterol levels. Other maternal parameters 
such as age composed only 0.5% of the metabolite variances, in average. Dietary 
intake, presented in Figure 5-3 B. explained less than 1.5% of the total variance in 
these selected metabolites, except for glutamine. Coffee and tea intake was the 
most important dietary factor affecting levels of glutamine (3.2%), alanine and 
glycine. Fruit intake explained 0.6% of leucine levels.  
Figure 5-4 focuses on metabolites which were mainly associated with fetal growth in 
Sabadell when measured at week 12. The variance in metabolites related to 
mitochondrial processes (TCA cycle, lipid oxidation and oxidative stress) was 
attributed to multiple covariates such as succinate by hours of sleep (1.1%), 5-
oxoproline by CRP, T3 and age respectively (1.5%, 1.2%, and 0.9%), acetone by 
vitamin D, T3 and iodine (2.3%, 1.6% and 1.1%, respectively). Creatine/creatinine 
mixed signal was associated to age (1%), as reported in previous studies. N-acetyl 
signals from mixed glycoproteins and breakdown products, N-acetyl glycoproteins 
and N-acetyl neuraminic acids, were related to Vitamin D levels (1.5-3.7%) and 
more specifically N-acetyl glycoproteins to triglycerides (1.5%) and T3 (1.3%). None 
of the covariates explained more than 0.6% of the variance in steroid hormones. 
Variations in levels of metabolites that are a part of the nicotinamide pathway such 
as 1-methylnicotinamide and N-methylnicotinic acid (trigonelline) were associated 
with the CRP (2.1-2.8%) and N-methylnicotic acid to T3 and T4 (1.5%-1.9%). 
Finally, coffee and infusion consumption explained 11.4% of the variance in N-
methylnicotinic acid.  
These results indicate that the proportion of variance in metabolites associated with 
fetal growth is mainly attributed to pregnancy-related changes and cohort. However, 
some metabolites also showed significant associations with measurable maternal 




parameters such as vitamin D availability or thyroid hormone levels. Based on the 
cohort comparison presented in Chapter 4, some of these parameters were 
dramatically different in Gipuzkoa and Sabadell, including vitamin D levels (3-fold 
higher in Sabadell), CRP (10-fold higher in Sabadell) and thyroid hormones.  





Figure 5-3 Proportion of variance explained in urinary metabolites, associated with 
fetal growth by lifestyle, clinical parameters (A.) and diet intake (B.). The metabolites 
selected belonged to the BCAA, glucose or lipid metabolism.  





Figure 5-4 Proportion of variance explained in urinary metabolites, associated with 
fetal growth by lifestyle, clinical parameters (A.) and diet intake (B.). Metabolic 
pathways are indicated above the barplots. 




 Sources of variation in metabolites specific to each cohort and each 5.1.2
trimester of pregnancy 
Due to the unique characteristics of each cohort, with regards to lifestyle and clinical 
parameters, and with regards to their unique associations with fetal growth 
outcomes in the first trimester, specific sources of variation in metabolite levels were 
of interest. In addition, unique metabolic profiles at weeks 12 and 34 of gestation 
might result in different association with lifestyle parameters throughout pregnancy. 
Therefore, we sought sources of variation in metabolites specific to each cohort and 
each trimester of pregnancy using simple linear regression models to assess the 
variance explained (R2) by individual, maternal, clinical and epidemiological 
parameters, both continuous and categorical (logistic regression), in metabolite 
levels. Four dot plots, Figure 5-7, Figure 5-8, Figure 5-9 and Figure 5-10, summarize 
the proportion of variance explained in metabolite signatures of fetal growth. 
Metabolites displayed were all abbreviated at the bottom of the plots are classified 
by metabolic pathways and coloured accordingly. The y-axis represents the 
variance explained (R2) by maternal predictors in metabolite levels, calculated in 
separate regression models. Each maternal predictor (n=42) is shape-coded 
according to its category (clinical, diet, lifestyle, season or socio-demographic) and 
colour-coded according to its attribute (e.g. cholesterol in pink or fruit intake in light 
blue). The colour and shape legend key is presented in Figure 5-6 and is applicable 
to all four dot plots. Significance (p-values from ANOVA tests on null and nested 
models) and actual R2 values can be provided on demand but are not included in 
this thesis.  
Steroid hormone levels (metabolite names in pink) at week 12 were significantly 
associated with maternal clinical measures also measured at week 12 (in Gipuzkoa 
and Sabadell, Figure 5-7and Figure 5-8). Key associations with clinical measures 
included blood cholesterol levels, which is an essential substrate for steroid 
hormone production, as found in Gipuzkoa with R2=1-1.7%, p<0.03, (pink circle, 
Figure 5-7) and in Sabadell (only Pn3-G, Figure 5-8). Iodine, the main source of 
which is diet and which is essential for thyroid function during pregnancy, was 
related to Pn3-G in Sabadell (R2=6.4% and P3G) and in Gipuzkoa (with Pn3-G 
R2=2.4%). Unique clinical associations with steroid hormone metabolites were 
observed in Gipuzkoa including with thyroid hormone T4 with Pn3-G, and unique 
associations in Sabadell included Vitamin D with oestrogens. It was noted in 




Chapter 4 that Sabadell women presented higher levels to vitamin D than in 
Gipuzkoa. Lifestyle factors were also significant predictors of steroid hormone 
levels, in particular tobacco smoking before and at the beginning of pregnancy (dark 
blue squares in dot plots) which is known to impair placental development and 
function, including steroid hormone production (BERNSTEIN et al. 1989). In this 
PhD, women who smoked at the beginning of pregnancy had lower levels of 
progesterone metabolites at week 12 with R2= 1.3-3.3%. Smoking at week 34 
showed weaker associations, than early during pregnancy, with progesterone 
metabolites in both cohorts with R2<1.5%. Steroid hormone levels at week 34 were 
associated with the type of water ingested at home (bottled mineral water/municipal 
tap water/other, represented with orange squares). This was significantly associated 
with oestrogens at week 34 in both cohorts, however, the model was driven by only 
3 women in each cohort who consumed water from private wells and had lower 
levels oestrogens (Figure 5-9 and Figure 5-10 for Gipuzkoa and Sabadell, 
respectively). Finally, the season at sampling (yellow crosses) and the season at the 
time of birth (red crosses) were often associated with P3N-G and oestrogens across 
the two cohorts and the two time points. 
Metabolites belonging to BCAA and glucose metabolism, including Leucine, 
Isoleucine, Valine, 3-HIB, 3-HIV, lactate and alanine, were related to the thyroid 
hormone T3 (orange circle) at week 12 and to a lesser extent at week 34. Stronger 
associations were observed in Gipuzkoa with R2=1.2 - 4.6% than in Sabadell with 
R2=1.0 – 2.7%. Other markers of thyroid functions were available such as TSH or 
iodine (substrate for thyroid hormones) but metabolite associations with these 
markers were not as consistent as with T3. Metabolite associations were only found 
with T4 in Gipuzkoa at week 34. Leucine, its derivate 3-HIV, lactate, alanine and 
choline were related to physical activity (dark red square, R2=2.4-3.4%) at week 12 
and with night work at week 34 (R2 up 6.2% for 3-HIV) in particular in Gipuzkoa. 
More specifically these metabolites were lower in women with sufficient to intense 
activity compared to women with little to moderate activity. Coffee consumption 
(brown triangles) was associated with significant reduced levels of 3-HIV, alanine, 
glutamate and glycine in both cohorts at both weeks 12 and 34. The season at 
sampling explained some of the variation in BCAA levels at week 12 with R2=1.9-
3.4% in both cohorts. However, the seasonal pattern was opposite in the two 
cohorts with lower BCAA levels in spring in Sabadell compared to other seasons 




and higher BCAA levels in spring in Gipuzkoa (as shown in Figure 5-5). Finally, 
socio-demographic factors (crossed squares) in particular ethnicity (in red) were 
associated with leucine and its catabolic intermediate 3-HIV at week 12 in Sabadell, 
with lower leucine and higher 3-HIV levels in women from South America (n=36) 
compared to the ones from Spain (n=398) or Europe (n=11) with R2=4.4% for 
Leucine (p=0.001). These associations were also observed in Gipuzkoa but to a 
lesser extent probably due to a smaller non-Spanish population (n=8). 
 
Figure 5-5. Boxplot of BCAA levels at week 12 of gestation according to the season of 
sampling in Gipuzkoa and in Sabadell.  
P-values were calculated using an ANOVA test. 
Other metabolite classes such as nicotinamide-related metabolites were strongly 
associated with coffee consumption (R2 up to 22%), smoking and also diabetic 
status in the case of 2Py. Metabolites related to mitochondrial processes and 
oxidative stress, including citrate, succinate and 5-oxoproline, which were negatively 
associated with fetal growth outcomes in Sabadell at week 12, were specifically 
explained by dietary total fat intake in Sabadell at week 12 with R2=1.8-2.2%. 
Interestingly, women in Sabadell consumed more fat than in Gipuzkoa with 47% of 
Sabadell women who consumed more than 95 grams/day versus 18% in Gipuzkoa. 
Carnitine, a metabolite responsible of lipid uptake in mitochondria, was related to 
iodine (dark green circle) and triglycerides (purple circle) only in Gipuzkoa.   





Figure 5-6 Colour and shape legend keys for Figures 6-5 to 6-8  
Details on the variables including coding can be found in Chapter 3 and Chapter 4. 
 





Figure 5-7. Variance explained in urinary metabolites at week 12, associated with fetal 
growth by lifestyle, clinical parameters, diet intake, lifestyle and other socio-
demographic factors in the Gipuzkoa cohort. Metabolic pathways are indicated below 
the metabolite





Figure 5-8. Variance explained in urinary metabolites at week 12, associated with fetal growth by lifestyle, clinical parameters, diet intake, lifestyle 
and other socio-demographic factors in the Sabadell cohort. Metabolic pathways are indicated below the metabolites






Figure 5-9. Variance explained in urinary metabolites at week 34, associated with fetal 
growth by lifestyle, clinical parameters, diet intake, lifestyle and other socio-
demographic factors in the Gipuzkoa cohort. Metabolic pathways are indicated below 
the metabolites





Figure 5-10 Variance explained in urinary metabolites at week 34, associated with fetal growth by lifestyle, clinical parameters, diet intake, lifestyle 
and other socio-demographic factors in the Sabadell cohort. Metabolic pathways are indicated below the metabolite





 The mediating role of key lifestyle/clinical factors 5.1.3
A final set of analyses was performed in order to assess the importance of maternal 
lifestyle/clinical parameters in explaining the urinary metabolite-fetal growth 
associations.  Adjusting for maternal parameters did not change dramatically the 
observations made on metabolite-outcome associations as reported in Table 5-1 for 
birth weight metabolic associations. This was particularly true for maternal age 
which did not affect metabolite-outcomes. Adjusting for the rate of weight gain 
during pregnancy had a moderate effect but was observed for most metabolite-birth 
weight associations. Correcting for gestational weight gain lowered the metabolite-
outcome associations in Sabadell (maximum -34% change in birth weight estimates) 
and enhanced the associations in Gipuzkoa (maximum +20%) for steroid 
metabolites, BCAA metabolites, choline and alanine. Leucine and isoleucine 
positive associations with birth weight were affected after adjusting by T3 (measured 
in the first trimester) in both cohorts (8-22.5% change in beta estimates).  Adjusting 
for paternal education (categories: not able to read and write, without education or 
unfinished primary school, primary school, secondary school, university) or maternal 
ethnicity (Spanish or non-Spanish) affected associations between BCAA-related 
metabolites and birth weight only in the Sabadell cohort.  
Urinary metabolic associations at week 12 that predicted reduced fetal growth early 
in pregnancy in the Sabadell cohort demonstrated more dramatic changes after 
adjustment for lifestyle/clinical parameters as shown in Table 5-2. Again adjusting 
for the thyroid hormone T3 changed the magnitude of associations between BCAAs 
and fetal weight (at week 20) by up to 17% but more importantly modified other 
metabolic associations related to mitochondrial processes such as 5-oxoproline, 
succinate, citrate and carnitine. Adjusting for maternal urinary levels of iodine, a 
marker of iodine intake through diet, had the strongest impact on the associations 
between urinary metabolic markers of fetal growth at week 12 increasing the 
magnitude of association by up to +88%, for BCAA-related metabolites, creatinine, 
oxidative stress marker, 5-oxoproline, TCA cycle metabolites, N-acetylserotonin, 
carnitine. However, the associations with N-acetyl signals from glycoproteins and 





neuraminic acid were reduced by -55%. Adjusting for CRP, a marker of 
inflammation and stress, also changed the magnitude of association for BCAAs, 5-
oxoproline, N-acetylserotonin and N-acetyl residues. Adjusting for calorie intake and 
fat intake (which are highly related), also modified some of the associations 
observed between fetal weight at week 20 and all the metabolites mentioned above 
(except N-acetyl residues). 
This final set of analyses adjusting for maternal parameters provided further 
information on which parameters might explain some the associations observed 
between urinary metabolites and fetal growth outcomes. Metabolic associations 
observed at week 34 were only partially explained by maternal parameters such as 
gestational weight gain during pregnancy. Metabolic associations observed at week 
12 with early fetal growth in Sabadell were overall stronger after adjusting for iodine 
levels and CRP. These associations were weaker after adjusting for fat intake and 
T3 which might inform on some underlying cause of associations. 
 





Table 5-1. Percent change estimates for the adjusted associations between birth weight (z-scores) and maternal urinary metabolites at week 34 
before and after including intermediate clinical/lifestyle parameters. All the models were adjusted at least for maternal weight, height, father’s height, 
parity, gestational week at urine collection and at birth and child’s gender. In brackets, the change in the regression estimate before and after adjustment is 
presented (Changes >10% are in bold). 
  



















Progesterone metabolite 0.6% 0.6 (3.3%) 0.6 (-0.4%) 0.6 (-1.3%) 0.6 (0.1%) 0.6 (-1.9%) 0.7 (12.1%)* 0.6 (0%) 0.6 (-8.6%) 
Pregnanediol-3-G 0.7% 0.7 (1.8%) 0.6 (-3.4%) 0.7 (-0.5%) 0.6 (-1.6%) 0.7 (3.7%) 0.8 (18.1%)* 0.7 (1.5%) 0.6 (-6.7%) 
Oestrogen metabolite 0.8% 0.7 (-1.8%) 0.8 (0%) 0.8 (2.3%) 0.8 (0.4%) 0.8 (8.7%) 0.9 (20.3%)* 0.8 (-0.1%) 0.8 (1.9%) 
Leucine 1.5% 1.4 (-3.4%) 1.5 (0.9%) 1.6 (11.4%)* 1.5 (0.5%) 1.6 (11.4%)* 1.6 (9.9%) 1.5 (-0.3%) 1.6 (6.4%) 
Isoleucine 1.8% 1.8 (-1.5%) 1.8 (0.3%) 2 (7.9%) 1.8 (1.5%) 1.9 (5.1%) 2.1 (15.1%)* 1.8 (1.4%) 2 (9.9%) 
Valine 2.2% 2.2 (0%) 2.3 (4.6%) 2.3 (2.3%) 2.2 (0.1%) 2.3 (4.5%) 2.6 (15.7%)* 2.3 (0.4%) 2.2 (-3.3%) 
3-hydroxyisobutyrate 0.6% 0.6 (-5.5%) 0.6 (1.8%) 0.6 (7.5%) 0.6 (0.3%) 0.6 (5.5%) 0.5 (-9%) 0.6 (0.1%) 0.6 (-6.1%) 
Alanine 0.7% 0.7 (-2.8%) 0.7 (2.8%) 0.7 (1%) 0.7 (-0.1%) 0.7 (8.3%) 0.7 (-5.2%) 0.7 (-0.5%) 0.7 (-4.7%) 




































Progesterone metabolite 0.4% 0.4 (5.5%) 0.4 (-2.1%) 0.4 (-5.8%) 0.4 (5.8%) 0.4 (-1.5%) 0.3 (-17.8%)* 0.4 (0.1%) 0.4 (3.3%) 
Pregnanediol-3-G 0.4% 0.4 (10.3%)* 0.4 (10.1%)* 0.4 (14.5%)* 0.4 (0.4%) 0.4 (1.9%) 0.3 (-2.9%) 0.4 (4.2%) 0.3 (-3.9%) 
Oestrogen metabolite 1.0% 1.1 (11.2%)* 1 (-0.4%) 1 (-3.4%) 1 (1.1%) 1 (-3.8%) 0.9 (-5.6%) 1 (-0.1%) 1 (0.1%) 
Leucine 0.7% 0.5 (-20%)* 0.6 (-5.5%) 0.5 (-22.5%)* 0.7 (1.6%) 0.6 (-18.1%)* 0.6 (-13.8%)* 0.6 (-11.1%)* 0.8 (16.1%)* 
Isoleucine 0.7% 0.7 (-0.3%) 0.7 (-2.9%) 0.6 (-14.9%)* 0.7 (1.4%) 0.6 (-12.1%)* 0.6 (-13.4%)* 0.6 (-10%)* 0.8 (10.7%)* 
Valine 0.9% 0.8 (-4.8%) 0.9 (-0.8%) 0.9 (2.8%) 0.9 (0.7%) 0.8 (-9.9%) 0.6 (-24.9%)* 0.7 (-14.3%)* 0.9 (1.4%) 
3-hydroxyisobutyrate 0.9% 0.9 (-1.5%) 0.9 (-2.2%) 0.9 (6.3%) 0.9 (0.3%) 0.9 (0.8%) 0.7 (-15.9%)* 0.8 (-8.6%) 0.8 (-11.7%)* 
Alanine 0.6% 0.6 (-0.4%) 0.5 (-4.4%) 0.6 (1.9%) 0.6 (0.6%) 0.5 (-2.7%) 0.4 (-34.1%)* 0.5 (-9.7%) 0.5 (-7.7%) 
Choline 0.6% 0.6 (2.2%) 0.6 (1.8%) 0.6 (-3.3%) 0.6 (1.2%) 0.6 (2%) 0.5 (-11.9%)* 0.6 (-3.8%) 0.5 (-6.9%) 





Table 5-2. Percent change estimates for the adjusted associations between fetal weight at week 20 (z-scores) and maternal urinary metabolites at 
week 12 before and after including intermediate clinical/lifestyle parameters. All the models were adjusted at least for gestational week at urine 
collection. In brakets, the change in the regression estimate before and after adjustment is presented (Changes >10% are in bold). 
  







CRP Urine iodine 













Leucine -0.9% -0.9 (1.9%) -1 (9.5%) -0.8 (-9.4%) -1.2 (34.8%)* -1.4 (56.1%)* -0.9 (-0.7%) -0.9 (-2.7%) -0.8 (-10.3%)* -0.8 (-8.2%) -0.9 (-3%) -0.9 (2.8%) -1 (5.5%) 
Isoleucine -0.7% -0.7 (4%) -0.7 (4.1%) -0.8 (13.6%)* -0.8 (23.3%)* -1.1 (68.5%)* -0.6 (-10.2%)* -0.7 (-1.8%) -0.6 (-5.7%) -0.6 (-6.3%) -0.7 (-2.4%) -0.7 (4.2%) -0.7 (1.2%) 
Valine -0.8% -0.8 (-2.5%) -0.7 (-4.4%) -0.6 (-17%)* -0.9 (19%)* -1.4 (87.5%)* -0.7 (-6.9%) -0.7 (-6%) -0.7 (-14%)* -0.7 (-12.2%)* -0.7 (-6.3%) -0.8 (3.7%) -0.8 (3.9%) 
Creatinine* -1.5% -1.4 (-7.3%) -1.4 (-7.2%) -1.3 (-16.2%)* -1.5 (-3.6%) -1.7 (14.9%)* -1.6 (3.2%) -1.5 (0.4%) -1.3 (-10.4%)* -1.4 (-7.6%) -1.4 (-5.6%) -1.6 (4.3%) -1.5 (1.1%) 
5-oxoproline -1.5% -1.5 (0.1%) -1.4 (-4.3%) -1.2 (-20.1%)* -1.7 (15.8%)* -2.4 (61.3%)* -1.3 (-11.1%)* -1.5 (-0.4%) -1.3 (-10%)* -1.4 (-7.8%) -1.5 (0.7%) -1.4 (-4.3%) -1.5 (1.4%) 
Succinate -1.3% -1.3 (-3.4%) -1.2 (-6%) -1 (-22%)* -1.3 (-4.5%) -1.4 (9.3%) -1.3 (-3.1%) -1.3 (-1%) -1.2 (-6.3%) -1.2 (-6.3%) -1.3 (2.3%) -1.3 (-4.6%) -1.3 (0.8%) 
Citrate -0.7% -0.7 (-3.9%) -0.7 (7.4%) -0.5 (-34.4%)* -0.7 (0.4%) -1.2 (69.2%)* -0.6 (-7.6%) -0.7 (0.3%) -0.6 (-9.4%) -0.6 (-8.8%) -0.7 (3.5%) -0.8 (21.2%)* -0.7 (0.8%) 
NAS -0.9% -0.9 (-4.5%) -0.8 (-7.3%) -0.8 (-15.5%)* -1.2 (30.3%)* -1.5 (68.2%)* -0.9 (3.6%) -0.9 (-4.2%) -0.8 (-12.8%)* -0.8 (-10.2%)* -0.9 (-3.1%) -0.7 (-17.7%)* -0.9 (2.6%) 
Carnitine -0.6% -0.6 (0.5%) -0.6 (-4.4%) -0.5 (-19.1%)* -0.5 (-14.3%)* -0.9 (60.8%)* -0.6 (-1.8%) -0.6 (-1.2%) -0.5 (-10.3%)* -0.6 (-4%) -0.5 (-14.9%)* -0.6 (3.8%) -0.6 (3.3%) 
NAG  -1.3% -1.2 (-4.3%) -1.3 (-0.8%) -1.3 (0.4%) -1.6 (22.6%)* -0.6 (-54.5%)* -0.9 (-27%)* -1.3 (0.8%) -1.3 (-1.3%) -1.3 (-1%) -1.3 (-0.4%) -1.3 (-0.5%) -1.3 (0.2%) 
NAN -2.5% -2.4 (-1.6%) -2.5 (1.5%) -2.4 (-1.2%) -3.5 (39.7%)* -1.1 (-56.3%)* -2.3 (-8.7%) -2.6 (5.3%) -2.6 (4.2%) -2.5 (2.4%) -2.6 (4.2%) -2.6 (5.5%) -2.5 (1.1%) 
 
Abbreviations: NAG, N-acetyl-glycoproteins NAN, N-acetyl neuraminic acid NAS, N-acetylserotonin. * Overlapped signal from creatinine and creatine




The second part of this study utilised extensive information on maternal 
demographic, clinical and lifestyle parameters to understand individual variation in 
metabolic predictors of fetal growth in a large-scale pregnant population. Beyond a 
major proportion of variation observed in metabolic predictors due to pregnancy-
related changes, cohort differences made up to 30% of variance explained for 
BCAA-related metabolites (on average). Demographic, clinical and lifestyle 
parameters measured through the INMA study were found to only explain a small 
proportion of variance in urinary metabolite levels. The best predictors of urinary 
metabolite levels included clinical makers such as vitamin D (Serum 25-
hydroxyvitamin D [25(OH)D]), thyroid hormones (T3), inflammatory marker CRP and 
the rate of maternal gestational weight gain. Lifestyle habits such as physical 
activity, coffee intake and smoking also explained some of the metabolite variations. 
Maternal age had surprisingly weak associations with urinary metabolites and 
moderate influence could be detected from the season and different ethnicities. In 
our study, dramatic vitamin D, urinary iodine levels and CRP differences between 
Sabadell and Gipuzkoa might mediate some of the unique metabolic signatures of 
fetal growth observed. Further examinations of the mediating role of maternal 
clinical/lifestyle predictors in the associations between maternal urinary metabolites 
and fetal growth outcomes were explored by adjusting for individual factors. The 
aims were to aid in developing causal hypotheses for fetal growth predictors and 
potentially define high-risk subgroups for preventive actions.  
 Most important lifestyle/clinical predictors 5.2.1
 Gestational weight gain 5.2.1.1
Factors explored seemed to explain only a minor fraction of the association between 
maternal urinary metabolites and fetal growth outcomes observed in the third 
trimester (only tested for birth weight, not for head growth). The rate of weight gain 
was the variable with the strongest impact on metabolite-outcome associations. 
Further stratification of the data (results not shown) showed that weight gain was a 
confounder, where only a change in the intercept was observed and not in the 
magnitude of the association (slope), suggesting no modification effect /interaction. 
The rate of weight gain during pregnancy is a strong predictor of fetal size during 
late gestation and at birth, as demonstrated in the literature (Hinkle et al. 2015). 
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Therefore when the rate of weight gain is added to the predictive model of fetal 
growth it diminished the metabolite-outcome associations. 
 Vitamin D status 5.2.1.2
Specific influences from lifestyle factors on progesterone metabolite levels were 
identified, in particular reduction of hormone levels following tobacco smoking at the 
beginning of pregnancy. Indeed, environmental challenges were shown to affect the 
endocrine system, which may be of particular importance during pregnancy. 
Previous reports from both animal and human studies corroborate these results, 
where decreased progesterone levels were observed following stress and smoking 
(BERNSTEIN et al. 1989; Ng et al. 2006). Unsurprisingly, cholesterol was related to 
progesterone metabolites at week 12, based on their biochemical pathway 
proximity. Interestingly, Sabadell women showed an unique inverse association 
between vitamin D levels at week 12 and oestrogens at week 34 of gestation 
(p=0.03). Vitamin D was previously shown to modify regulation of the oestrogen 
receptor (ER) and thus attenuating oestrogenic effects such as cell growth 
(Colonese et al. 2015). Further evidence would be needed to evaluate the influence 
of vitamin D intake or changes in cholesterol levels at the beginning of pregnancy on 
the risk for abnormal fetal growth.  
Metabolites related to BCAA catabolism and glucose metabolism were also related 
to circulatory levels of vitamin D. In our study, the Sabadell women had almost three 
fold higher levels of vitamin D compared to Gipuzkoa women. Vitamin D, which 
main source is sunlight exposure and dietary intake, was previously shown to help 
maintain normal pregnancy and support fetal growth through delivery of calcium and 
control secretion of placental hormones (Shin et al. 2010). However, vitamin D 
status was shown to have a U-shaped distribution of risk on SGA outcome, where 
insufficient or excess intake was linked to higher rates of SGA (Bodnar et al. 2010). 
It is important to note that maternal deficit of vitamin D (<20 ng ml−1) was 
associated with increased risk of fetal overweight in the INMA cohort (Morales et al. 
2011). Prior studies using LC-MS metabolic profiling methods corroborate these 
results including the identification of low vitamin D3 metabolites in maternal serum in 
the first trimester as predictors of macrosomia (Ciborowski et al. 2014; Heazell et al. 
2012). Investigation in the mediating role of vitamin D in the metabolic associations 
at week 34 observed in this PhD with birth weight suggested that vitamin D 
deficiency combined with high excretion of oestrogen derivates and BCAAs could 
predict LGA (Figure 9-10 B.). Inversely, FGR occurred predominantly in women in 
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the highest tertile of vitamin D and low urinary valine levels (Figure 9-10 A.). 
Therefore combined use of vitamin D status and urinary metabolic profiles may help 
to differentiate women at risk of abnormal fetal growth and offers insight into 
potential mechanisms of vitamin D population variations. Recent evidences 
demonstrated that vitamin D deficiency may participate to the onset of gestational 
diabetes since vitamin D is able to induce insulin secretion and to enhance insulin 
responsiveness for glucose transport (Colonese et al. 2015). In addition, vitamin D 
supplementation among pregnant women has beneficial effects on metabolic status 
and systemic inflammation, as measured with CRP levels (Asemi et al. 2013). 
Appropriate levels of vitamin D may be reached with dietary supplementation; 
however there has been a continued debate over the correct dose and form due to 
the complexity of its absorption, metabolism and multiple interaction with other 
macronutrients (Braithwaite et al. 2013). 
 Iodine status and thyroid function 5.2.1.3
Metabolites related to BCAA catabolism and glucose metabolism, including Leucine, 
Isoleucine, Valine, 3-HIB, 3-HIV, lactate and alanine, were related to thyroid 
metabolism in particular the level of the thyroid hormone T3 in the first trimester. T3 
is the most active form of thyroid hormone (x5 activity than T4). Thyroid hormones 
are critical for many aspects of pregnancy and fetal growth, in particular for the in 
utero development of the brain and skeletal-muscular system. There are also 
essential for glucogenesis in the fetus during gestation, acting on hepatic glucogenic 
pathways and on the mechanisms activating in utero glucogenesis, by increasing 
the rates of glucose oxidation (Fowden et al. 2001). Urinary iodine varied between 
the Sabadell and Gipuzkoa cohorts in the same way as iodine intake from 
supplements and salt (wide consumption of iodine supplements in Gipuzkoa 
compared to Sabadell), with the highest median level found in Gipuzkoa (169 µg/L) 
and the lowest in Sabadell (90 µg/L) (Rebagliato et al. 2013). An increased risk of 
raised TSH during the first half of pregnancy for women who consumed 
supplements containing iodine was previously found in the INMA study; in addition, 
an association between supplement consumption and lower levels of T4 was found, 
but only in women from Sabadell (Rebagliato et al. 2010). Safety of supplementary 
or excessive iodine intake was previously questioned because of the possible 
consequence on maternal and fetal thyroid dysfunction by either directly inhibiting 
thyroid hormone production or by triggering thyroid autoimmunity (Markou et al. 
2001). Interestingly, iodine deficient populations appear to be more at risk of iodine-
induced hypothyroidism (EU Commission 2002). In this chapter, iodine status was 
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found to enhance the first trimester metabolic associations with EFW at week 20 
after inclusion in the regression models. Indeed, further stratification of the women 
according to their iodine status suggested that a low iodine status was beneficial 
when also combined with lower urinary levels of BCAAs, oxidative stress makers 
such as 5-oxoproline and succinate or N-acetylserotonin (results shown in Annexe 
Figure 9-9). 
 Potential adverse oxidative stress occurring via smoking, inflammatory stress in 5.2.1.4
Sabadell in the first trimester 
Sabadell women presented unique results with a larger proportion of the third 
trimester associations between BCAAs and birth weight explained by 
lifestyle/clinical factors compared to Gipuzkoa. These factors included different 
paternal education, smoking habits (beginning of pregnancy) statuses, cholesterol 
and triglyceride levels. In addition, first trimester metabolic associations with EFW at 
week 20 (only explored in Sabadell) were more strongly explained than associations 
with birth weight by some factors such as T3, iodine levels and CRP. Metabolites 
related to BCAA catabolism and mitochondrial oxidative stress, also negatively 
associated with early fetal growth in Sabadell, were independently related to blood 
levels of CRP, an acute-phase reactant and a frequently used marker of low-grade 
systemic inflammation. Interestingly, CRP was 10-fold higher in Sabadell compared 
to Gipuzkoa as revealed in Chapter 4. Women excreting higher levels of 5-
oxoproline, N-acetylserotonin, citrate, N-acetyl neuraminic acid, 4-deoxythreonic 
acid at week 12 had fetuses with smaller EFW at week 20 (but not at week 34 or at 
birth). These associations were of higher magnitude in women with also high levels 
of CRP (>10 mg/L) (results shown in Annexe Figure 9-11). These observations 
underlie potential mechanisms where inflammation, as by measured by CRP, is 
related to oxidative stress and subsequent impaired early fetal growth. Previous 
studies corroborate this result were elevated CRP values during pregnancy were 
associated with a higher risk of SGA (Ernst et al. 2011). In addition, CRP has also 
emerged as a predictor of incident type 2 diabetes mellitus and GDM, implicating 
chronic subclinical inflammation as a factor in the pathophysiology of diabetes (Wolf 
et al. 2003). Interestingly, N-acetylserotonin an intermediate substrate in the 
endogenous production of melatonin from serotonin might be representative of anti-
oxidative mechanisms (Aversa et al. 2012). This would need to be confirmed in 
further experimental studies both in term of mechanism and metabolite ID (in this 
study overlapped signals did not allow to identify all the peaks even after spike-in 
experiments).  
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Maternal smoking at the beginning of pregnancy, a causal factor for placental 
dysfunction through oxidative stress mechanisms, was related to metabolites related 
to mitochondrial oxidative stress and protective mechanisms such as 5-oxoproline, 
citrate, carnitine and potentially N-acetylserotonin. Associations between the 
aforementioned maternal urinary metabolites at week 12 and EFW at week 20 in the 
Sabadell cohort were stronger in smokers (stratification by maternal smoking status 
at the beginning of pregnancy in Annexe Figure 9-12). Interestingly, L-carnitine 
supplementation in cigarette smoke-exposed mothers was found to reversed the 
detrimental maternal impacts on kidney pathology in mouse male offspring (Nguyen 
et al. 2015). This suggests a particularly important role for carnitine during 
pregnancy, as to increase antioxidant defences and mitochondrial function during 
placental development. 
Factors that enhanced the metabolite-outcome associations after being included in 
the models such as CRP, iodine and smoking before pregnancy may help to stratify 
women at higher risk. Indeed, results suggested that a low iodine status and low 
CRP were correlated with greater fetal growth when also combined with lower 
urinary levels of BCAAs, oxidative stress makers such as 5-oxoproline and 
succinate or N-acetylserotonin (results shown in annexe).  
 Other maternal factors 5.2.1.5
Other factors such as the season of sampling and the country of origin of the 
mothers also influenced the levels of urinary metabolites. Previous INMA studies 
confirmed that mothers born in Latin America demonstrated significantly different 
environmental exposures to organochlorine, pesticides and mercury (Vrijheid et al. 
2010). In addition, physical activity during the first trimester was significantly 
associated with levels of BCAAs in particular leucine in Gipuzkoa. Lower levels of 
excreted leucine in women with moderate to intense activity corroborate results from 
a recent study on obesity suggesting that exercise increase the utilisation of leucine 
in muscle and prevent hyperaminoacidemia  associated with lack of exercise and 
insulin resistance (Elliott et al. 2015).  
 Causality  5.2.2
We have identified novel inter-relationships between fetal/birth weight, metabolites, 
and lifestyle/clinical factors but we cannot determine the temporal sequence of 
cause and effect using these data. Urinary metabolites might be representative of 
lifestyle/clinical factors which potentially impact directly upon fetal growth outcomes. 
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However it is important to note that the metabolome reflects a whole host of 
environmental, genetic and lifestyle factors, and only a small percentage of the 
variation of each single metabolite was explained by any one individual 
lifestyle/clinical parameter. Therefore, a likely explanation for the metabolite-
outcome associations would be that urinary metabolites associated with fetal growth 
measured a phenotype for which underlying causes arose from a combination of 
lifestyle/clinical factors and their interaction with maternal genetic/epigenetic 
predispositions. Potential errors or approximations in the lifestyle/clinical factor 
measurements included might also hide true associations. Only crude measures of 
dietary habits (food frequency questionnaires) and single spot measurements of 
clinical parameters were available. Also, many environmental stressors were not 
measured in this study such as stress-related markers. CRP, a robust marker of 
stress-induced systemic chronic inflammation, may be an approximate measure of 
stress levels (including arising from acute infection, psychological stress (shown to 
be related to low income), obesity) in the pregnant mother. Therefore, this marker 
may partially measure stress which affects fetal growth in the first trimester as well 
as urinary metabolites in the same time period. The residual variance explained by 
CRP in metabolite-outcome associations is therefore small but detectable. Further 
experimental research would be required to demonstrate causality.   






Figure 5-11 Summary diagram of the relationship between urinary metabolites found 
associated with fetal growth early in pregnancy in the Sabadell cohort and potential 
intermediate factors. 
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 TCAA biomonitoring during pregnancy Chapter 6 
In this chapter, I aimed to quantify the exposure to adverse chemicals during 
pregnancy, specifically individual uptake of water DBPs, from ingestion of 
chlorinated tap water (Study n#3). In order to create sensitive measures of 
environmental exposure to HAA toxins, a non-volatile sub-type of DBPs, a targeted 
analysis of internal TCAA levels in each pregnant woman’s urine using quantitative 
and highly sensitive LC-MS was conducted. This biomarker of exposure will be for 
future use in epidemiological analysis of birth and child outcomes (not in the 
framework of this PhD).  
 Background 6.1
In Spain, a great variability exists in THM and HAA concentrations in municipal 
drinking water. Contaminant levels were found to be up to three times higher in 
cities in the Mediterranean area compared to the Cantabrian area (including Basque 
country) (Villanueva et al. 2003). Indeed, waters in Mediterranean regions exhibit 
higher chloride and organic carbon levels (primary ingredient of organic matter) than 
in the Cantabrian area. This is partially explained by the multiple reuses of water for 
agricultural irrigation, urban and industrial effluent discharges in Mediterranean 
regions. In contrast, surface waters in the Cantabrian area are of higher quality, 
especially as a result of high amounts of rain collected by the river system. This was 
verified in a more recent THM study conducted in the INMA cohort by our 
collaborators, where Villanueva et al. presented THM area level in the public water 
supply (Villanueva et al. 2011). Great differences in total residential THMs were 
observed between the Gipuzkoa and the Sabadell cohorts with respectively median 
total THM levels of 16.9 and 114.7 µg/L, (reproduced results from publication in 
Figure 6-1). Unlike THMs, HAA levels are rarely monitored due to the absence of 
regulation for this type of compounds in drinking water. However, the Gipuzkoa 
cohort was the focus of a study on water quality which specially assessed HAA area 
levels. 
In this PhD we were specifically interested in individual intake of HAA in utero which 
has not been thoroughly investigated before, due to the lack of routinely available 
information. This is of particular interest to investigate in the future whether HAA 
exposure during pregnancy might be associated with risk of birth outcomes, such as 
6 . 1  B a c k g r o u n d  | 195 
 
 195 
FGR. Hence, personal intake of HAA was assessed only in individuals selected in a 
nested case control study drawn from the Gipuzkoa and Sabadell cohorts, 
specifically designed for this PhD, and not from the whole cohorts.  
Personal intake of HAAs, which are non-volatile chemicals, is believed to mainly 
occur through oral ingestion of cold tap water. Despite much higher HAA area levels 
expected in Sabadell than in Gipuzkoa (likely comparable differences than observed 
for THMs), different water consumption patterns between the two cohorts are 
expected to greatly affect personal uptake. This is supported by previous work from 
Villanueva et al. who found that estimated personal intake of THMs via ingestion 
was lower in Sabadell than in Gipuzkoa due to different reported water use (i.e. 
ingestion of bottled vs. municipal water). Estimated individual intake of HAAs during 
pregnancy in the whole Gipuzkoa cohort has already been calculated based on area 
levels measured between 2006 and 2008 (Santa Marina et al. 2010) [in Spanish].  
Unfortunately, HAA area levels were only available for this PhD for the period 
between August 2007 and August 2011 which did not match when women in 
Gipuzkoa were pregnant, i.e. between June 2006 and August 2008. The rest of the 
data presented in the publication were not available. As a result, estimated personal 
intake of HAAs based on area levels and water consumption could not be computed 
for most of the women included in our case-control study. Instead, personal intake 
was evaluated based on the best biomarker available to assess HAA exposure, 
TCAA in urine samples. First, results are presented on spatial and temporal 
variations of HAA area levels in the public water supply for the whole population in 
Gipuzkoa between August 2007 and August 2011, in particular TCAA area-levels. 
Second, results on individual TCAA levels based on biomonitoring will be presented 
in the case control study nested in the Gipuzkoa and Sabadell cohorts. 
 
 




Figure 6-1. THMs exposure during the second trimester of pregnancy in five cohorts 
part of the INMA project. A. Area levels at the residence (µg/L) and B. estimated 
individual uptake though ingestion (µg/day) of THMs were determined. The box is 
delimited by the percentile 25 and percentile 75. The central line in the box represents the 
median and points outside the adjacent lines are outliers. The outlined cohorts in red were 
included in the TCAA biomarker study in this PhD. (Extracted from (Villanueva et al. 2011)) 
 Results 6.2
 HAA area levels in Gipuzkoa cohort 6.2.1
Total HAA levels in the water supply in the Gipuzkoa cohort between August 2007 
and December 2011 was equal to 17.5 µg/L (SD=6.6 µg/L). This value is the 
average over 11 measures over 4 years taken from 35 points representing the water 
supply network. 25 municipalities (89 616 inhabitants) in the study area were 
analysed with two points in the municipalities of over 5,000 inhabitants and a point 
in the rest of the networks. The most abundant HAAs were DCAA and TCAA with 
concentrations equal to 4.6 and 3.9 µg/L respectively.  




Table 6-1. Distribution of disinfection by-products in the Gipuzkoa cohort (in µg/L) 
Disinfection by-product  Abbreviation Mean STD 
Total THMs   16.9 7.9 
Haloacetic acids HAA     
monochloroacetic MCAA  0.5 0.2 
dichloroacetic DCAA  4.6 2.6 
trichloroacetic TCAA 3.9 2 
monobromoacetic MBAA  0.8 2.2 
dibromoacetic DBAA 1 0 
HAA5 HAA5 10.8 4.9 
bromochloroacetic BCAA 2.0 1.1 
dichlorobromoacetic BDCAA 2.7 1.4 
dibromochloroacetic DBCAA 1.8 0.6 
tribromoacetic TBAA 0.2 0.2 
Total HAAs (9) Total HAAs (9) 17.5 6.6 
Temporal variations were observed in TCAA levels although without clear seasonal 
patterns, as shown in Figure 6-2. Spatial variations were important as well across 
the 35 sampling points covering the water supply network, with levels of TCAA 
above 10µg/L in two locations, averaged over 4 years. Further information was not 
available for these two sampling points.  
 




Figure 6-2. Variations in TCAA area-levels across time and different water sources in 
the Gipuzkoa area. The green frame indicate the time period at which pregnant women 
in the Gipuzkoa cohort were recruited. 
 TCAA biomonitoring 6.2.2
 Nested case-control study – population description 6.2.2.1
TCAA concentrations was measured in a total of 396 urine samples collected from 
pregnant women in their third trimester at around 32nd week of gestation. A nested 
case-control study was designed by analysing all cases of FGR and SGA from both 
Gipuzkoa (n=41) and Sabadell (n=58) cohorts and a sub-group of controls which 
were randomly matched to cases according to the child’s gender (n=123 and 174, 
respectively in Gipuzkoa and Sabadell). No additional layers of matching were used 
to avoid the control series being less representative of the person-time experience 
of the total cohort. Baseline characteristics can be compared between cases, 
selected controls and the full control pool in Table 6-2. Mothers were mostly aged 
29-36 years old, went to secondary school and university and are primiparous or 
had one child before. A larger proportion of women smoked among the cases than 
the controls. Selected controls are overall representative of the larger control pool. A 
more detailed table with water variables and hypothesis testing results between 
each group (controls and FGR/SGA cases) is presented in Annexe. 
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Table 6-2 Baseline characteristics of the participants included in the nested case-control study amongst the Gipuzkoa and Sabadell Cohort 
 












 n % n % n % n % n % n % 
  41 100% 123 100% 363 100% 58 100% 174 100% 401 100% 
Male 21 51% 63 51% 174 48% 25 43% 75 43% 210 52% 
Female 20 49% 60 49% 189 52% 33 57% 99 57% 191 48% 
Maternal age: ≤20 0 0% 1 1% 2 1% 4 7% 1 1% 8 2% 
21-28 8 20% 23 19% 64 18% 21 36% 50 29% 116 29% 
29-36 29 71% 89 72% 268 74% 29 50% 113 65% 243 61% 
>36 4 10% 10 8% 29 8% 4 7% 10 6% 33 8% 
Maternal education: 
Without education/unfinished primary school 0 0% 1 1% 1 0% 0 0% 1 1% 1 0% 
Primary 7 17% 11 9% 38 10% 21 36% 45 26% 112 28% 
Secondary 16 39% 35 28% 122 34% 23 40% 74 43% 169 42% 
University 18 44% 76 62% 201 55% 14 24% 54 31% 117 29% 
Smoking at the beginning of pregnancy: 15 37% 24 20% 70 19% 25 43% 47 27% 111 28% 
At 12 weeks 9 22% 11 9% 34 9% 16 28% 25 14% 59 15% 
At 32 weeks 9 22% 10 8% 30 8% 16 28% 22 13% 53 13% 
Parity: nulliparous 30 73% 66 54% 192 53% 32 55% 100 57% 224 56% 
1 8 20% 54 44% 155 43% 23 40% 61 35% 174 43% 
2 2 5% 3 2% 13 4% 3 5% 11 6% 26 6% 
≥3 1 2% 0 0% 3 1% 0 0% 1 1% 2 0% 
Body mass index: Underweight      2 5% 3 2% 10 3% 4 7% 14 8% 23 6% 
Normal 32 78% 93 76% 277 76% 44 76% 108 62% 260 65% 
Overweight 7 17% 22 18% 56 15% 8 14% 37 21% 82 20% 
Obese 0 0% 5 4% 20 6% 2 3% 15 9% 36 9% 
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 Description of Urinary TCAA levels 6.2.2.2
TCAA was detected in 395 out of 396 spot urine samples using quantitative and 
highly sensitive LC-MS. Only one sample fell below the LOD which was a FGR case 
from the Sabadell cohort. Overall urinary TCAA concentrations ranged from a 
minimum 14.0 nmol/L to a maximum of 292.0 nmol/L with a median value of 39 
nmol/L in Gipuzkoa, whereas values in Sabadell were significantly higher (p-value 
[Mann-Whithney test]= 8.436e-12) from 16.0 nmol/L to a maximum of 2160.2 nmol/L 
with a median value of 61.0 nmol/L. TCAA results were corrected for concentration-
dilution of spot urine samples using specific gravity (ratio of the relative density of 
urine to water). Corrected TCAA concentrations ranged from 16.5 nmol/L to a 
maximum of 1248.0 nmol/L with a median value of 48.7 nmol/L in Gipuzkoa, 
whereas values in Sabadell were also significantly higher (p- value [Mann-Whithney 
test] = 0.0006) from 15.6 nmol/L to a maximum of 2052.0 nmol/L with a median value 
of 62.7 nmol/L. TCAA concentrations are also presented separately for cases and 
controls in each cohort in Table 6-3. Median values were compared between FGR 
cases and controls and between SGA cases and controls. Higher levels of urinary 
TCAA are observed in controls compared to SGA cases in the Gipuzkoa cohort 
(p=0.055) whereas the inverse relationship is observed in the Sabadell cohort 
although not reaching significance (p=0.1 for FGR cases). 
Water use patterns were dramatically different between the two cohorts as shown in 
Figure 6-3. Indeed, 202 out 232 women in Sabadell consumed uniquely mineral 
water with zero reported ingestion of tap water, whereas women in Gipuzkoa 
ingested between 0.25 to 1.75L/day of tap water. This variable was categorised in 
four levels for the following analysis as presented in Figure 6-3 with red bars for the 
cut off points. Table 6-4 presents variations in urinary TCAA levels according to 
water use patterns and other potential TCAA exposure sources that were available 
through frequency questionnaires at week 32 of pregnancy. Urinary TCAA median 
values varied significantly in Gipuzkoa across the water use pattern, in particular 
according the total amount of tap water ingested (both at home and outside) with p-
value=0.021 and the type of water source at home (median TCAA= 40.8 versus 
53.8 nmol/L for municipal or bottled water, p-value=0.3). In Sabadell, such a clear 
trend between urinary TCAA and tap water intake was not observed, as shown in 
Figure 6-4, instead women with no reported tap water intake had high TCAA levels 
with a median equal to 64.3 nmol/L. In Sabadell, the time spent showering in 
min/day was significantly associated with urinary TCAA as shown in Figure 6-4, with 
6 . 2  R e s u l t s  | 201 
 
 201 
almost 2-fold higher TCAA levels in women showering less than 5 minutes a day 
versus than the ones showering more than 15 minutes a day. Reported regular 
exposure to cleaning products (common domestic cleaning products in Spain, such 
as bleach, ammonia, solvents, furniture polishes, glass cleaners, air fresheners, 
multiuse cleaners, ironing sprays, floor cleaning sprays, oven sprays and carpet 
sprays) was also significantly associated with urinary TCAA in Gipuzkoa, with 
median TCAA equal to 30.9 nmol/L in exposed women (only 11) versus 49.5 nmol/L 
in non-exposed. This variable, as well as solvent use, were included in this analysis 
since chlorinated cleaning products, containing trichloroethylene or 
tetrachloroethylene (also called perchloroethylene), might be inhaled and 
metabolised to TCAA. However, the association with urinary was opposite to the 
direction expected, suggesting a spurious association.  




Table 6-3. Urinary trichloroacetic acid (TCAA) concentrations with and without specific gravity adjustments in a nested case-control study 
 















FGR p-values SGA p-values 





41 28 - 58 38 27 - 54 32 26 - 52 0.419 0.134 




51.33 31 - 80 38.18 25 - 79 34.8 23 - 79 0.091 0.055 
n  164 123   26   33       





61 39 - 88 59.5 42 - 113 59 39 - 114 0.438 0.737 




61.02 39 - 104 80.14 43 - 164 73 40 - 150 0.108 0.516 
n  232 174   42   49       
Abbreviations: FGR, Fetal growth restricted; SG, specific gravity; SGA, small for gestational age. 




Figure 6-3 Histograms of total ingestion of tap water (L/day) calculated using self-
reported water consumption from Questionnaire in Gipuzkoa (n=164) and Sabadell 
(n=232).
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Table 6-4. Distribution of TCAA according to water-related variables and other 
potential exposure sources. Non-parametric test was used to determine significant 
difference in TCAA levels according to water-variables (Kruskal-Wallis test) 






  N Median Range 
p-
value 
N Median Range 
p-
value 
Cold tap water 
intake 
≤0.25 L/day 34 41.17 17 ; 204 0.009 206 63.64 16 ; 2052 0.796 
>0.25-0.625  L/day 32 39.3 21 ; 204   6 41.73 28 ; 221   
>0.625-1.12  L/day 44 46.91 18 ; 414   5 55.2 38 ; 937   
>1.12-1.75  L/day 53 58.5 16 ; 1248   13 58.15 28 ; 1235   
Main source of 
drinking water at 
home 
Municipal 122 53.8 16 ; 1248 0.348 22 57.99 28 ; 1235 0.947 
Private well 2 36.45 28 ; 44   2 68.4 31 ; 106   
Bottled 37 40.8 17 ; 204   199 63 16 ; 2052   
Other 3 32.4 21 ; 174   8 61.67 23 ; 396   
Main source of 
drinking water 
outside home 
Municipal 33 56 16 ; 1248 0.605 8 60.54 24 ; 248 0.784 
Private well 0     ;     0     ;     
Bottled 130 46.25 17 ; 414   218 63.79 16 ; 2052   
Other 0     ;     3 54.86 28 ; 1235   
Running water at 
week 34 
never or 1-3 month 19 41.33 18 ; 204 0.044 201 63 16 ; 2052 0.564 
1 to 6 week 6 32.75 17 ; 150   0     ;   
 1-3 day 41 40.24 21 ; 204   11 45.75 24 ; 282   
4+ day 97 55.58 16 ; 1248   18 57.99 28 ; 1235   
Mineral water at 
week 34 
never or 1-3 month 49 54 21 ; 1248 0.704 14 56 28 ; 1235 0.936 
1 to 6 week 59 46.29 16 ; 195   1 58.15 58 ; 58   
1-3 day 27 45 17 ; 348   23 64.29 20 ; 937   
4+ day 28 44.07 18 ; 204   192 62.36 16 ; 2052   
Water filter use 
Yes 14 58.85 20 ; 175 0.582 12 56.51 28 ; 937 0.644 




Yes, often 43 45 17 ; 342 0.322 121 61.04 16 ; 2052 0.700 
Not often 121 50 16 ; 1248   110 65.29 16 ; 1235   
Solvent use 
Yes 13 52 18 ; 141 0.641 20 65.5 23 ; 270 0.613 




Yes 138 49.75 18 ; 1248 0.005 190 64.43 16 ; 937 0.254 
No 6 22.6 17 ; 39   13 51 23 ; 143   
Showering 
≤5 min/day 56 49.46 17 ; 204 0.835 54 45.68 16 ; 324 0.036 
>5-10 min/day 81 43.2 18 ; 1248   113 66 16 ; 2052   
>10-15 min/day 20 51.75 16 ; 204   45 61.2 16 ; 937   
>15 min/day 5 58.91 29 ; 101   15 81.82 30 ; 306   




Figure 6-4. Urinary TCAA-corrected (log) distribution in Gipuzkoa (A.) and Sabadell 
(B.) according the amount of cold tap water intake (corrected values by specific 




 percentiles. Numbers in red 
represents the sample size for each group. 
 Discussion 6.3
This chapter evaluated exposure to TCAA during pregnancy in a total of 395 women 
based on a one-time urinary TCAA biomarker. This biomarker was related to water 
use patterns in only one cohort. The associations between TCAA exposure and two 
measures of fetal growth restriction, i.e. SGA and a customised definition: FGRw, 
were investigated.  
TCAA in water supply network in the Gipuzkoa region was relatively low: 3.9µg/L 
compared to the Bradford study in UK (mean 11.3 µg/L). To our knowledge, the 
median urinary TCAA levels observed in this study (median 48.7 nmol/L≈8 μg/L in 
Gipuzkoa and 68.7 nmol/L≈11.2 μg/L in Sabadell) were higher levels than in any 
other study. Indeed, the Bradford study observed mean urinary TCAA levels of 37.1 
nmol/L≈6.1 μg/L, in a US general population sample median 3.3 μg/L (Calafat et al. 
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2003) and a Chinese sample of pregnant women 7.7 μg/L (Zhou et al. 2012). 
Comparison with urinary TCAA levels observed by Costet et al. (2012) is not 
meaningful because the analytical LOD (10 µg/L) was twenty times higher than in 
the present study. In our study, urinary TCAA levels were poorly related to tap water 
ingestion, in particular in Sabadell where women reported drinking mainly mineral 
water but presented high levels of urinary TCAA. This could be explained by other 
sources of exposures to TCAA than drinking cold tap water that were not measured 
in this study such as other drink/food consumption (i.e. coffee, tea or soups) or due 
to different accuracy levels in water usage report. However, in Sabadell showering 
seemed to be a source of exposure to HAA probably due to the occasional ingestion 
of water while cleaning. The absence of such association in Gipuzkoa might be due 
to lower levels of HAAs in the tap water. Smith et al. in the Bradford study found that 
TCAA ingestion at home, using an exposure metric incorporating both volume of tap 
water intake and tap water TCAA concentration at home, to be a good predictor 
(Smith et al. 2013). It was also revealed that employment status during pregnancy 
was important for self-reported water use since differential error may occur. 
Therefore, using a biomarker of exposure was recommended as a more reliable 
exposure indicator for employed women.  
Limitations of our study included the use of only one spot urine sample. Ideally, 
repeat urinary TCAA would have been measured to reflect exposure over a 
sufficient time period because within-subject variability may be relatively high 
compared to between subject variability according to Smith et al. (2012). However, 
in our study we demonstrated significant geographical differences between urinary 
TCAA levels in two cohorts which increased our power compared to Smith et al. 
study that had a confined geographical study location with a small range of 
exposure. We also selected a time point for TCAA exposure assessment relevant to 
critical exposure windows during pregnancy, e.g. third trimester for fetal growth.  
To our knowledge, this is the largest epidemiological cohort in a developed country 
examining DBPs using TCAA biomarker and fetal growth. The adverse association 
between adjusted urinary TCAA and FGR was only close significance in the 
Sabadell where OR was 1.12 (CI: 0.94-3.82, p-value=0.13) after correction for 
confounding factors such as smoking exposure. The positive impact of TCAA 
exposure on FGR and SGA cases in Gipuzkoa might reveal the healthy impact of 
drinking cold tap water instead of other liquids. However, this association was 
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inversed in Sabadell were HAA levels ae much higher and no cold tap water 
drinking habits are reported. Therefore, in Sabadell the urinary TCAA levels might 
be actually measuring the adverse exposure to HAAs. Future epidemiological 
analyses should be done on this dataset to explore further confounding factors and 
potentially stratified TCAA exposure. Indeed, a one-time urinary TCAA biomarker 
may not be reliable enough and exposure stratification would allow for measurement 
error, or at least account for instability within individuals. 
This current study was drawn based on a large EU project started in 2006, where 
potential human health risks associated with long-term exposure to DPBs were 
assessed (HIWATE project). Based on this project, a detailed chemical analysis of 
the occurrence of DPBs in drinking water across 11 sites and its association with in 
vitro mammalian cell toxicity provided useful insights (Jeong et al. 2012). Indeed for 
each sampling site, chronic mammalian cell cytotoxicity correlated highly with the 
numbers of DBPs identified and the levels of DBP chemical classes. Interestingly, 
the sampling site with the highest cytotoxic potency was the site of Barcelona, Spain 
(Sabadell).  
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 Concluding remarks and recommendations Chapter 7 
This chapter will put the key findings of this thesis into the context of the most recent 
research in epidemiology and maternal-fetal medicine and I will give 
recommendation for future research. I will also give an overview of the clinical and 
policy significance of this work. 
 Conclusions on PhD findings 7.1
The present study represents the largest human investigation (n >800) in which non-
targeted proton nuclear magnetic resonance spectroscopy has been used to 
understand the progression of urinary metabolic profiles during pregnancy in two 
independent Spanish populations.  
Reproducibility of NMR-based metabolic profiling was confirmed and the proportion 
of analytical error was quantified for each metabolite peak subsequently used in the 
epidemiological analysis. Intra and inter-individual variations in maternal urine 
profiles were then identified based on the analysis of QC samples and repeat 
samples at week 12 and 34th of gestation. A large proportion of the metabolites 
measured were affected by the time of gestation but steroid by-products of 
progesterone and oestrogens were particularly increased between week 12 and 34 
(by three-fold). Surprisingly, our study was the first to confirm the identity of these 
metabolites via 1H NMR even if there were previously identified as important urinary 
markers during pregnancy (Diaz, Barros, Goodfellow, Duarte, Carreira, et al. 2013; 
Sachse et al. 2012; Pinto et al. 2014).  Metabolites identified in maternal urine are 
representative of complex metabolic interactions between the mother, placenta and 
fetus as presented by the yellow arrow going through Figure 7-1. This study enabled 
the semi-quantification of major urinary metabolites, including unique markers 
during pregnancy, for use in the next stage of the analysis with fetal growth 
outcomes.  
Metabolic signatures of fetal growth were identified in the third trimester urine 
samples of pregnant mothers, validated in two independent cohorts. These 
signatures included steroid hormone breakdown products that were newly 
characterised in our study and branched-amino acids (BCAAs), alanine, choline and 
glycine. Our results indicate that during the third trimester of pregnancy, mothers 
would tend to rely more heavily on BCAA catabolism and other substrates for 
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gluconeogenesis to ensure the availability of glucose in maternal blood for fetal 
demand, as summarised in Figure 7-1. Interestingly, these metabolic adaptations 
were found previously in metabolic disorders such as type 2 diabetes in non-
pregnant population (Adams 2011). Overall metabolic phenotypes at week 12 could 
not predict fetal weight at week 34 or at birth, but only at weeks 12 and 20 and with 
little consistency across the two populations. This suggests that early fetal growth 
patterns may be affected independently to size at birth and implies that early fetal 
growth is impaired while catch-up growth might occur later during gestation. 
Understanding of the impact of early fetal growth impairment or acceleration on 
childhood outcomes requires further investigations. Unique adverse metabolic 
signatures at week 12 of fetal growth were found in Sabadell related to 
mitochondrial oxidative stress, systemic inflammation and renal function.  
These findings potentially captured the metabolic signatures of a myriad of 
physiological (both maternal and fetal), environmental, and other lifestyle 
characteristics associated with fetal growth, as presented in top part of Figure 7-1. 
To facilitate the interpretation of human pregnancy metabolomics data, clinical and 
lifestyle parameters were utilised. Our samples were coming from a large-scale 
cohort study with rich epidemiological data available. This design allowed not only 
identifying the differences across birth weight distribution but also studying different 
population groups such as women presenting vitamin D deficiency. Results indicate 
the potential importance of vitamin D and iodine intake on metabolic profiles and 
fetal growth patterns. In addition, unique first trimester metabolic associations with 
fetal growth in Sabadell might be explained by underlying chronic inflammation 
(CRP marker), smoking and lack of exercise in this population. However, we have 
not been able to identify major sources of inter-individual variation in urinary profiles 
despite using an array of demographic, clinical and lifestyle parameters measured 
through the INMA study. The biological interpretation of metabolic changes in 
human biofluids remains challenging.  Urinary metabolic profiles provide a time-
averaged view of the global metabolism including end-products of endogenous and 
exogenous metabolites. Humans are considered as super-organisms where 
biological processes take place in a network of tissues, organs and symbiotic 
microorganisms (Goodacre 2007; Nicholson et al. 2005). Observed changes in 
systemic metabolites are often difficult to assign to a particular organ, microbial 
colony or specific food intake. During pregnancy, this complexity is multiplied by the 
presence of a new metabolically active organ, the placenta, and a foreign human 
body, the fetus. Therefore, maternal urine composition during gestation is the result 
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of complex metabolic interactions between the mother, placenta and fetus acting 
together to reach a normal fetal growth under limited nutrient availability and 
maternal uterine capacity.  
Finally, a sensitive measure of environmental exposure to HAA toxins for future use 
in epidemiological analysis of birth and child outcomes was presented. This included 
a targeted analysis of internal TCAA levels in each pregnant woman’s urine using 
quantitative and highly sensitive LC-MS. Unfortunately, data on area level of HAA 
concentrations in the public water supply could not be combined with individual 
water use (from questionnaire data) and urinary biomarker levels, to create a 
comprehensive HAA exposure metric. 
This cohort study gives a realistic representation of the population at large in 
comparison with matched case-control design as observed in metabonomics studies 
in prenatal care, which aims for population homogeneity. On the other hand, 
biological variability and lack of control over time of sampling might have hindered 
specific physiological signatures. In the case of urine samples, specific issues can 
arise from variation in drug intake (drug metabolites), urine ionic strength and 
dilution which can amplify the noise level in NMR spectra (peak shifting). This was 
partially addressed in our study by primary working on selected peak integrals 
instead of full resolution spectra. Although urine collection remains a simple and 
non-invasive methods which is attractive for investigation prognostic biomarkers, in 
particular in mother-child cohort settings, its interpretation is relatively difficult 
compared to blood samples. 




Figure 7-1 A summary of the proposed underlying mechanisms of fetal growth 
determinants based on metabolic profiling signatures observed in this PhD 
 Future work: extension of this PhD 7.2
Based on these contributions there is room to the extent the current findings as 
follows. First, a wider coverage of the pregnant metabolome through applications of 
targeted LC-MS methods would allow further investigations of the mitochondrial 
oxidation functions and of the steroid milieu. Second, further exploitation of the 
already acquired NMR based metabolic profiling data for prediction of post-natal 
outcomes would add value to the research on fetal origins of metabolic diseases. 
Third, further understanding of the impact of environmental exposures on fetal 
growth outcomes and maternal metabolic profile could be provided by conducting an 
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epidemiological analysis with HAA exposure and potential other exposure 
biomarkers. 
NMR-based metabolic profiles acquired in this PhD could be complemented with 
untargeted MS based platforms to enhance overall sensitivity as well as 
quantification of a wide class of steroid hormone by-products. A substantial progress 
was made in the metabolomics of pregnancy steroids using LC-MS (Hill et al. 2014). 
This approach may be effective in predicting multifactorial disorders with a polygenic 
background and in the diagnostics of fetal and maternal pathologies. A unique 
steroid milieu in pregnancy was recently shown to protect the fetal brain from 
oxidation stress, neuro-excitatory oestrogens and others exogenous toxicants (i.e. 
THC, (Vallée et al. 2014)). Despite extensive research on the steroid hormone role 
in maintaining pregnancy, the role of particular isoforms of oestrogens and 
progesterone metabolites and the balance between free steroids and their 
conjugates, on fetal growth remains unanswered. Indeed balance between active 
and inactive forms of steroids may be crucial for the regulation of their biological 
activity and consequently for sustaining the pregnancy and fetal programming (Hill 
et al. 2014). A recent study published a UPLC-MS method to profile unconjugated 
and conjugated progesterone metabolites in urine of pregnant women (Jäntti et al. 
2013). This method uses a triple quadrupole instrument with selected reaction 
monitoring. The chromatography method includes a 30 minutes LC gradient using 
3mL of purified urine sample. This method could be developed further to be 
applicable to a large scale study using a smaller urine sample size (~1mL) and a 
shorter LC gradient. Steroid hormone profiles during pregnancy could then be 
correlated to fetal growth outcomes and also to data collected from children such as 
neurodevelopmental outcomes.  
NMR based metabolic signatures of fetal growth contribute to a better 
understanding of the impact of maternal metabolic environment on fetal growth and 
in future studies could also be used to understand the origins of post-natal outcome 
development. Indeed, analysing global metabolomics data for all women in each 
cohort, the study design enabled multiple outcomes to be modelled, such as for fetal 
growth as continuous variables, in terms of head size and body weight. This study 
design will also allow future epidemiological analysis to be carried out in relation to 
early-life outcomes in children, such as neurodevelopment outcomes. Metabolic 
profiling of pre-natal samples can potentially enhance understanding of obesity-
related developmental origins of health and disease (DOHaD) (Hivert et al. 2015). 
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Indeed, metabonomics may capture exposures related to maternal diet, maternal 
adiposity and hyperglycemia or adverse environmental factors (i.e. smoking) that 
are notoriously difficult to quantify. These metabolic signatures of abnormal fetal 
growth can help to further refine birth phenotypes associated with excess adiposity 
and related metabolic disturbances over the life course. In a previous study, 
association between maternal obesity before pregnancy and offspring metabolic 
signatures of obesity and adiposity in children aged 6-10 years was recently 
demonstrated, including increased levels of circulatory BCAAs in obese children 
compared to lean controls (Perng et al. 2014). Birth weight and other anthropometric 
measurements are often used in life-course epidemiology to assess cardio-
metabolic risks in adult life, however, these measurements could be completed with 
metabolic signatures able to differentiate ‘metabolically healthy but obese’ persons 
from persons at risk. For instance, abnormal BCAA levels during pregnancy could 
be used to predict future obesity outcomes in children in the INMA cohort which are 
followed up until adolescence. 
HAA exposure in utero has not been thoroughly investigated, due to the lack of 
routinely available information on HAA levels in public drinking water supplies (only 
THM levels are routinely collected by water companies). Therefore, an 
epidemiological study incorporating HAA exposure assessment using a valid 
biomarker of HAA in a large population of pregnant women as was presented in this 
PhD would be highly valuable. In addition, metabolic profiling has a great potential 
to serve environmental exposure sciences and pregnancy research as a tool to 
identify intermediate biomarkers linking exposure and outcomes. This original 
concept was defined previously as the ‘meet-in-the-middle’ approach where 
preclinical biomarkers correlated to specific exposures in prospective studies can be 
elevated in cases and support the causal association between exposure and 
outcomes (Chadeau-Hyam et al. 2011). A range of environmental exposures are 
available in INMA Sabadell and some are also available in INMA Gipuzkoa.  
I would also propose examining BPA/Phthalate-associations with urinary metabolic 
profiles and then exploring other exposures available in both cohorts presented in 
this PhD such as organochlorines, mercury and air pollutants. Indeed, endocrine 
disrupting chemicals (EDCs) such as Bisphenol A (BPA) and phthalates are also 
considered metabolism disruptors (Casals-Casas 2011), and as such are expected 
to have a detectable influence on the metabolome. A handful of studies have 
applied metabolomics to study the effects of low dose exposure (ie equivalent to 
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human exposure) in animal models. Some have found striking differences in the 
offspring of exposed mothers (Sumner 2009, Cabaton 2013), while other which 
specifically looked at the urinary metabolome of exposed mice themselves have 
found more modest changes (Zeng 2013, Chen 2014)  which were supported by 
similar changes observed at higher doses or additional measurement of enzyme 
levels. Changes detected among exposed INMA Sabadell pregnant women would 
support the role of these chemicals in influencing health. We may only expect some 
subtle changes associated with phthalate / BPA exposure detectable by urinary 
NMR metabolomics in pregnant women. Similarity to changes found in the 
aforementioned animal studies would however support any detected associations. 
 Recommendation for future research  7.3
Beyond the scope of this PhD, recommendations are given for future research in 
molecular epidemiology (based on metabolic profiling) in any population, in 
pregnancy-birth cohort settings, and to further understanding of obstetrics 
outcomes. 
 Methodological recommendations for metabonomics in 7.3.1
epidemiological settings 
Recent developments in NMR spectroscopic-based profiling demonstrated 
significant improvements over the protocols proposed by Beckonert et al. which 
were presented in this thesis (Beckonert et al. 2007). These developments include 
the use of cooling system for sample handling before acquisition, avoiding 
significant temperature variations during data acquisitions and robotic liquid handler 
for sample preparation (e.g. a Bruker Sample Track system and a Liquid Handler 
215 preparation robot or similar). The current protocol proposed by Bruker and the 
MRC-NIHR National Phenome Centre, demonstrated that the separation in quality 
control samples should be less than 1% of the variance across a healthy population 
(Dona et al. 2014). Maximising automatic procedures in sample preparation, sample 
acquisition set-up (locking, tuning, matching, and shimming, pulse calibration, and 
optimized water pre-saturation power for individual samples), but also for the 
processing (phasing, baseline correction, and calibration) was proven to lead to 
minimal variation in the chemical shift of each metabolite resonance. The new 
equipment also achieve a higher resolution than for previous spectra acquired with a 
similar 14.1 T magnet for 1 H 600 MHz. due to much better shimming and a better 
signal-to-noise thanks to improved electronics. Future NMR-based metabonomics 
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studies should consider using more standardised protocols as proposed above, in 
order to archive higher reproducibility and resolution. In addition, using quality 
controls, as conducted in this PhD for the analysis of Sabadell samples, is crucial for 
epidemiological applications where measurement error should be quantified and 
included in interpretation of effect size.  
 Recommendation for future applications of metabolic profiling in large 7.3.2
mother-child cohorts 
Metabonomics studies applied previously in a prenatal context used a single time 
point to seek associations with birth outcomes. Multiple time point collections 
throughout pregnancy were lacking to understand the progression of abnormal fetal 
growth. This PhD used first and third trimester samples from pregnant women, 
which permitted to identify different physiological mechanisms occurring at different 
time windows. However, more time points should be included in future studies with 
for instance collections every month or at key points during fetal developments. 
Longitudinal and experimental studies are warranted to disentangle temporality and 
causality of the relationships between abnormal fetal growth and circulating 
metabolite levels. This can be partially done by analysing samples collected at 
multiple time points of pregnancy and estimating pre-natal and post-natal growth at 
multiple time points. Dramatic differences between cohorts at week 12 and 34 
observed in this study emphasise the importance to interpret maternal biofluid 
metabolic markers separately at early and late stages of gestation. In addition, for 
future metabonomics studies in pregnancy we would recommend collection of 
samples around the same gestational week for all the women. Indeed, simply 
correcting for the gestational age of the fetus in a regression model will not be 
sufficient for meaningful biological interpretation. 
 Recommendations for furthering understanding of maternal-placental-7.3.3
fetal pathways and subsequent obstetrics outcomes 
Further understanding of the biological mechanisms underlying fetal growth 
variations across individuals could be provided by the integration of other -omic 
platforms, complimentary to metabolomics. One area of potential great importance 
is the role of the placental microbiome in fetal growth outcomes. Traditionally the 
placenta and amniotic fluid have been considered sterile in normal term 
pregnancies. Indeed, intra-uterine infection and transduction of the microbes into the 
amniotic cavity were believed to occur only in pregnancy with high risk of preterm 
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delivery and was identified as a main contributor to premature rupture of 
membranes (PROM) condition. It has been only recently demonstrated that the 
fetus in healthy women is indeed exposed to bacteria via the placenta and this fact 
is still the subject of controversy (Aagaard et al. 2014). The placental microbiome is 
likely providing important metabolic and immune contributions to the growing fetus. 
However, the overlap between the metabolic functions of the placenta and the 
developing fetus are largely unknown. Future studies could include analyses of 
placental tissues which are often under-used in pregnancy research even if this 
tissue is often collected in large mother-child cohorts to provide new insights. 
 Clinical and policy significance of this work 7.4
Findings presented in this thesis can be translated to improve clinical screening for 
high risk pregnancies and create new interventions and strategies for personalised 
programmes for pregnant women. 
The first scan visit at 11–14-week is the most pertinent clinical screening for high-
risk pregnancies that would benefit from personalised management. The addition of 
metabolic markers to clinical assessment could provide further information on the 
physiological status of the pregnant mothers in particular in case of failure of 
placental function due to oxidative stress. Up to now no single biomarker were found 
predictive and specific enough of abnormal fetal growth (IUGR or macrosomia) for 
clinical use, including in this PhD. Clinical assessment may benefit from a 
combination of markers and it should in particular include Doppler ultrasonography. 
Routine screening process uses Doppler indices to assess uterine artery blood flow 
which is sensitive to abnormal placental formation. Its clinical utility was 
demonstrated with a 29% reduction in perinatal deaths and significantly fewer labour 
inductions and caesarean deliveries in high-risk pregnancies using Doppler in 
comparison with no Doppler (Alfirevic et al. 2013). In addition algorithms could be 
computed taking into account previous pregnancy history, ethnicity, baseline 
lifestyle factors and one could imagine even environmental exposures. These 
algorithms should also be flexible to include any local specificity in case there is 
wide spread vitamin D deficiency for instance or a lack/excess of iodine 
supplementation.  
Creation of intervention in high risk pregnancies is an important area currently being 
developed, as well as personalised programmes for pregnant mothers. Simple 
supplementations during pregnancy received considerable interest beyond current 
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obstetric practice to treat high-risk pregnancies. In the absence of available 
treatment, clinically induced preterm delivery is an option to save extreme cases of 
FGR or macrosomia. However, if abnormal growth is identified early enough, or 
high-risk identified, there should be treatments available avoiding preterm delivery 
which has considerable long term adverse effects on the offspring. Several 
metabolic pathways identified in this PhD as exerting control over fetal growth could 
be targeted. Although causality could not be demonstrated here, modifications of 
some of these metabolic pathways could be tested in clinical trials to evaluate their 
safety and efﬁcacy. In fact most of the suggested modifiable pathways have already 
been the subject of animal studies. A few animal models are available and were 
sensitive to a number of therapies such as the rat reduction of utero-placental 
perfusion pressure (RUPP) model. FGR is in this animal model is induced by 
clipping the maternal aorta and ovarian arteries, resulting in maternal hypertension 
and oxidative stress (Spencer et al. 2014). These therapies showed in particular 
potential to treat poor placentation, to improve fetal growth, and to prevent adverse 
neonatal outcomes. Interestingly, melatonin, carnitine and creatine are currently 
tested for their anti-oxidant properties (Keller et al. 2009; Dickinson et al. 2014). 
Clinical trials are planned or in progress to evaluate their safety and efﬁcacy 
(Spencer et al. 2014). There are also interventions, potentially identified as future 
targets in this PhD that did not show consistent evidence such as dietary 
modification, progesterone or calcium to prevent SGA. These interventions were 
actually not recommended in a recent guideline by the Royal College of 
Obstetricians and Gynaecologists even if for instance balanced energy/protein 
supplementation has been associated with a modest increase in mean birth weight 
and a reduction in the incidence of SGA neonates (RR 0.68, 95% CI 0.56–0.84) 
(RCOG 2014; Ota et al. 2015). Due to the potent growth promoting effects of 
branched amino acids in the third trimester, maternal protein supplementation in 
pregnancies at risk of FGR to improve fetal growth remains an attractive option. For 
example dietary isoleucine was found to significantly reduce the degree of growth 
retardation normally observed in fetuses from pregnant rats fed a phenylketonuria-
inducing diet.. However, adverse fetal outcomes observed in several clinical studies 
highlight the need to fully understand the mechanisms by which additional amino 
acids in the maternal diet are transferred to the fetus and how the fetus handles the 
protein load (Brown et al. 2011). 
Interventions to modify environment/lifestyle habits with known negative impact on 
fetal growth outcomes may also be effective when applicable. Using cognitive 
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behavioural therapy and incentives as the main intervention strategies for smoking 
cessation before pregnancy demonstrated consistent improvements in birthweight 
(Lumley et al. 2009). Similar strategies could be imagined to modify maternal 
behaviour based on screening results. Indeed, if clinical screenings are undertaken 
in the first trimester of pregnancy and include relevant information on the maternal 
environment, strategies could be tailored for each woman based on their 
environmental settings and their specific risk factors. However, information overload 
issues should be considered before recommending more incentives to pregnant 
women. Identifying practices that are most effective to reduce exposures and 
biomonitoring to motivate individuals to reduce chemicals exposure through 
behavioural changes might be more effective. I would suspect that actually taking a 
urine sample and giving women a tailored advice may be more useful than giving 
wide-reaching information overload. However, some studies in smokers for example 
showed that genotyping for cancer risk did not actually trigger change in people 
behaviour. Explaining to the pregnant mothers with simple words that they are their 
baby’s first ‘environment’, and for example that chemicals such as caffeine are 
passed from breast milk, might be well received. 
Results on pre-natal modifiable factors that affect size at birth are pertinent to the 
fetal origin hypothesis and may have far-reaching public health implications. Indeed, 
intervening during gestation means that primary prevention of coronary heart 
disease and type-2-diabetes may ultimately depend on changing maternal 
metabolism through dietary supplementations and daily habits to mediate 
environmental exposures. 
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 Annexes Chapter 8 
 Biochemical methods: theory 8.1
 Nuclear magnetic resonance (NMR) spectroscopy 8.1.1
The physical basis of NMR spectroscopy and its instrumentation will be briefly 
described in this section, however more detailed information can be found 
elsewhere (Keeler 2011). NMR spectroscopy observes atomic nuclei of the 
molecular framework itself, unlike UV spectroscopy which is limited to electrons part 
of conjugated systems. Concomitantly, NMR can unveil the location on the 
molecular framework of most of the common functional chemical groups. 
Basic principles of NMR 
Most nuclei, including 1H, 13C and 19F, possess an intrinsic angular momentum or 
what is also defined as a nuclear spin (I) in quantum physics. This is an intrinsic 
property of molecules. Since a nucleus is a charged particle, its motion creates an 
associated magnetic moment (). The axis of the spin precesses around the 
magnetic field direction, comparable to a spinning top as it precesses in the earth’s 
gravitational field as represented in Figure 8-2. 
Figure 8-1. Schematisation of a nucleus precessing 
with an associated magnetic moment () 
represented as a vector 
 
 
Each isotope and more precisely, each nuclide 
(determined number of neutrons) has a specific constant representing the strength 
of the nuclear magnet, the magnetogyric ratio. Under quantum restrictions, the 
magnetic moment and the angular momentum are vector quantities and can take 
only quantified values with associated energy states. Like bar magnets and 
compass needles, a nucleus placed in an external static magnetic field, B0, tends to 
align its magnetic moment with that field. Because 1H and 13C have a spin number 
of ½ they can take only two orientations (2 I+1=2) which correspond to two energy 
states α and β, with α parallel to the field and β anti-parallel as displayed in Figure 
8-2Error! Reference source not found.. The two states are represented in 
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classical mechanics as vectors spinning around the directional axis of the magnetic 
field B0.  
 
Figure 8-2. Spin physics of NMR spectroscopy 
In the absence of a static magnetic field the distribution of magnetic 
moments of nuclei is isotropic, with all orientations possible, as a bar magnet 
will rotate to minimise the energy. When a static external magnetic field is 
applied, B0, the nuclei’s spins align with the field and precess around the Bo 
axis, rather than at random angles. 
 
The rate of precession, called the Larmor frequency, depends on the intensity of B0 
and the magnetogyric ratio of the nuclide. When a population of protons are placed 
in an external magnetic field, the collection of nuclear spins will be distributed with a 
minute excess in the lower energy state α as defined by the Boltzmann distribution 
(of the order of 1 in 105 or 106). The excess of nuclear spin parallel to B0 results in a 
magnetisation vector M0.  




Figure 8-3 Schematisation of the 
energy states distribution (B) of 
protons in an external magnetic field 
described by the Boltzman 
distribution (B0 : magnetic field, h : 
Planck constant, ν : resonance 
frequency or Larmor frequency) 
 
 
Transition between the different energy levels is possible but can only be promoted 
by applying an electromagnetic wave to the nuclei, ν, with an appropriate frequency, 
as described in Figure 8-3Error! Reference source not found.. This phenomenon 
is known as resonance, when the frequency (radiofrequency) of the externally 
applied electromagnetic field matches the Larmor frequency of the nucleus of 
interest. During the NMR experiment, the nuclei are excited, energy is absorbed and 
the population of nuclei in α and β states becomes more equal. 
Saturation can occur if the number of nuclei in the two energy states becomes more 
exactly equal. When the radio wave stops, the nuclei tend to return to their initial 
equilibrium state: this process is called relaxation.  
NMR spectrometer and obtaining an NMR spectrum 
During every NMR experiment, a 90 degree pulse is emitted (B1), perpendicular to 
the applied field B0 tipping the net magnetisation of the sample through a 90° angle. 
The protons are simultaneously excited, but each has a different frequency of 
precession depending on its chemical environment. After the pulse, all the excited 
nuclei lose the absorbed energy over a time scale of the order of seconds and relax 
around the z-axis. The different electromagnetic radiations emitted are recorded to 
form the free-induction decay (FID) signal. Fourier transformation (FT) is a 
mathematical operation which allows the extraction of the individual frequencies of 
each proton from the FID to give an NMR spectrum.  
Spectrometers subject the sample to a single pulse that covers a broad range of 
frequencies of nuclei of interest. The spectrometer magnetic field strength is often 
converted to the Larmor frequency of the nucleus of interest – for example for 1H, 14 
Tesla spectrometer corresponds to 600 Megahertz (MHz) or 150 MHz for 13C. MHz 
is referring to the Larmor frequency of a specific nucleus precession in the magnetic 
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field. To achieve extreme magnetic field strength of several hundred MHz and great 
field homogeneity, superconducting magnets are employed. The higher the 
magnetic field, B0, the greater the energy difference between spin states of nuclei 
and therefore the greater the sensitivity of the NMR. With higher magnetic field 
strength spectrometers the spectral resolution (signal separation) is also improved. 
In metabonomics, especially applied to complex biofluids such as urine, these 
effects are really important to minimise the sample acquisition time and measure 
metabolites in smaller concentrations. The sample, in a glass NMR tube, is placed 
in the probe where a radio-frequency (RF) coil produces an oscillating magnetic field 
and a RF detector coil records the FID. The recorded signal is transmitted to a 
computer after going through an amplifier and an analogue-to-digital converter 
(ADC).  
In metabonomics, 1H and 13C NMR play the most important role. 1H Hydrogen is 
primarily used in NMR of organic molecules because of its spin I=1/2, extensive 
occurrence, high natural abundance (99.98%) and therefore high sensitivity. 13C 
NMR spectra inform directly on the molecular framework but are less sensitive 
because of the low 13C nucleus natural abundance of 1.1%. 
NMR parameters 
The slight variations in the resonance frequency of identical nuclei in different 
environments give rise to chemical shift, δ. To allow the comparison of resonance 
frequencies from spectrometers with different magnetic field strengths, a scale 
independent of the field is used (ppm). It is obtained by dividing the resonance 
frequency in Hz by the spectrometer frequency in MHz The chemical shift is thus 
expressed in parts per million (ppm). The chemical shift can range within 15 ppm in 
the case of the proton and more than 200 ppm for 13C nuclei. Each nucleus 
experiences a different chemical environment and therefore has a different 
exposure to the native B0 field. The atom’s circulating electrons generate an induced 
field themselves, which shield the nucleus from B0 and implies that they resonate at 
different frequencies. The type of bonds and neighbouring chemical groups of 
different electronegativity will influence the electron movements and therefore the 
chemical shift. If there is an electronegative element substituted on the same carbon 
as the proton of interest for example, its chemical shift will be higher, i.e. deshielded.  
If protons are close enough on the molecule, two or three bonds away, their energy 
states, α or β, can influence the electronic environment of the neighbouring protons. 
This phenomenon is called spin-spin coupling and results in the splitting of NMR 
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signals. The shape of the signal (singlet, doublet, triplet or multiplet), called 
multiplicity, gives an indication of the number of neighbouring protons and of the 
stereochemistry. The energy of this interaction is given by the spin-spin coupling 
constant J (in Hz), that can be measured as a frequency difference between two 
peaks in a multiplet. 
Absolute values of the intensities of NMR signals are dependent on a complex set of 
parameters such as the spectrometer, sample and experimental conditions. 
However, semi-quantitative measure of the compounds present in a sample can be 
obtained by calculating the peak integral which is proportional to the total number 
of nuclei. Relative intensities can be used to determine molar ratio of components in 
the mixture using for example the creatinine signal in urine samples (based on 
external creatinine quantification). Using an internal standard of known 
concentration with correction for the number of protons for a given resonance, 
enables calculation of the absolute concentration of any other molecule in the 
sample. However, for accurate quantification several parameters require careful 
consideration in particular the spectra must be acquired under fully relaxed 
conditions (Griffiths 1998). 
NMR experiment acquisition 
Before starting an NMR experiment, the sample needs to be solubilised in a solvent, 
usually deuterated (2H) water. The deuterium is essential to provide a separate 
nucleus frequency reference to primary measured 1H or 13C which is known as the 
‘lock’ and to avoid a drift of the magnetic field over time. The frequency of the 
deuterium resonance is monitored continuously against a fixed frequency produced 
by the instrument. Tiny adjustments are made to the field in order to correct 
frequency drifts and temporary magnetic field inhomogeneities. In addition, 
deuterated solvents are used in 1H NMR because otherwise the abundance of 
protons in water would preclude the detection of the metabolite’s proton signals.  
The probe needs to be tuned, which consists of adjusting the resonance frequency 
of the RF coil to the frequency of the nuclei of interest, similar to tuning a radio to a 
FM station. Matching corresponds to adjusting the impedance of the resonant circuit 
until it corresponds with the impedance of the transmission line connected to it.  
Application of NMR to metabonomics requires the use of specific pulse sequences, 
that are relatively simple compared to other application such as in protein structure 
elucidation. One main problem faced in 1H NMR of aqueous biological samples is 
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the overabundance of background water protons, with a concentration up to 110mM 
which prevent the detection of metabolites at µM or lower concentrations. This 
signal can be selectively suppressed by applying a pre saturation water suppression 
sequence. Prior to the acquisition a RF irradiates all the H2O protons. The RF 
frequency, O1, is adjusted in order to supress the water peak efficiently and not to 
affect the neighbouring protons in the region 4.5-6 ppm. 
The length of the 90° pulse, P1, for a fixed pulse power is determined in order to 
ensure that the majority of the nuclei are flipped by 90° in the XY plane. Adjusting 
P1 improves the signal amplitude. In practice, P1 is adjusted step-by-step until all 
the signals disappear after a 360° pulse is applied, i.e. when the net magnetisation 
vector is perpendicular to the receiver coil. This value is then divided by 4.  
The pulse sequence can then be set up entering the values of P1 and O1. This 
pulse sequence and the FID acquisition will be repeated a number of times, defined 
by the number of scans (ns), and the individual spectra averaged, improving the 
signal-to-noise ratio.  
The last steps of shimming and adjusting the receiver gain (rg) are applied to each 
sample prior to the acquisition. Shimming aims to homogenise the magnetic field 
around a specific sample to improve the peak line width and therefore the 
resolution. Adjusting the rg will determine the degree of amplification of the gain and 
therefore the dynamic range of the ADC. As the rg is increased the signal is 
amplified and the ADC digitises the FID at more levels. However, when the rg is too 
high the thermal noise created by the electronics of the spectrometer is also 
amplified creating a spectrum with a distorted baseline and a low signal-to-noise 
ratio. The rg should be adapted to the concentration of the sample and therefore 
adjusted in case of high sample variation in dilution (i.e. for human urine samples). 
Principle of spectral processing  
To reduce experimental artefacts the following steps were taken to obtain an 
analysable spectrum from the FID. Firstly, the FID was multiplied by a window 
function, the exponential decay function, in order to reduce the noise in the 
spectrum. This was considered as a smoothing function which led to moderate line 
broadening but improved the peak shape. A line-broadening function of 0.3 Hz was 
applied to all spectra prior to Fourier transformation (FT). After the Fourier 
transformation the spectra had to be phased. Indeed, the bulk of the magnetisation 
detected on the y axis after being flipped in the x-y plane was in practice not 
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perfectly aligned. In the time domain, the magnetic oscillations following a cosine 
wave were subsequently not in phase and needed to be corrected to produce an 
interpretable spectrum. A second artefact due to imperfections and nonlinearities of 
the electronic detection process created a distorted baseline. This could be adjusted 
by subtracting a fitted polynomial or spline function to the raw spectra. 
Two dimensional NMR spectroscopy 
Two dimensional (2D) NMR spectroscopy is a powerful technique to resolve de 
novo structure of metabolites; revealing the connectivity between signals and 
increasing the signal dispersion. However, until recently 2D NMR had limited 
applications in sample profiling due to long experiment time (hours to days). In 2D 
NMR spectra both axes represent the frequency via the chemical shift and a third 
dimension corresponds to the peak amplitude (represented as line contours). 2D 
NMR spectra are in fact constituted of a series of 1D spectra acquired under 
systematic incrementation of an experimental parameter, the inter-pulse delay 
between two pulses (P1). A series of pulses are applied, characterised as a pulse 
sequence, which allow the nuclei from different spin systems to transfer their 
magnetisation from one to another. Depending on the pulse sequence, the 
magnetisation can spread out through an increasing number of bonds. Two types of 
peaks can be observed on a 2D spectra: diagonal peaks which correspond to the 
peaks in a 1D-NMR experiment (same x- and y-coordinates), while the cross peaks 
indicate couplings between pairs of nuclei. 2D experiments can measure coupling 
between the same type of nuclei, usually 1H-1H, called homo-nuclear, or different 
types, usually 1H-13C, termed hetero-nuclear.  
 Mass spectrometry (MS) coupled to liquid chromatography (LC-MS) 8.1.2
The basic principles of MS detection and separation techniques will be described in 
this section.  
 Prior separation techniques 8.1.2.1
Analyte separation prior to MS analysis is usually required when the sample is a 
complex mixture. Method separation such as gas and liquid chromatography and 
capillary electrophoresis are used for metabonomics. Generally, different classes of 
compound will require different separation techniques. Gas chromatography (GC) is 
a powerful technique to resolve the metabolome however it requires extensive prior 
sample treatment to convert polar compounds to volatile substances. Liquid 
chromatography (LC), on the other hand, using high or ultra-high performance 
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(HPLC or UPLC) columns provides high-throughput performance with limited 
sample preparation in particular when the analytes are already in an aqueous matrix 
(such as urine). 
 
In this thesis, in order to help metabolite identification, urinary metabolite separation 
was performed by gradient reversed phase chromatography (RP) which enabled 
profiling of non-polar and weakly polar metabolites. The compounds were carried 
primarily in a polar mobile phase with a gradient that increases in non-polar 
composition throughout the run, and the use of a non-polar stationary phase. A 
pump allowed the movement of the mobile phase through the column, which 
contained hydrophobic silica gel beads coated with alkanes like octadecane (C18). 
In UPLC, the silica particles were under 2 µm in size, which allows for better 
resolution, efficiency and speed for the analysis compared to HPLC (Plumb et al. 
2004). The analytes were separated according to their physico-chemical properties, 
e.g. hydrophobicity or proton dissociation constant (pka). Depending on the analyte 
affinity for the stationary phase, based on hydrophobic interactions in the case of RP 
chromatography, it was more or less retained. Because the retention time varied 
between the substances it could be used as a measure to help the identification. In 
a reverse gradient, the polar compounds such as organic acids are eluted first, and 
the non-polar compounds such as phospholipids have a higher retention time. 
 Principles of mass spectrometry 8.1.2.2
MS detects and identifies compounds based on their mass to charge ratio (m/z). To 
quantify this ratio, the molecules are ionised and transported through a vacuum 
using a combination of magnetic or electric fields. Each ion proceeds at a different 
speed and takes a different course depending on its m/z. Thus, the ions are 
separated and detected in proportion to their number, sometimes after being 
fragmented. The final result can be displayed as a chromatogram obtained from ion 
energy converted into an electrical signal by the detector (Siuzdak 2006). The term 
‘spectrometry’ in MS shouldn’t be confused with techniques employing matter and 
electromagnetic waves interaction. This term was coined due to the resemblance of 
MS spectrum with optic spectrographs (the spectrum of mass values used to be 
recorded on a photographic plate). 
The mass spectrometer can be divided in four components:  
1. the inlet, where the sample is introduced, 
2. the ionisation source, where the ions are produced in a gas phase 
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3. the analyser(s), which can separate ions according to their mass and 
sometimes trigger ion fragmentation by collision  
4. the detector.  
When the MS is coupled to a LC system which separates the analytes prior to the 
mass analysis, the inlet is directly connected to the liquid chromatography system, 
introducing small quantities of the sample without disturbing the internal vacuum.  
The first challenge in LC-MS coupling is the need to produce gas-phase ions for the 
mass analyser. Electrospray ionisation (ESI), used in this thesis, solved this problem 
by producing ions free of solvent. ESI technique is considered a ‘soft-ionisation’ 
technique, together with MALDI, since it avoids molecule fragmentation by collision 
(Fenn et al. 1989). It is particularly well adapted to metabonomics because it allows 
the detection of small amount of biological metabolites. Sample evaporation, also 
termed desolvation, is obtained by applying a strong electric field to a narrow 
capillary tube where the liquid is transported. The electric field produces charges at 
the surface of the liquid which creates an aerosol of highly charged droplets. A gas 
flow perpendicular to the ion projection reduces the spray dispersion and leads the 
sample to the mass analyser. An electrochemical process, with oxidation/reduction 
reactions taking place at the tip of the capillary tube, also allows the ions to proceed. 
Acids added to the sample can therefore (e.g. acetic acid) improve the conductivity 
and provide protons during the ionisation process. Different types of ions can be 
produced, such as quasi-molecular ions with a hydrogen cation addition, denoted 
[M+H]+, or another cation such as sodium ion, [M + Na]+, or with the removal of a 
hydrogen nucleus, [M − H]−. 
Waters MS technologies (Manchester, UK) used for this thesis were equipped with a 
Z-spray system, which permitted the neutral molecules and any contaminants to be 
removed, and only charged ions to enter into the vacuum.  
During the ionisation process of complex mixtures, two chemical species may 
compete for the charges and a compound with a better desolvation constant (for 
example a lipophilic molecule) will dominate the spectrum. This issue encountered 
with LC-MS, termed the ion suppression, can be solved by adapting the 
chromatographic method with a better gradient to separate most metabolic species 
or using a sample pre-treatment such as solid phase extraction (SPE).  
Mass analysers 
Different types of mass analysers exist based on different ion separation techniques, 
each with their unique area of application and characteristics. A mass analyser will 
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be selected depending on its resolution, i.e. its ability to resolve two closely related 
masses, mass accuracy, i.e. capacity to deliver accurate and precise measurement 
(ratio of the m/z measurement error to the true m/z), the mass range, the dynamic 
range which is the range between the smallest and largest m/z peak that can be 
measured in the same run, and finally the scan rate which is the number of spectra 
per unit time that can be generated. This last parameter is particularly important 
when the MS is coupled to an online separation technique (e.g. LC-MS) and the 
sample composition is changing throughout the acquisition.  
Time-of-Flight (TOF) analysers are able to measure the ion masses simultaneously 
and with accuracy. These analysers are appealing for metabonomic applications 
due to their high scan rate, appropriate for LC coupled applications, their high mass 
accuracy , which is required for untargeted approaches, and low cost. TOF MS 
selects the charged molecules according to their velocities, using ion optics and 
accelerating potential. The ‘arrival time’ registered at the detector, reflects the time 
of flight of the ions, which depends on their m/z. Heavier ions will reach the detector 
first. 
Quadrupole instruments, as the name implies, are formed of four rods placed in 
parallel. An oscillating electric voltage is applied between the rods which selectively 
stabilises or destabilises the paths of ions passing through. Only the ions in a 
certain range of m/z ratio are filtered out prior to hitting the detector, by controlling 
their trajectory and their collision with the rods. Different modes of scanning can be 
used with the quadrupole, it can either act as a detector by varying the potentials on 
the rods and allowing a wide range of m/z values to be swept rapidly, or as a mass 
filter to monitor unique m/z ions at a time. Quadrupole analysers are inexpensive but 
are at the lower end of mass analysers in terms of resolution, scan rate and mass 
accuracy. However, they are proven very useful when combined with a TOF 
analyser (Q-TOF) or in a linear combination of three quadrupoles (TQ or QQQ). 
Besides measuring metabolite concentration and profiling samples, LC-MS can be 
employed to annotate the metabolome. High resolution m/z ratios and isotope 
patterns provide information on the molecular composition. In the example of the 
spectrum of TCAA (Error! Reference source not found.), the unique isotope 
pattern of molecules with three chlorine atoms allows the analyst to confidently 
assign this molecule. However, to obtain structural information, fragmentation 
patterns are needed. Intentional fragmentation can occur using collision-induced 
dissociation by colliding accelerated ions with neutral molecules such as helium or 
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nitrogen gases. The resulting fragmentation pattern of a molecule will inform on the 
presence of chemical groups and their position which can be matched against a 
database. Fragmentation studies in LC-MS can be done on Q-TOF and TQ 
instruments. 
 
Figure 8-4. Mass spectrum of Trichloroacetic acid (TCAA) (experimental data using a 
Nanospray Orbitrap instrument) 
The isotopic ratio of 35Cl/37Cl yields to four peaks at interval of two mass 
units in the ratio 3:3:1:0 for ion species containing three chlorine atoms 
 
The method of choice for quantification is the TQ which consists of three quadrupole 
mass analysers in series where the second quadrupole can operate as a regular ion 
guide or a collision cell. A very low LOD is obtained thanks to the selection of one or 
few ions at the time by the first quadrupole, the second quadrupole operating as a 
collision cell and the third quadrupole selecting only one fragment. This method, 
termed selected reaction monitoring (SRM) or MRM when multiple ions are 
monitored, is used in targeted LC-MS methods such as in this thesis for the TCAA 
assessment. TQs, however, are not adapted to untargeted profiling because of their 
inability to preform high mass accuracy analysis. Q-TOFs, on the other hand, 
perform well for high mass accuracy untargeted approaches. It was also used for 
MRM-like studies in this thesis (steroid identification). The quadrupole allows for 
mass selection and the TOF for ion detection. An additional element placed in 
between, the collision cell, permits fragmentation of the molecules.
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 Annexe tables  8.2
Table 8-1. Gipuzkoa and Sabadell cohort characteristics of the population included in the analysis and of the full cohort 
  














Characteristics   n % n % n % n % n % 
All   419 100.0% 639 100.0% 398 100.0% 479 100.0% 657 100.0% 
Age ≤20 0 0.0% 2 0.3% 16 4.0% 16 3.3% 20 3.0% 
 
21-30 190 45.3% 284 44.4% 196 49.2% 240 50.1% 324 49.3% 
 
31-40 224 53.5% 345 54.0% 185 46.5% 221 46.1% 310 47.2% 
 
>40 5 1.2% 7 1.1% 1 0.3% 2 0.4% 2 0.3% 
  Missing 0 0.0% 2 0.3% 0 0.0% 0 0.0% 1 0.2% 
Working situation at 32 weeks Worker 358 85.4% 505 79.0% 279 70.1% 344 71.8% 477 72.6% 
 
Unemployed 30 7.2% 45 7.0% 50 12.6% 52 10.9% 73 11.1% 
 
Student 4 1.0% 5 0.8% 0 0.0% 1 0.2% 1 0.2% 
 
Housewife 26 6.2% 46 7.2% 41 10.3% 50 10.4% 62 9.4% 
  Missing 1 0.2% 39 6.1% 28 7.0% 32 6.7% 44 6.7% 
Education level 
Without education or unfinished primary 
school 1 0.2% 2 0.3% 3 0.8% 3 0.6% 5 0.8% 
 
Primary 48 11.5% 84 13.1% 118 29.6% 136 28.4% 184 28.0% 
 
Secondary 146 34.8% 232 36.3% 173 43.5% 210 43.8% 279 42.5% 
 
University 223 53.2% 318 49.8% 101 25.4% 127 26.5% 185 28.2% 
  Missing 1 0.2% 4 0.6% 3 0.8% 3 0.6% 4 0.6% 
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Ethnicity White 402 95.9% 587 91.9% 373 93.7% 436 91.0% 591 90.0% 
 
American Indian 6 1.4% 11 1.7% 10 2.5% 11 2.3% 15 2.3% 
 
Other 0 0.0% 1 0.2% 4 1.0% 3 0.6% 4 0.6% 
 
Missing 9 2.1% 39 6.1% 7 1.8% 19 4.0% 47 7.2% 
Smoking Beginning of pregnancy 90 21.5% 143 22.4% 123 30.9% 137 28.6% 185 28.2% 
 
At 12 weeks 47 11.2% 77 12.1% 66 16.6% 70 14.6% 94 14.3% 
 
At 32 weeks 42 10.0% 70 11.0% 63 15.8% 65 13.6% 88 13.4% 
 
Never 210 50.1% 284 44.4% 169 42.5% 215 44.9% 292 44.4% 
  Missing 1 0.2% 41 6.4% 27 6.8% 32 6.7% 44 6.7% 
Passive smoking exposition   243 58.0% 347 54.3% 246 61.8% 284 59.3% 383 58.3% 
  Missing 1 0.2% 41 6.4% 28 7.0% 33 6.9% 46 7.0% 
Alcohol consumption  At 12 weeks: 0.04-1g/day 126 30.1% 202 31.6% 89 22.4% 106 22.1% 147 22.4% 
 
≥1g/day 15 3.6% 27 4.2% 29 7.3% 34 7.1% 53 8.1% 
 
Missing 11 2.6% 13 2.0% 1 0.3% 1 0.2% 3 0.5% 
 
At 32 weeks: 0.04-1g/day 158 37.7% 227 35.5% 115 28.9% 144 30.1% 193 29.4% 
 
≥1g/day 25 6.0% 34 5.3% 38 9.5% 42 8.8% 58 8.8% 
  Missing 3 0.7% 44 6.9% 26 6.5% 30 6.3% 42 6.4% 
Parity 0 231 55.1% 345 54.0% 224 56.3% 259 54.1% 365 55.6% 
 
1 169 40.3% 252 39.4% 142 35.7% 181 37.8% 243 37.0% 
 
2 15 3.6% 35 5.5% 25 6.3% 31 6.5% 40 6.1% 
 
≥3 4 1.0% 6 0.9% 4 1.0% 4 0.8% 5 0.8% 
  Missing 0 0.0% 2 0.3% 3 0.8% 4 0.8% 46 7.0% 
Social class: Maternal CSP I 73 17.4% 101 15.8% 33 8.3% 36 7.5% 50 7.6% 
 
CSP II 57 13.6% 92 14.4% 51 12.8% 55 11.5% 76 11.6% 
 
CSP III 124 29.6% 173 27.1% 116 29.1% 135 28.2% 199 30.3% 
 
CSP IV 133 31.7% 225 35.2% 161 40.5% 204 42.6% 279 42.5% 




CSP V 25 6.0% 47 7.4% 33 8.3% 39 8.1% 53 8.1% 
  Missing 0 0.0% 2 0.3% 0 0.0% 0 0.0% 0 0.0% 
Social class: Paternal CSP I 45 10.7% 65 10.2% 40 10.1% 48 10.0% 68 10.4% 
 
CSP II 63 15.0% 90 14.1% 40 10.1% 42 8.8% 66 10.0% 
 
CSP III 56 13.4% 82 12.8% 62 15.6% 72 15.0% 109 16.6% 
 
CSP IV 227 54.2% 360 56.3% 198 49.7% 238 49.7% 329 50.1% 
 
CSP V 15 3.6% 28 4.4% 27 6.8% 36 7.5% 46 7.0% 
  Missing 0 0.0% 15 2.3% 27 6.8% 0 0.0% 39 5.9% 
Ethnicity White 402 95.9% 587 91.9% 373 93.7% 436 91.0% 591 90.0% 
 
American indian 6 1.4% 11 1.7% 10 2.5% 11 2.3% 15 2.3% 
 
Other 0 0.0% 1 0.2% 4 1.0% 3 0.6% 4 0.6% 
  Missing 9 2.1% 39 6.1% 7 1.8% 19 4.0% 47 7.2% 
Marital situation live with child’s father 409 97.6% 430 67.3% 387 97.2% 461 96.2% 645 98.2% 
 
live with partner 0 0.0% 0 0.0% 1 0.3% 1 0.2% 1 0.2% 
 
live with her parents 2 0.5% 2 0.3% 3 0.8% 4 0.8% 5 0.8% 
 
live alone 0 0.0% 0 0.0% 1 0.3% 1 0.2% 2 0.3% 
  others 1 0.2% 1 0.2% 1 0.3% 1 0.2% 2 0.3% 
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Child gender Male 218 52.0% 306 47.9% 186 46.7% 230 48.0% 311 47.3% 
 
Female 200 47.7% 300 46.9% 187 47.0% 221 46.1% 308 46.9% 
  Missing 1 0.2% 34 5.3% 25 6.3% 28 5.8% 38 5.8% 













  Missing 4 1.0% 39 6.1% 28 7.0% 31 6.5% 41 6.2% 
Birth length (cm)   393 49.0 (1.9) 562 49.0 (1.9) 362 49.4 (2.2) 437 49.4 (2.2) 603 49.4 (2.0) 
  Missing 26 6.2% 78 12.2% 36 9.0% 42 8.8% 54 8.2% 
Gestational age (weeks)   416 39.7 (1.3) 605 39.7 (1.3) 369 39.6 (1.6) 446 39.6 (1.6) 612 39.7 (1.5) 
  Missing 3 0.7% 35 5.5% 29 7.3% 33 6.9% 45 6.8% 
Preterm Birth Cases 11 2.6% 21 3.3% 15 3.6% 18 4.3% 20 4.8% 
  Missing 3 0.7% 35 5.5% 29 7.3% 33 6.9% 45 6.8% 
Low-Birth Weight Cases 10 2.4% 27 4.2% 20 4.8% 20 4.8% 29 7.0% 
  Missing 4 1.0% 39 6.1% 28 7.0% 31 6.5% 41 6.2% 
Small for gestational age 
<10th pct for 
weight 33 7.9% 51 8.0% 35 8.8% 47 9.8% 69 10.5% 
 
Missing 7 1.7% 43 6.7% 32 8.0% 36 7.5% 48 7.3% 
 
<10th pct for 
height 64 15.3% 93 14.6% 46 11.6% 58 12.1% 87 13.2% 
 
Missing 29 6.9% 82 12.8% 40 10.1% 47 9.8% 61 9.3% 
 
<10th pct for head 
circumference 47 11.2% 68 10.6% 68 17.1% 88 18.4% 128 19.5% 
  Missing 29 6.9% 80 12.5% 39 9.8% 46 9.6% 60 9.1% 
Fetal growth restriction 
<10th pct for 
weight 25 6.0% 51 8.0% 28 7.0% 43 9.0% 58 8.8% 




Missing 9 2.1% 43 6.7% 36 9.0% 41 8.6% 54 8.2% 
 
<10th pct for 
height 35 8.4% 54 8.5% 33 8.3% 42 8.8% 59 9.0% 
 
Missing 31 7.4% 82 12.8% 44 11.1% 52 10.9% 67 10.2% 
 
<10th pct for head 
circumference 32 7.6% 52 8.1% 39 9.8% 46 9.6% 61 9.3% 
  Missing 31 7.4% 80 12.5% 43 10.8% 51 10.6% 66 10.0% 

























2 0.5% 2 0.3% 0 0.0% 0 0.0% 0 0.0% 
 
None 364 86.9% 538 84.2% 156 39.2% 197 41.1% 216 32.9% 
 
Missing 22 5.3% 60 9.4% 153 38.4% 175 36.5% 323 49.2% 
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Table 8-2. Relationship between metabolite measurements and sample position in the 




R2 % p-value 
Progesterone metabolite -0.002 0.018 7.01E-01 
Pregnanediol-3-G -0.002 0.053 5.10E-01 
UA 0.75(d) -0.007 0.932 5.46E-03 
Oestrogen metabolite -0.005 0.243 1.57E-01 
UA 0.93(s)PF -0.020 6.170 4.01E-13 
Leucine -0.003 1.010 3.78E-03 
Isoleucine -0.002 0.534 3.54E-02 
Valine -0.003 1.301 1.00E-03 
3-hydroxyisobutyrate -0.009 3.083 3.63E-07 
4-deoxyerythronic acid -0.001 0.042 5.56E-01 
UA 1.15(mix) 0.003 0.194 2.06E-01 
3-hydroxybutyrate+3-aminoisobutyrate -0.006 1.800 1.07E-04 
4-deoxythreonic acid -0.002 0.331 9.79E-02 
UA 1.25 (d) -0.001 0.042 5.54E-01 
3-hydroxyisovalerate -0.005 2.118 2.59E-05 
UA 1.29(s) -0.003 0.667 1.87E-02 
Lactate -0.009 0.907 6.08E-03 
2-hydroxyisobutyrate -0.003 0.983 4.27E-03 
Alanine -0.005 0.650 2.02E-02 
UA 1.67(s) -0.001 0.182 2.19E-01 
Lysine 0.000 0.008 8.02E-01 
Acetate -0.003 0.300 1.15E-01 
UA 1.99(t) -0.001 0.276 1.31E-01 
N-acetyl glycoprotein fragments -0.002 0.537 3.49E-02 
N-acetyl neuraminic acid -0.008 0.385 7.41E-02 
Acetone -0.004 0.430 5.90E-02 
p-cresol sulfate -0.001 0.024 6.59E-01 
Pyroglutamate (5-oxoproline) -0.004 1.557 3.17E-04 
Succinate -0.004 0.436 5.75E-02 
Glutamine -0.002 0.326 1.00E-01 
Citrate -0.007 2.059 3.38E-05 
3-aminoisobutyrate -0.001 0.156 2.56E-01 
Dimethylamine 0.000 0.002 8.90E-01 
UA 2.78(s) -0.002 0.264 1.40E-01 
UA 2.83(s) -0.002 0.238 1.61E-01 
Trimethylamine -0.001 0.046 5.38E-01 
N-acetylserotonin -0.001 0.117 3.26E-01 
UA 2.93(s) -0.005 0.644 2.08E-02 
Creatinine+creatine -0.001 0.041 5.62E-01 
Choline -0.002 0.074 4.35E-01 
Carnitine 0.000 0.002 8.91E-01 
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TMAO -0.001 0.012 7.55E-01 
Proline betaine 0.003 0.096 3.73E-01 
Scyllo-inositol -0.004 0.074 4.35E-01 
Glycine -0.001 0.035 5.91E-01 
Guanidinoacetate -0.004 1.225 1.41E-03 
UA 3.93(s) -0.005 0.531 3.60E-02 
UA 3.95(s) -0.001 0.206 1.91E-01 
UA 6.48(d) -0.006 0.189 2.15E-01 
Fumarate -0.012 1.052 3.38E-03 
UA 6.59(s) -0.006 0.365 8.36E-02 
Furoylglycine 0.004 0.119 3.24E-01 
2Py -0.002 0.073 4.38E-01 
4-hydroxyphenylacetate -0.001 0.037 5.79E-01 
Tyrosine 0.000 0.004 8.61E-01 
UA 7.32 (mix) 0.002 0.138 2.86E-01 
Phenylacetylglutamine 0.000 0.000 9.69E-01 
3-Indoxylsulfate 0.000 0.000 9.57E-01 
Hippurate -0.002 0.025 6.48E-01 
UA(pyrodoxine) -0.002 0.514 3.90E-02 
Formate 0.002 0.145 2.74E-01 
UA 8.79(d) 0.008 0.123 3.33E-01 
N-Methylnicotinic acid 0.009 0.253 1.49E-01 
1-Methyl-nicotinamide -0.001 0.008 7.96E-01 
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List of metabolite changes in maternal urine from 1st and 3rd trimesters of gestation. Tables 3 and 4 present the spectral integration region of the peaks, 
the median and interquartile range for each metabolite in each trimester, the median fold change, the p-value from Mann-Whitney tests on paired data and 
finally the q-value from the false discovery rate calculation which accounts for multiple testing. Table 1 is for Sabadell cohort and Table 2 is for Gipuzkoa 
cohort. 




1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
Oestrogen metabolite 0.7774 0.7922 4.44E+05 2.00E+05 6.52E+05 1.63E+06 1.27E+06 1.95E+06 3.7 7.70E-55 1.85E-53 
Progesterone metabolite 
  
3.83E+01 2.41E+01 6.16E+01 1.20E+02 9.49E+01 1.58E+02 3.1 9.92E-51 1.02E-49 
Pregnanediol-3-G 
  
2.31E+02 1.79E+02 3.02E+02 6.58E+02 5.29E+02 7.96E+02 2.9 3.47E-55 1.25E-53 
UA 0.92(s)PF 
  
7.01E+01 4.58E+01 1.02E+02 1.59E+02 1.16E+02 2.13E+02 2.3 1.02E-38 5.64E-38 
UA 0.75(d) 0.741 0.7643 3.99E+05 1.62E+05 6.29E+05 6.36E+05 4.10E+05 9.30E+05 1.6 5.30E-16 1.36E-15 
Lactate 1.32 1.35 2.05E+07 1.70E+07 2.56E+07 3.13E+07 2.42E+07 4.17E+07 1.5 1.97E-37 1.01E-36 
Alanine 1.472 1.505 1.65E+07 1.41E+07 2.09E+07 2.24E+07 1.79E+07 3.03E+07 1.4 9.25E-34 4.44E-33 
4-deoxyerythronic acid 1.097 1.124 6.79E+06 5.49E+06 7.89E+06 8.96E+06 7.39E+06 1.12E+07 1.3 1.24E-41 8.15E-41 
UA 8.79(d) 8.772 8.805 2.78E+05 9.67E+04 4.89E+05 3.68E+05 1.34E+05 1.14E+06 1.3 5.54E-08 8.31E-08 
1-Methyl-nicotinamide 9.269 9.297 4.65E+05 3.23E+05 6.16E+05 6.02E+05 4.57E+05 7.92E+05 1.3 5.00E-15 1.24E-14 
Fumarate 6.521 6.529 2.13E+05 1.51E+05 2.98E+05 2.72E+05 1.92E+05 4.21E+05 1.3 8.03E-14 1.75E-13 
UA 1.25 (d) 1.244 1.263 6.40E+06 5.71E+06 7.12E+06 8.04E+06 6.68E+06 9.14E+06 1.3 7.05E-39 4.23E-38 
Isoleucine 1.005 1.025 1.54E+06 1.29E+06 1.79E+06 1.91E+06 1.67E+06 2.20E+06 1.2 2.02E-29 7.67E-29 
4-deoxythreonic acid 1.222 1.244 9.29E+06 8.35E+06 1.04E+07 1.13E+07 9.80E+06 1.27E+07 1.2 9.25E-32 4.16E-31 
Choline 3.201 3.211 8.60E+06 7.55E+06 1.03E+07 1.01E+07 8.21E+06 1.29E+07 1.2 2.40E-14 5.41E-14 
3-hydroxyisobutyrate 1.063 1.086 4.44E+06 3.72E+06 5.34E+06 5.15E+06 4.39E+06 6.73E+06 1.2 2.09E-24 6.83E-24 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
Furoylglycine 6.636 6.657 6.64E+05 5.04E+05 9.14E+05 7.68E+05 5.22E+05 1.34E+06 1.2 7.76E-06 1.12E-05 
UA 3.95(s) 3.946 3.959 2.29E+07 2.05E+07 2.58E+07 2.58E+07 2.28E+07 2.88E+07 1.1 3.75E-19 1.00E-18 
Formate 8.453 8.469 2.26E+06 1.80E+06 2.86E+06 2.51E+06 2.05E+06 3.01E+06 1.1 1.38E-03 1.69E-03 
UA 6.59(s) 6.585 6.606 1.20E+06 7.61E+05 1.57E+06 1.33E+06 8.62E+05 1.79E+06 1.1 3.15E-05 4.36E-05 
Guanidinoacetate 3.792 3.809 3.10E+07 2.72E+07 3.54E+07 3.38E+07 3.03E+07 3.85E+07 1.1 7.12E-11 1.25E-10 
Leucine 0.9503 0.9695 5.12E+06 4.53E+06 5.77E+06 5.56E+06 5.00E+06 6.19E+06 1.1 2.64E-13 5.59E-13 
Glycine 3.561 3.577 5.44E+07 4.50E+07 6.76E+07 5.84E+07 4.98E+07 7.51E+07 1.1 1.66E-12 3.33E-12 
UA 6.48(d) 6.477 6.494 4.16E+05 2.62E+05 6.02E+05 4.39E+05 2.72E+05 7.02E+05 1.1 2.34E-02 2.68E-02 
UA 1.67(s) 1.655 1.681 6.43E+06 5.95E+06 6.98E+06 6.76E+06 6.17E+06 7.37E+06 1.1 3.94E-05 5.35E-05 
3-hydroxyisovalerate 1.264 1.28 8.44E+06 7.46E+06 9.50E+06 8.75E+06 7.51E+06 9.72E+06 1.0 3.94E-01 4.24E-01 
UA 1.29(s) 1.282 1.29 2.03E+06 1.80E+06 2.33E+06 2.10E+06 1.89E+06 2.42E+06 1.0 3.45E-02 3.82E-02 
UA 1.15(mix) 1.132 1.161 5.13E+06 4.07E+06 6.38E+06 5.31E+06 4.52E+06 6.51E+06 1.0 3.06E-03 3.61E-03 
Acetone 2.229 2.249 6.03E+06 5.54E+06 6.59E+06 6.17E+06 5.63E+06 6.78E+06 1.0 1.08E-01 1.18E-01 
N-acetyl neuraminic acid 2.054 2.091 1.47E+07 1.39E+07 1.57E+07 1.50E+07 1.39E+07 1.63E+07 1.0 1.28E-03 1.58E-03 
Succinate 2.4 2.417 1.10E+07 9.64E+06 1.31E+07 1.11E+07 9.36E+06 1.38E+07 1.0 5.79E-01 5.87E-01 
N-acetyl glycoprotein 
fragments 
2.022 2.054 2.29E+07 2.09E+07 2.52E+07 2.31E+07 2.08E+07 2.54E+07 1.0 5.26E-01 5.41E-01 
2-hydroxyisobutyrate 1.355 1.366 4.87E+06 4.32E+06 5.43E+06 4.85E+06 4.36E+06 5.54E+06 -1.0 7.67E-01 7.67E-01 
Valine 1.034 1.056 2.72E+06 2.32E+06 3.11E+06 2.68E+06 2.38E+06 3.11E+06 -1.0 4.53E-01 4.73E-01 
Pyroglutamate (5-
oxoproline) 
2.387 2.4 3.45E+06 3.19E+06 3.83E+06 3.38E+06 3.08E+06 3.75E+06 -1.0 8.48E-03 9.85E-03 
UA 1.99(t) 1.97 2 1.01E+07 9.25E+06 1.12E+07 9.80E+06 9.07E+06 1.07E+07 -1.0 2.75E-04 3.48E-04 
UA 3.93(s) 3.927 3.942 3.66E+07 2.67E+07 5.10E+07 3.50E+07 2.68E+07 4.54E+07 -1.0 3.14E-02 3.53E-02 
Proline betaine 3.297 3.311 1.00E+07 7.51E+06 1.35E+07 9.45E+06 7.54E+06 1.30E+07 -1.1 4.34E-01 4.59E-01 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
Tyrosine 6.89 6.916 3.50E+06 3.02E+06 4.12E+06 3.30E+06 2.80E+06 3.95E+06 -1.1 1.86E-04 2.40E-04 
Pyroglutamate (5-
oxoproline) 
2.417 2.424 2.47E+06 2.28E+06 2.76E+06 2.32E+06 2.08E+06 2.60E+06 -1.1 2.18E-08 3.42E-08 
3-Indoxylsulfate 7.494 7.523 2.82E+06 2.34E+06 3.43E+06 2.65E+06 2.21E+06 3.12E+06 -1.1 5.04E-05 6.72E-05 
Citrate 2.5 2.576 6.78E+07 5.98E+07 8.15E+07 6.34E+07 5.26E+07 7.61E+07 -1.1 7.19E-09 1.15E-08 
UA 2.75 2.748 2.759 2.46E+06 2.24E+06 2.73E+06 2.29E+06 2.10E+06 2.50E+06 -1.1 9.02E-12 1.75E-11 
UA(pyrodoxine) 7.672 7.689 2.91E+06 2.64E+06 3.29E+06 2.71E+06 2.46E+06 3.06E+06 -1.1 2.47E-06 3.63E-06 
Trimethylamine 2.861 2.88 4.62E+06 3.83E+06 5.56E+06 4.30E+06 3.57E+06 5.13E+06 -1.1 1.56E-10 2.62E-10 
Glutamine 2.43 2.473 2.13E+07 1.88E+07 2.40E+07 1.98E+07 1.71E+07 2.28E+07 -1.1 7.77E-11 1.33E-10 
UA 2.83(s) 2.818 2.845 5.66E+06 5.13E+06 6.47E+06 5.21E+06 4.73E+06 5.80E+06 -1.1 3.89E-11 7.19E-11 
Dimethylamine 2.716 2.736 1.57E+07 1.40E+07 1.73E+07 1.42E+07 1.27E+07 1.56E+07 -1.1 3.99E-13 8.21E-13 
2Py 6.657 6.671 6.47E+05 4.96E+05 8.12E+05 5.80E+05 4.57E+05 6.92E+05 -1.1 1.03E-04 1.35E-04 
UA 7.32 (mix) 7.306 7.335 5.11E+06 4.58E+06 5.76E+06 4.57E+06 4.16E+06 5.08E+06 -1.1 1.01E-14 2.34E-14 
N-acetylserotonin 2.9 2.91 2.61E+06 2.26E+06 3.03E+06 2.31E+06 2.02E+06 2.67E+06 -1.1 6.66E-11 1.20E-10 
UA 2.78(s) 2.774 2.793 3.39E+06 3.00E+06 3.85E+06 2.97E+06 2.66E+06 3.27E+06 -1.1 5.78E-21 1.60E-20 
Hippurate 7.527 7.583 2.62E+07 1.78E+07 4.28E+07 2.28E+07 1.45E+07 3.55E+07 -1.2 2.56E-05 3.61E-05 
3-aminoisobutyrate 2.587 2.643 9.14E+06 8.00E+06 1.04E+07 7.91E+06 7.05E+06 8.87E+06 -1.2 4.18E-21 1.20E-20 
N-Methylnicotinic acid 9.113 9.142 6.59E+05 3.53E+05 1.13E+06 5.67E+05 3.33E+05 9.95E+05 -1.2 2.99E-03 3.58E-03 
Lysine 1.701 1.755 1.59E+07 1.33E+07 1.89E+07 1.37E+07 1.26E+07 1.53E+07 -1.2 1.60E-30 6.39E-30 
UA 2.93(s) 2.923 2.939 5.21E+06 4.17E+06 6.41E+06 4.42E+06 3.58E+06 5.66E+06 -1.2 2.33E-10 3.81E-10 
4-hydroxyphenylacetate 6.851 6.88 3.28E+06 2.75E+06 3.83E+06 2.78E+06 2.38E+06 3.29E+06 -1.2 1.26E-11 2.39E-11 
Acetate 1.914 1.931 1.00E+07 8.64E+06 1.19E+07 8.41E+06 7.63E+06 9.34E+06 -1.2 4.70E-31 1.99E-30 
TMAO 3.261 3.287 4.48E+07 3.64E+07 5.72E+07 3.62E+07 2.91E+07 4.92E+07 -1.2 2.88E-08 4.42E-08 
p-cresol sulfate 2.339 2.353 1.25E+07 9.19E+06 1.58E+07 9.66E+06 7.31E+06 1.26E+07 -1.3 3.68E-21 1.10E-20 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
Phenylacetylglutamine 7.343 7.384 2.48E+07 1.93E+07 3.21E+07 1.88E+07 1.46E+07 2.39E+07 -1.3 2.60E-24 8.15E-24 
Creatinine+creatine 3.027 3.067 2.38E+08 2.14E+08 2.70E+08 1.71E+08 1.52E+08 1.93E+08 -1.4 3.14E-52 4.52E-51 
UA 0.93(s)PF 
  
9.57E+01 7.27E+01 1.23E+02 6.68E+01 4.68E+01 9.04E+01 -1.4 6.63E-25 2.27E-24 
Carnitine 3.223 3.236 1.73E+07 1.24E+07 2.20E+07 7.62E+06 5.77E+06 1.04E+07 -2.3 2.59E-49 2.33E-48 
Scyllo-inositol 3.362 3.369 7.55E+06 6.49E+06 9.11E+06 3.02E+06 2.57E+06 3.57E+06 -2.5 1.64E-51 1.97E-50 
3-hydroxybutyrate+3-
aminoisobutyrate 
1.17 1.208 3.98E+07 3.23E+07 4.94E+07 1.35E+07 1.20E+07 1.55E+07 -3.0 1.80E-57 1.30E-55 
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1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
Progesterone metabolite 
  
9.69E+01 6.56E+01 1.36E+02 3.00E+02 2.29E+02 3.86E+02 3.1 1.62E-64 1.67E-63 
Pregnanediol-3-G 
  
2.63E+02 2.08E+02 3.39E+02 7.13E+02 5.77E+02 8.43E+02 2.7 2.79E-68 1.00E-66 
Oestrogen metabolite 0.7774 0.7922 5.18E+05 4.42E+05 6.01E+05 1.34E+06 1.15E+06 1.62E+06 2.6 8.53E-69 6.14E-67 
UA 0.92(s)PF 
  
1.86E+02 1.39E+02 2.36E+02 4.38E+02 3.27E+02 5.61E+02 2.4 1.69E-62 1.52E-61 
UA 8.79(d) 8.772 8.805 1.57E+05 7.34E+04 2.90E+05 3.30E+05 1.12E+05 1.15E+06 2.1 4.13E-22 8.25E-22 
Lactate 1.32 1.35 2.08E+07 1.67E+07 2.59E+07 3.32E+07 2.57E+07 4.29E+07 1.6 2.30E-46 1.03E-45 
Fumarate 6.521 6.529 1.56E+05 1.16E+05 2.05E+05 2.30E+05 1.68E+05 3.43E+05 1.5 1.42E-27 3.31E-27 
UA 6.48(d) 6.477 6.494 2.61E+05 1.91E+05 3.93E+05 3.72E+05 2.20E+05 6.74E+05 1.4 4.28E-12 6.16E-12 
Furoylglycine 6.636 6.657 5.35E+05 4.20E+05 6.67E+05 7.59E+05 4.86E+05 1.42E+06 1.4 8.32E-20 1.50E-19 
1-Methyl-nicotinamide 9.269 9.297 4.30E+05 2.95E+05 5.66E+05 6.00E+05 4.51E+05 8.54E+05 1.4 1.64E-31 4.64E-31 
UA 0.75(d) 0.741 0.7643 6.53E+05 5.52E+05 7.82E+05 8.83E+05 7.56E+05 1.07E+06 1.4 1.38E-40 4.73E-40 
Alanine 1.472 1.505 1.76E+07 1.48E+07 2.06E+07 2.32E+07 1.84E+07 2.90E+07 1.3 7.17E-41 2.58E-40 
4-deoxyerythronic acid 1.097 1.124 8.74E+06 7.14E+06 1.03E+07 1.12E+07 9.70E+06 1.35E+07 1.3 2.61E-47 1.25E-46 
3-hydroxyisobutyrate 1.063 1.086 5.00E+06 4.36E+06 5.90E+06 6.04E+06 5.05E+06 7.28E+06 1.2 5.73E-31 1.53E-30 
4-deoxythreonic acid 1.222 1.244 1.02E+07 9.19E+06 1.14E+07 1.23E+07 1.10E+07 1.39E+07 1.2 2.50E-51 1.39E-50 
Succinate 2.4 2.417 1.09E+07 9.45E+06 1.28E+07 1.30E+07 1.07E+07 1.62E+07 1.2 8.25E-22 1.61E-21 
Choline 3.201 3.211 8.57E+06 7.51E+06 1.06E+07 1.02E+07 8.26E+06 1.31E+07 1.2 1.16E-18 2.04E-18 
UA 1.25 (d) 1.244 1.263 7.40E+06 6.75E+06 8.10E+06 8.73E+06 7.81E+06 9.96E+06 1.2 2.52E-53 1.65E-52 
UA 6.59(s) 6.585 6.606 9.06E+05 6.05E+05 1.19E+06 1.06E+06 6.33E+05 1.54E+06 1.2 7.45E-07 1.01E-06 
Isoleucine 1.005 1.025 1.89E+06 1.75E+06 2.05E+06 2.15E+06 1.97E+06 2.36E+06 1.1 1.89E-45 8.01E-45 
Formate 8.453 8.469 2.35E+06 1.90E+06 3.02E+06 2.64E+06 2.16E+06 3.22E+06 1.1 5.08E-06 6.53E-06 
Guanidinoacetate 3.792 3.809 3.12E+07 2.78E+07 3.59E+07 3.49E+07 3.05E+07 3.96E+07 1.1 1.90E-13 2.84E-13 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
UA 3.95(s) 3.946 3.959 2.32E+07 2.10E+07 2.64E+07 2.55E+07 2.25E+07 2.82E+07 1.1 2.42E-08 3.35E-08 
3-hydroxybutyrate+3-
aminoisobutyrate 
1.17 1.208 1.42E+07 1.31E+07 1.60E+07 1.53E+07 1.41E+07 1.70E+07 1.1 8.78E-11 1.24E-10 
Proline betaine 3.297 3.311 1.07E+07 7.31E+06 1.63E+07 1.13E+07 7.86E+06 1.91E+07 1.1 1.14E-03 1.30E-03 
UA 1.15(mix) 1.132 1.161 5.97E+06 5.24E+06 6.92E+06 6.31E+06 5.49E+06 7.39E+06 1.1 1.23E-03 1.38E-03 
UA 1.29(s) 1.282 1.29 2.14E+06 1.96E+06 2.41E+06 2.26E+06 2.06E+06 2.46E+06 1.1 1.34E-05 1.67E-05 
Glycine 3.561 3.577 4.87E+07 3.99E+07 6.00E+07 5.14E+07 4.07E+07 6.23E+07 1.1 2.13E-02 2.32E-02 
UA 3.93(s) 3.927 3.942 3.49E+07 2.51E+07 4.76E+07 3.66E+07 2.92E+07 4.87E+07 1.0 8.86E-02 9.38E-02 
Pyroglutamate (5-
oxoproline) 
2.387 2.4 3.69E+06 3.49E+06 4.00E+06 3.81E+06 3.50E+06 4.26E+06 1.0 2.54E-04 3.04E-04 
Leucine 0.9503 0.9695 3.89E+06 3.60E+06 4.21E+06 4.01E+06 3.68E+06 4.45E+06 1.0 1.38E-06 1.80E-06 
Tyrosine 6.89 6.916 3.40E+06 2.84E+06 4.05E+06 3.47E+06 2.95E+06 3.98E+06 1.0 6.94E-01 7.03E-01 
Pyroglutamate (5-
oxoproline) 
2.417 2.424 2.51E+06 2.31E+06 2.80E+06 2.55E+06 2.32E+06 2.96E+06 1.0 6.98E-03 7.73E-03 
UA 1.67(s) 1.655 1.681 7.17E+06 6.80E+06 7.73E+06 7.29E+06 6.81E+06 7.91E+06 1.0 1.59E-01 1.65E-01 
2-hydroxyisobutyrate 1.355 1.366 4.93E+06 4.43E+06 5.50E+06 4.96E+06 4.40E+06 5.53E+06 1.0 2.86E-01 2.94E-01 
3-hydroxyisovalerate 1.264 1.28 8.20E+06 7.20E+06 9.07E+06 8.16E+06 7.27E+06 9.22E+06 -1.0 9.61E-01 9.61E-01 
Valine 1.034 1.056 3.30E+06 3.08E+06 3.60E+06 3.23E+06 2.99E+06 3.49E+06 -1.0 2.46E-04 3.00E-04 
2Py 6.657 6.671 5.88E+05 4.81E+05 7.30E+05 5.73E+05 4.56E+05 6.97E+05 -1.0 2.98E-02 3.20E-02 
Acetone 2.229 2.249 6.46E+06 6.09E+06 6.92E+06 6.27E+06 5.96E+06 6.74E+06 -1.0 6.39E-04 7.42E-04 
Citrate 2.5 2.576 7.10E+07 6.14E+07 8.53E+07 6.89E+07 5.69E+07 8.01E+07 -1.0 1.08E-06 1.44E-06 
UA 2.75 2.748 2.759 2.57E+06 2.37E+06 2.86E+06 2.42E+06 2.24E+06 2.62E+06 -1.1 5.49E-13 8.06E-13 
N-acetyl glycoprotein 
fragments 
2.022 2.054 2.54E+07 2.33E+07 2.80E+07 2.39E+07 2.24E+07 2.60E+07 -1.1 2.24E-21 4.24E-21 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
3-Indoxylsulfate 7.494 7.523 2.77E+06 2.25E+06 3.36E+06 2.59E+06 2.16E+06 3.13E+06 -1.1 8.64E-06 1.09E-05 
UA 1.99(t) 1.97 2 1.17E+07 1.10E+07 1.27E+07 1.07E+07 1.01E+07 1.15E+07 -1.1 1.44E-31 4.32E-31 
UA 2.83(s) 2.818 2.845 6.37E+06 5.74E+06 7.22E+06 5.76E+06 5.29E+06 6.51E+06 -1.1 1.62E-15 2.65E-15 
Acetate 1.914 1.931 1.07E+07 9.76E+06 1.25E+07 9.55E+06 8.67E+06 1.12E+07 -1.1 8.20E-15 1.31E-14 
UA 2.78(s) 2.774 2.793 4.21E+06 3.79E+06 4.67E+06 3.71E+06 3.40E+06 4.09E+06 -1.1 3.18E-28 7.63E-28 
UA 7.32 (mix) 7.306 7.335 5.19E+06 4.74E+06 5.72E+06 4.57E+06 4.12E+06 5.11E+06 -1.1 1.67E-25 3.64E-25 
Lysine 1.701 1.755 1.65E+07 1.47E+07 1.95E+07 1.45E+07 1.35E+07 1.59E+07 -1.1 1.13E-49 5.80E-49 
UA(pyrodoxine) 7.672 7.689 3.09E+06 2.78E+06 3.40E+06 2.71E+06 2.48E+06 3.08E+06 -1.1 2.56E-20 4.72E-20 
3-aminoisobutyrate 2.587 2.643 9.74E+06 9.10E+06 1.07E+07 8.54E+06 7.88E+06 9.36E+06 -1.1 1.60E-41 6.08E-41 
N-acetylserotonin 2.9 2.91 1.95E+06 1.76E+06 2.15E+06 1.70E+06 1.56E+06 1.87E+06 -1.1 1.52E-41 6.06E-41 
Trimethylamine 2.861 2.88 5.25E+06 4.46E+06 6.08E+06 4.56E+06 3.77E+06 5.52E+06 -1.2 9.22E-35 3.02E-34 
Dimethylamine 2.716 2.736 1.68E+07 1.50E+07 1.97E+07 1.46E+07 1.28E+07 1.67E+07 -1.2 2.85E-22 5.86E-22 
Glutamine 2.43 2.473 2.25E+07 2.00E+07 2.54E+07 1.95E+07 1.72E+07 2.21E+07 -1.2 7.55E-33 2.36E-32 
N-Methylnicotinic acid 9.113 9.142 9.70E+05 4.90E+05 1.79E+06 8.36E+05 4.24E+05 1.57E+06 -1.2 5.62E-04 6.64E-04 
UA 2.93(s) 2.923 2.939 5.71E+06 4.82E+06 6.71E+06 4.89E+06 4.09E+06 5.88E+06 -1.2 1.55E-18 2.65E-18 
4-hydroxyphenylacetate 6.851 6.88 3.27E+06 2.80E+06 3.96E+06 2.69E+06 2.32E+06 3.25E+06 -1.2 5.35E-25 1.13E-24 
TMAO 3.261 3.287 5.83E+07 4.52E+07 9.16E+07 4.60E+07 3.63E+07 6.38E+07 -1.3 9.32E-15 1.46E-14 
Phenylacetylglutamine 7.343 7.384 2.78E+07 2.21E+07 3.50E+07 2.14E+07 1.66E+07 2.63E+07 -1.3 9.32E-29 2.31E-28 
p-cresol sulfate 2.339 2.353 1.33E+07 1.01E+07 1.66E+07 9.98E+06 7.83E+06 1.28E+07 -1.3 9.73E-27 2.19E-26 
UA 0.93(s)PF 
  
8.48E+01 6.66E+01 1.06E+02 6.09E+01 4.46E+01 8.23E+01 -1.4 1.68E-31 4.64E-31 
Creatinine+creatine 3.027 3.067 2.52E+08 2.28E+08 2.79E+08 1.81E+08 1.60E+08 2.07E+08 -1.4 4.70E-67 6.77E-66 
Hippurate 7.527 7.583 3.98E+07 2.65E+07 5.82E+07 2.76E+07 1.78E+07 4.05E+07 -1.4 1.08E-14 1.65E-14 
Carnitine 3.223 3.236 1.82E+07 1.36E+07 2.38E+07 9.70E+06 7.17E+06 1.28E+07 -1.9 1.07E-52 6.40E-52 






1st trimester 3rd trimester       
  δ1 δ2 median 25th  75th  median 25th 75th MFC p-value FDR 
N-acetyl neuraminic acid 2.054 2.091 6.49E+07 4.48E+07 9.22E+07 2.09E+07 1.96E+07 2.29E+07 -3.1 9.42E-60 7.53E-59 
Scyllo-inositol 3.362 3.369 7.25E+06 4.93E+06 1.03E+07 2.26E+06 1.92E+06 2.86E+06 -3.2 1.14E-55 8.24E-55 
  






 containing resonances at 0.56 (s), 0.63(s), and 0.92 (s) ppm in NMR spectra 
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Controls FGR cases SGA cases 
  






























Female 60 48.8 10 40 17 51.5 0.561 0.934 99 56.9 25 59.5 28 57.1 1.000 0.625 
Male 63 51.2 15 60 16 48.5 
  





No 99 80.5 15 60 21 63.6 0.037 0.061 126 72.4 23 54.8 29 59.2 0.814 0.383 
Yes 24 19.5 10 40 12 36.4 
  
47 27.0 19 45.2 20 40.8 
  
BMI 
(0,18.5] 3 2.4 2 8 2 6.1 0.398 0.383 14 8.0 2 4.8 4 8.2 0.284 0.518 
(18.5,25] 93 75.6 19 76 27 81.8 
  
108 62.1 33 78.6 38 77.6 
  
(25,30] 22 17.9 4 16 4 12.1 
  
37 21.3 5 11.9 5 10.2 
  
(30,100] 5 4.1 0 0 0 0.0 
  
15 8.6 2 4.8 2 4.1 
  
Maternal age <21 1 0.8 0 0 0 0.0 0.594 0.960 1 0.6 3 7.1 4 8.2 0.244 0.212 
 
21-28 23 18.7 7 28 6 18.2 
  
50 28.7 12 28.6 20 40.8 
  
 
<28-36 89 72.4 15 60 24 72.7 
  
113 64.9 23 54.8 22 44.9 
  
 
<36-70 10 8.1 3 12 3 9.1 
  




water at home 
Municipal 91 74.0 19 76 24 72.7 0.725 0.803 20 11.5 2 4.8 2 4.1 0.902 0.506 
Private 
well 
2 1.6 0 0 0 0.0 
  
2 1.1 0 0.0 0 0.0 
  
Bottled 28 22.8 5 20 8 24.2 
  
147 84.5 37 88.1 46 93.9 
  
Other 2 1.6 1 4 1 3.0 
  






Municipal 28 22.8 1 4 4 12.1 0.052 0.391 8 4.6 0 0.0 0 0.0 1.000 0.611 
Private 
well 
0 0.0 0 0 0 0.0 
  
0 0.0 0 0.0 0 0.0 
  
Bottled 94 76.4 24 96 29 87.9 
  
162 93.1 41 97.6 48 98.0 
  
Other 0 0.0 0 0 0 0.0 
  
3 1.7 0 0.0 0 0.0 
  
solvent use Yes 10 8.1 3 12 3 9.1 0.437 0.714 16 9.2 2 4.8 4 8.2 1.000 0.589 
 
No 100 81.3 18 72 23 69.7 
  





No 104 84.6 17 68 22 66.7 0.089 0.185 137 78.7 31 73.8 38 77.6 0.770 1.000 
Yes 6 4.9 4 16 4 12.1 
  
18 10.3 3 7.1 4 8.2 
  







Controls FGR cases SGA cases 
  

































No 106 86.2 20 80 24 72.7 1.000 0.708 143 82.2 34 81.0 41 83.7 1.000 0.415 
Yes 4 3.3 1 4 2 6.1 
  
12 6.9 0 0.0 1 2.0 
  
Running water 
at week 34 
never/1-3 
month 
14 11.4 4 16 4 12.1 0.681 0.494 148 85.1 38 90.5 46 93.9 0.889 0.563 
1 to 6 
week 
5 4.1 0 0 1 3.0 
  
0 0.0 0 0.0 0 0.0 
  
1-3 day 29 23.6 5 20 12 36.4 
  
10 5.7 1 2.4 1 2.0 
  
4+ day 75 61.0 15 60 16 48.5 
  
15 8.6 3 7.1 2 4.1 
  
Mineral water 
at week 34 
never/1-3 
month 
36 29.3 6 24 11 33.3 0.728 0.920 11 6.3 3 7.1 3 6.1 0.958 0.887 
1 to 6 
week 
46 37.4 11 44 11 33.3 
  
1 0.6 0 0.0 0 0.0 
  
1-3 day 19 15.4 2 8 6 18.2 
  
17 9.8 5 11.9 5 10.2 
  
4+ day 22 17.9 5 20 5 15.2 
  
144 82.8 34 81.0 41 83.7 
  
Filter use 
Yes 10 8.1 2 8 3 9.1 1.000 0.733 12 6.9 0 0.0 0 0.0 0.195 0.462 
No 81 65.9 17 68 21 63.6 
  
8 4.6 2 4.8 2 4.1 
  
mean THM 
area levels at 
home 
 





Yes, often 31 25.2 6 24 9 27.3 1.000 0.824 91 52.3 24 57.1 25 51.0 1.000 0.866 
Not often 92 74.8 19 76 24 72.7 
  






1.125 0.62 - 1.8 1.125 0.62 - 1.8 0.625 0.62 - 1.1 0.533 0.245 0 0 - 0 0 0 - 0 0 0 - 0 0.390 0.118 
 
  




 Annexe Figures 8.3
 
Figure 8-5 Distribution of z-scores for estimated fetal weight in Sabadell cohort 
 
Figure 8-6 Distribution of z-scores for Biparietal diameter in Sabadell cohort 





Figure 8-7 Distribution of z-scores for estimated fetal weight in Gipuzkoa cohort 
 
 
Figure 8-8 Distribution of z-scores for Biparietal diameter in Gipuzkoa cohort 






Figure 8-9. Heatmap of metabolite inter-correlation in urinary 
1
H NMR spectral profiles from 
Gipuzkoa at week 12 of gestation (metabolite order created using the complete linkage method 
for hierarchical clustering) 





Figure 8-10 Heatmap of metabolite inter-correlation in urinary 
1
H NMR spectral profiles from 
Gipuzkoa at week 34 of gestation (metabolite order created using the complete linkage method 
for hierarchical clustering) 





Figure 8-11 Heatmap of metabolite inter-correlation in urinary 
1
H NMR spectral profiles from 
Sabadell at week 12 of gestation (metabolite order created using the complete linkage method 
for hierarchical clustering) 





Figure 8-12 Heatmap of metabolite inter-correlation in urinary 
1
H NMR spectral profiles from 
Sabadell at week 34 of gestation (metabolite order created using the complete linkage method 
for hierarchical clustering) 
 
 





Figure 8-13 Associations between maternal urinary metabolites at week 12 (as measured in 1H 
NMR spectra) and fetal weight at week 20 in the Sabadell cohort according to different levels of 
Iodine (urinary levels) 





Figure 8-14 Vitamin D deficiency and urinary metabolic predictors of fetal growth outcome in the INMA cohort (Gipuzkoa and Sabadell) with A. 
Distribution of urinary valine in the third trimester of gestation in FGR, LGA and appropriate FG outcome (customised growth chart in for birth 
weight) stratified by vitamin D status at week 12 of gestation (Box plots represent median and range of metabolite concentration with numbers in white 
corresponding to individual counts per categories) B. Associations between Vitamin D at week 12, urinary oestrogens and valine at week 34 (NMR 
spectral integrals) according to fetal growth outcome categories (blue: FGR, green: appropriate weight at birth, yellow: LGA)





Figure 8-15. Associations between maternal urinary metabolites at week 12 (as measured in 
1
H 
NMR spectra) and fetal weight at week 20 in the Sabadell cohort according to different levels of 
C-reactive protein (CRP) 





Figure 8-16 Associations between maternal urinary metabolites at week 12 (as measured in 
1
H NMR spectra) and fetal weight at week 20 in the 
Sabadell cohort according to maternal smoking status at the beginning of pregnancy 
